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Target-guided synthesis is an approach to drug discovery that uses the
biological target as a template to direct synthesis of its own best inhibitors from
small molecule fragments. The process bridges the gap between chemical synthesis
of drug candidates and their biological binding assay, merging the two operations
into a single process whereby the active site or a binding pocket within the structure
of the biological target directly controls the assembly of the best inhibitor in situ.
Two different approaches to target-guided synthesis, the thermodynamic approach,
making use of reversible reactions, and the kinetic approach, which uses an
irreversible reaction, have been employed to discover novel, isoform selective
inhibitors of the glutathione transferase (GST) enzyme family – possible drug targets
in cancer and parasitic disease treatments.
The thermodynamic approach described in this thesis uses the
aniline-catalysed reversible acyl hydrazone formation reaction to create a dynamic
covalent library of bivalent ligands designed to bind the dimeric structure of GST. In
the presence of GST one of the bivalent ligands was selectively amplified at the
expense of the other library members. This ligand was shown, via biological assays,
to be a specific inhibitor for one isoform of GST, the mu isoform mGSTM1-1.
A kinetic approach has also been investigated as a way to identify novel
bivalent GST inhibitors utilising the Huisgen 1, 3 dipolar cycloaddition reaction. An
azide and alkyne fragment library was designed to bind across the dimeric GST
structure. The inhibitor structures are therefore bivalent, containing two anchoring
fragments known to bind to the GST active site, linked by a triazolopeptide spacer.
The triazole provides the click chemistry disconnection, enabling rapid in situ
screening of candidate alkyne and azide fragments for inhibitor discovery. Whilst the
in situ reaction with GST yielded inconclusive results, a number of the triazole
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Chapter 1 - Introduction
1.1 Target-guided synthesis
Despite a trade surplus of some £7 billion in the UK in 2009,[1] the
pharmaceutical industry has come under much criticism over the last fifteen years
with the number of new drugs, defined as New Molecular Entities (NME), coming to
market levelling off whilst R&D costs continue to rise dramatically.[2] The
development of a new drug will typically take between 12 and 15 years. Of 25000
compounds tested in the laboratory, only five will make it to market and only one
will recoup its investment.[1] The discrepancy between cost and productivity has
resulted in a shift towards the development of new, more cost effective approaches to
drug discovery to both complement and advance current methods. These techniques
include the development of combinatorial chemistry and high-throughput
screening,[3, 4] improved computer-based virtual screening,[5] use of solid-phase and
microarray technology,[6] and the development of novel strategies such as
fragment-based drug design.[7]
The traditional method of structure based design relies on a step-wise
procedure whereby compound libraries are screened against the biological target to
identify lead compounds. These leads will then be further functionalised to increase
binding affinity. This approach can be very labour-intensive, with each new
compound having to be synthesised, purified and then assayed for activity against the
protein target, see Figure 1.
Figure 1: The traditional step-wise approach to drug discovery.
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Clearly one solution to reduce time and cost would be the combination of
synthesis with biological screening; a result achieved utilising target-guided
synthesis (TGS). This methodology uses the biological target as a template to
synthesise its own inhibitor from a mixture of small molecules, thereby reducing the
number of synthetic steps required as well as removing the need for biological
assaying of each possible product from the mixture.
Using the biological target as a template to synthesise its own inhibitor can be
approached with two different methods; using dynamic combinatorial chemistry
(DCC) or kinetically controlled TGS. DCC uses reversible reactions between small
molecule fragments to make use of Le Chatelier’s principle. “Le Chatelier’s
principle states that when an external change is made to a system in equilibrium, the
system will respond so as to oppose the change.”[8] In DCC a dynamic equilibrium is
set up and on addition of the biological target; the most strongly binding product will
be removed from the equilibrium mixture thereby shifting the equilibrium towards
the synthesis of more of this product, resulting in its amplification, as shown in
Figure 2.
Figure 2: Cartoon outlining the principles of DCC.
Kinetic TGS on the other hand makes use of irreversible reactions with
fragment libraries synthesised with functional handles attached. On addition of the
biological template, those fragments with the best binding affinity will be held in
close proximity by the biological target. This stabilises the transition state and
promotes formation of the product from the two best-binding fragments. The




Figure 3: Cartoon outlining the principles of kinetic TGS.
1.2 The first example of target-guided synthesis
The first reported use of TGS was an example of kinetic TGS discovered by
chance in 1969 by Chase and Tubbs.[9] Whilst designing irreversible inhibitors for
the enzyme carnitine acetyltransferase by synthesising bromoacetyl derivatives of the
substrates CoA and carnitine to alkylate amino acid residues on or near the enzyme
active site, it was noticed that in the presence of either bromoacetyl CoA and
(-)-carnitine or CoA and bromoacetyl-()-carnitine a highly potent reversible
inhibition was occurring. The authors determined that instead of alkylating nearby
amino acids, the close proximity in which the two substrates were being held
promoted the alkylation of the terminal thiol group of CoA to produce a biligand
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Figure 4: Reaction scheme outlining the proposed reversible inhibition of carnitine
acetyltransferase by the templated reaction of CoA and bromoacetyl-()-carnitine.
However, it was not until the 1980s that the idea of TGS as a method of drug
discovery was explored.[10] In 1986 Rideout described the in situ formation of
cytotoxic hydrazones.[11] A mixture of decanal and N-amino-N’-1-octylguanidine
(AOG) was added to human erythrocytes, which were lysed within 80 minutes.
Adding decanal or AOG alone resulted in no lysis after 420 minutes. The decanal
and AOG self assembled to cytotoxic hydrazones in situ. Since then, the use of DCC
as a drug discovery tool has really expanded, with kinetic TGS as a drug discovery
strategy lagging someway behind. Both approaches to TGS are reviewed in this
chapter.
1.3 Dynamic combinatorial chemistry
The concept of DCC is used in a wide variety of applications, not only the
drug discovery role described above but also in the design of synthetic receptors, self
replication systems and materials science.[12] The use of DCC with biological
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systems poses a particular set of requirements as the reversible reaction must be
functional under the physiological conditions essential for the stability of the
biological template. In 1997 Huc and Lehn proposed the reversible formation of
imines from the reaction of an aldehyde and an amine, Scheme 1A.[13] The reaction
between two reactive species that are readily available proceeded at pH 6.0 and was
successfully used to identify novel carbonic anhydrase II inhibitors. A drawback for
this approach is that the imine products are unstable and therefore cannot be isolated
or analysed directly. This necessitates a further in situ step of reduction of the imine
to an amine. This additional kinetic step can complicate the results of the initial
thermodynamic selectivity of the biological template leading to false positives and
false negatives.
A second reversible reaction, introduced to the biologically-templated DCC
arsenal by Ramström and Lehn, is disulfide bond formation, Scheme 1B.[14] The
suitability of the reaction was demonstrated in the discovery of new inhibitors for the
lectin concanavalin A. The reaction between disulfides and thiols undergoes rapid
interchange at pH ≥ 7 under aqueous conditions. The disulfide bond becomes stable 
at low pH (< 5) allowing the reversible library to be “locked” by a reduction in a pH.
Both the imine- and disulfide-forming reactions have been successfully employed in
the design and identification of many novel inhibitors.[12, 15]
Scheme 1: A) reversible imine formation, followed by in situ reduction to an amine,
B) reversible disulfide bond formation.
Several other reversible reactions that can be applied to
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biologically-templated DCC have been reported in the literature. The Miller group
took advantage of the reversible nature of transition metal complexation to create a
dynamic combinatorial library (DCL) of salicylaldimines forming coordination
complexes with divalent zinc, as outlined in Scheme 2A.[16] The reaction was shown
to be reversible under mild aqueous conditions and the DCL was used to find the
complex with the best binding affinity for a select double-stranded DNA sequence.
The first example of a carbon-carbon bond forming reaction used in DCC was
described by Flitsch et al., who made use of the reversible nature of the
enzyme-catalysed aldol reaction, Scheme 2B.[17] A small DCL was generated using
N-acetylneuraminic acid aldolase (NANA aldolase) as the aldol catalyst with one
library member amplified in the presence of the biological template wheat germ
agglutinin. Ramström and co-workers have demonstrated transthioesterification as a
viable reversible reaction for use in biologically-templated DCC, Scheme 2C.[18] A
proof of concept study with acetylcholinesterase as the biological target showed the
reaction proceeded at pH 7, at room temperature and with rapid equilibration of the
DCL.
Scheme 2: A) reversible metal complexation reaction, B) reversible enzyme-catalysed aldol
reaction, C) reversible transthioesterification reaction.
Recent developments in DCC can be divided into three areas; (i) application
to challenging targets, (ii) development of techniques for monitoring large libraries




1.3.1 Recent developments in DCC – (i) DCC for challenging
targets
The power of DCC as a tool for identifying novel enzyme inhibitors has
clearly been demonstrated over the last twenty years.[12, 15] The ability of DCC to be
used for more challenging targets is now being explored. DNA and RNA targets are
particularly problematic to medicinal chemists attempting to discover selective and
highly specific ligands.[19, 20] Balasubramanian and co-workers described the use of a
disulfide-based DCL to identify ligands for specific DNA G-quadruplex targets.[21]
Miller et al. used a solid phase DCC approach, described in more detail below, to
discover ligands for RNA structures involved in myotonic dystrophy type 1.[22] In
2011 the Marchán group reported a DCC approach to the identification of novel
ligands for the Tau exon 10 splicing regulatory element RNA, designing a DCL
based on disulfide chemistry.[23]
In 2010 Bradley, Diaz-Mochon and co-workers described a dynamic
approach to the identification of single-nucleotide polymorphisms (SNPs).[24] As
shown in Figure 5, recognition of a single, unknown, nucleobase in a DNA strand
was achieved starting with a peptide nucleic acid (PNA) strand. The PNA strand was
complementary to the target DNA except in the target position, where the PNA
contained only an amine or “blank”. Four aldehyde-modified nucleobases were then
added which were capable of reversibly binding in the blank position of the PNA
strand via an imine bond. The base pair corresponding to the unknown nucleotide
was amplified in binding to the blank position. Reduction of the unstable imine bond
followed by MALDI-TOF MS analysis led to the detection of the unknown
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Figure 5: Identification of SNPs using reversible dynamic imine chemistry.
To face the challenge posed by many of nature’s drug targets, a number of
strategies have been described that couple the power of DCC with an additional drug
discovery technique. Erlanson and co-workers combined DCC with a tethering
approach to unearth new inhibitors for the aurora A kinase.[25] One member of the
DCL was designed to form a disulfide linkage with a cysteine side chain located in
close proximity to the binding pocket in order to anchor the fragment. This fragment
was decorated with a second thiol capable of participating in a disulfide DCL, which
was used to probe a second binding pocket. A similar tethering approach is used by
Schofield et al. in their discovery of novel metallo-β-lactamase inhibitors.[26] Again,
one library member was a dithiol, with one thiol designed to complex with one of the
two zinc ions located in the active site of the enzyme and the other thiol reacting in a
disulfide DCL. ESI-MS was used to directly measure any library members
complexed with the enzyme.
Ciulli et al. employed a different approach to ligand design by creating a
DCL based on a thiol-derivatised adenosine building block to probe an
adenosine-binding enzyme, M. tuberculosis pantothenate synthetase, to identify new
binding species.[27] X-ray crystallography was then utilized to optimize the best
binding component, identified in the DCC, to create a highly-potent inhibitor.
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1.3.2 Recent developments in DCC – (ii) Compound detection in
large DCLs
A limiting factor in the use of DCC is the size of the library that can be
monitored. Currently, the vast majority of examples of DCC make use of small
libraries, typically of ten to one hundred components, to allow the separation and
observation of each library component by liquid chromatography. Work within the
Otto group has focused on identifying the optimum library size for DCC. In a report
describing the identification of ephedrine receptors, a library of at least 9000
components was set up using the disulfide exchange reaction between fragments with
multiple sulfide groups.[28] From this large library, receptors with strong binding
interactions with ephedrine were identified from only two vials and two LC-MS-MS
analyses. The Otto group has subsequently gone on to computationally simulate the
outcome of a range of DCLs of varying size in an attempt to determine the optimum
library size.[29] The models showed that whilst the probability of detecting strongly
binding library members drops off rapidly with an increase in library size, the
probability of producing a good binding component increases at a much faster rate.
This suggests that using larger DCLs is more advantageous.
In an attempt to avoid the necessity for monitoring the entire DCL, another
approach sees one of the components of the DCL tethered to a polymer bead
enabling simple separation of the binding ligands from the rest of the library. Miller
et al. described an early example of this approach in their identification of
DNA-binding compounds from a metal complex DCL using an immobilized DNA
receptor as the biological template.[16] The disulfide bond formation strategy,
described by Ramström and Lehn, utilized a polymer-bound form of the biological
target lectin concanavalin A to remove the best-binding ligands from the DCL to
allow for easier identification.[14] More recently, Liu and co-workers have reported a
strategy of immobilizing the biological template onto resin in their identification of
novel vancomycin analogues.[30] The resin-bound peptide target is added to the DCL
and the best ligand binds to the peptide on the resin and so it is easily separated from




Figure 6: Diagram outlining DCC with a solid phase-bound biological template.
Miller et al. chose to immobilize one of the reactive fragments on to a
polymer bead in order to identify novel ligands for RNA structures involved in
myotonic dystrophy type 1.[22] Disulfide exchange was utilized to set up a DCL of
components from 150 polymer-bound monomers and 150 solution-phase monomers
leading to a potential 11325-member resin-bound DCL. The RNA target, which was
fluorescently-tagged, was added to the DCL and successful interactions were
identified through the removal of fluorescent beads followed by mass spectral
analysis, as outlined in Figure 7.
Figure 7: Diagram outlining DCC with a solid phase-bound fragment library member.
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1.3.3 Recent developments in DCC – (iii) Novel DCC reactions
Work within the Greaney and Campopiano groups has focused on the
development and application of novel reversible reactions to be used in
biologically-templated DCC reactions. In 2005 they reported the conjugate addition
of thiols to enones as a suitable reaction with equilibration of a small five-member
library occurring within one hour at pH 8.[31] The methodology was used to identify
novel glutathione transferase (GST) inhibitors based on the reaction between a
thiol-containing tripeptide glutathione 2 and a series of analogues of ethacrynic acid,
a known substrate of GSTs, Figure 8.[32]
Figure 8: Application of the reversible conjugate addition of a thiol to an enone to the
discovery of novel GST inhibitors.
In 2010, the Greaney and Campopiano group reported the successful
application of the acyl hydrazone formation reaction in biologically-templated DCC,
Scheme 3.[33]
Scheme 3: Reversible formation of an acylhydrazone from the reaction between an
aldehyde and a hydrazide.
Based on the original DCC reaction of imine-formation from an aldehyde and
an amine, the acylhydrazone reaction between an aldehyde and hydrazide was
developed by the Sanders group as, unlike the imine, the acylhydrazone product is
Chapter 1
12
stable, so a secondary in situ step is not required. Many examples of DCC with this
reaction exist in the literature,[34-39] but as rapid equilibration only occurs at acidic pH
(approx. pH 4) there are few reports of this reaction being used in conjunction with a
biological template. Lehn reports the use of acylhydrazone formation to generate a
library of ligands at pH 4. This library is subsequently screened in a standard binding
assay to find potent inhibitors. This approach has been applied to discover ligands for
acetlycholinesterase,[40] the bifunctional enzyme HPr kinase/phosphatase from
Bacillus subtilis,[41] and the lectin concanavalin A.[42] The only direct application of
acylhydrazone formation with a biological template, prior to the work from Greaney
and Campopiano et al., came from Poulsen, who took advantage of the slow
equilibration of acyl hydrazones at pH 7, taking one week, to demonstrate an
acceleration in the formation of the best-binding library components in the presence
of the biological template carbonic anhydrase II.[43] In order to make the formation of
acylhydrazones a reaction that could be compatible with biological templates,
Greaney and Campopiano et al. took inspiration from work by Jencks in the 1960s,
who applied nucleophilic catalysis to semicarbazone formation using aniline
derivatives.[44] Nucleophilic catalysis has recently been applied to hydrazone and
oxime formation in peptide ligation systems by Dawson.[45, 46] The Greaney and
Campopiano groups demonstrated that a ten-member acylhydrazone library that took
five days to equilibrate at pH 6.2, could equilibrate in 6 hours in the presence of
aniline, which was acting as a nucleophilic catalyst.[33] The compatibility of the
aniline-catalysed acylhydrazone formation with a biological template was then
demonstrated in the discovery of novel GST inhibitors. GST isoform specificity was
demonstrated using a library based on an aldehyde analogue ALD01 of
1-chloro-2,4-dinitrobenzene (CDNB), the universal substrate of GSTs, with a
selection of hydrophobic hydrazides that were designed to bind into the hydrophobic
binding pocket of GST, as highlighted in Figure 9. The presence of the aniline
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Figure 9: Application of reversible acylhydrazone formation to the discovery of novel GST
inhibitors.
1.4 Kinetic target-guided synthesis
There are two main reasons for kinetic TGS being somewhat overlooked in
favour of DCC approaches. Firstly, the limiting requirements placed on the type of
reaction suitable for kinetic TGS. The reaction would ideally be very slow under
standard conditions allowing any protein-templated reactions to be clearly observed.
Furthermore, the reactive fragments need to be stable under conditions amenable to
the presence of the biological target; typically aqueous buffer, pH ~ 7, temperature
25-37 °C. The second reason for the lack of kinetic TGS strategies is the limitations
of the detection methods available to measure the products formed in the
protein-templated reactions. This has been addressed with the introduction of liquid
chromatography with mass spectrometry in selected ion monitoring (LC/MS-SIM)
mode, which is discussed in greater detail later in this introduction.[47]
Early examples of kinetic TGS in the literature, which have been well
reviewed,[48-50] include work by Benkovic and Bodger on multisubstrate inhibitors of
the enzyme glycinamide ribonucleotide transformylase (GAR Tfase).[51-53] Inhibitors
were developed using an enzyme-templated alkylation of substrates with a
folate-derived electrophile, Scheme 4 A1 and A2. Hu and Nguyen have described
alkylation of thiols with -chloroketones to generate inhibitors of carbonic anhydrase
II, Scheme 4B.[54]
A variation on kinetic TGS is catalyst-accelerated TGS. In this case a catalyst
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is required for the reaction to proceed in addition to the protein template. This form
of TGS is best exemplified in work described by Nicolau et al. in their development
of novel vancomycin-based multidentate ligands for vancomycin-dependent bacteria
using olefin metathesis in the presence of Grubb’s catalyst, Scheme 4C.[55, 56] In this
work, Nicolau et al. also demonstrate the use of a disulfide bond-forming reaction as
an alternative method for coupling the vancomycin analogues, Scheme 4D.[55, 56] In
this example the disulfide reaction is not set up under equilibrating conditions so the
kinetic response is therefore observed.
Scheme 4: Reactions used in kinetic TGS. A1 and A2) nucleophilic substitution for synthesis
of GAR Tfase inhibitors, B) thiol alkylation for synthesis of carbonic anhydrase II inhibitors,
C) olefin metathesis for synthesis of vancomycin dimers, D) disulfide bond formation for
synthesis of vancomycin dimers.
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More recent reports of kinetic TGS include Weber’s 2004 report outlining the
use of the Ugi reaction for the development of thrombin-CLEC inhibitors.[57] In this
approach multiple different reactive fragments are combined in a complex
equilibrium of reactions, with the final product removed from the equilibrium by a
final irreversible step, which can be amplified in the presence of the biological
template, Scheme 5A.
Manetsch and co-workers have demonstrated the reaction between a thio acid
and sulfonyl azide as a viable tool in kinetic TGS, Scheme 5B.[58] More importantly
they use this reaction to identify novel inhibitors for the antiapoptotic protein Bcl-XL
at the BH3 peptide binding domain, in the first example of a kinetic TGS strategy for
the development of inhibitors for protein-protein interactions. This is a key advance
in the application of kinetic TGS as a drug discovery tool as protein-protein
interactions are such an important target for the pharmaceutical chemist.[59] As
protein-protein interactions generally occur over a large surface area, this work
proves that the well defined binding pockets associated with enzymes and
protein-substrate interactions are not an essential requirement for a biological
template employed in TGS.
Small-molecule inhibitors of sirtuins were developed by taking advantage of
the known catalytic mechanism of the enzyme. The role of sirtuins in the cell is to
catalyse the deacetylation of acetylated lysine residues using NAD+ as a cofactor.[60]
The first step of the mechanism sees the oxygen of the acetylated lysine residue
attack the NAD+.[61] Based on this step, Suzuki and Miyata et al. designed a series of
acetylated lysine analogues with a nucleophilic α–carbon, which combined via a




Scheme 5: More reactions used in kinetic TGS. A) Ugi reaction for synthesis of
thrombin-CLEC inhibtors, B) reaction between thio acid and sulfonyl azide for synthesis of
Bcl-XL inhibitors, C) carbon-carbon bond formation for synthesis of sirtuin inhibitors.
Single-strand DNA has been used to template a number of
kinetically-controlled reactions designed to identify mutations within the template
DNA strand. In these reactions two short sequences of DNA or PNA are coupled
when a match is made for the template DNA. The first reported reaction to couple
the two short strands of DNA was the reaction between a 3’-phosphorothioate and an
oligonucleotide containing an electrophilic 5’-bromoacetyl group described by the
Letsinger laboratory, Scheme 6A.[63] Due to the difficulty in preparing the
5’-bromoacetyl oligonucleotides, the Letsinger group also explored the use of a
5’-tosyl modification as an alternative electrophilic leaving group, Scheme 6B.[64]
The Kool group have described autoligations between 3’-phosphorothioate
oligonucleotides with 5’-iodo modified oligonucleotides in response to the observed
degradation of the tosyl group, whilst in storage and in use.[65] They later went on to
describe the use of 5’-dimethylaminoazobenzenesulfonyl (dabsyl) modified
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oligonucleotides in place of the 5’-iodo modification.[66] As the dabsyl group also
acts as a quencher of fluorescence, the use of this group allows the combination of
chemical ligation and the switching on of fluorescence into one step. The Seitz group
have reported a similar approach to couple short PNA sequences together using
native chemical ligation, the reaction between a thioester and the thiol group of an
N-terminal cysteine residue to yield a new amide bond, Scheme 6C.[67] All of these
approaches have been successfully used to identify mutations in specific DNA
sequences, as the presence of a mutation results in a decrease in the ligation of the
reacting DNA or PNA short sequences.
Scheme 6: DNA-templated reactions between short, single-strand DNA or PNA sequences.
A) Reaction between 3’-phosphorothioate and 5’-bromoacetyl group. B) Reaction between
3’-phosphorothioate and 5’-iodo or tosyl or dabsyl leaving group. C) Reaction between
thioester and N-terminal cysteine.
1.5 In situ click chemistry
There are a number of drawbacks with the TGS approaches described above.
Some of the reactions used are between functional groups that are capable of
unwanted side reactions with the protein itself, some of the reactions require the
addition of an extra catalyst and other reactions have an observable background
reaction which can complicate the analysis. One reaction which overcomes such
problems, and so has expanded the scope of kinetic TGS in the last decade, is the
Huisgen 1,3 dipolar cycloaddition reaction of an azide and an alkyne to produce a
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1,2,3 triazole (Scheme 7). Both the azide and alkyne functional groups are












































Scheme 7: General reaction scheme for the Huisgen 1,3 dipolar cycloaddition reaction.
A) thermal reaction yields both regioisomers, B) copper (I)-catalysed reaction yields
1,4-triazole, C) ruthenium-catalysed reaction yields 1,5-triazole.
The Huisgen 1,3 dipolar cycloaddition reaction has become a tour de force in
organic chemistry over the last 10 years, with the development of the regiospecific
copper (I)-catalysed transformation to yield purely the 1,4- (anti) triazole product,
reported firstly by the Meldal group and later in a paper from the groups of Sharpless
and Fokin in 2002 (Scheme 7B).[68, 69] The reaction has been coined a “click
reaction”, due to its high efficiency as well as the absence of unwanted side products.
Click chemistry’s uses in chemistry today are numerous and far reaching with
applications in organic synthesis, bioorganic chemistry and materials and polymer
science.[70-72] A thorough review of the applications of click chemistry has been
published in 2010 in a themed issue by Chemical Society Reviews.[73] The discovery
of a ruthenium catalyst, described in Scheme 7C, which yields the complementary
product of pure 1,5- (syn) triazole was reported in 2005, again by the groups of
Sharpless and Fokin.[74]
In the absence of a copper or ruthenium catalyst the reaction’s high activation
barrier under standard conditions makes the click reaction an ideal candidate for a
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kinetic TGS approach. No background reaction should be observed, and thus any
product formed will be the result of two reacting fragments (azide and alkyne) being
brought into close proximity, via binding to the biological target, allowing these
fragments to react. The triazole products formed should, therefore, demonstrate a
good binding affinity for the biological target themselves.
1.5.1 Cucurbituril
In 1983 Mock et al. used the nonadecacyclic cage compound, cucurbituril 6
to catalyse a triazole-forming cycloaddition reaction.[75, 76] This was achieved as the
cucurbituril encapsulated the reactants, bringing them into close proximity thus
promoting reactivity, Figure 10. Not only was the reaction regioselective, with only
1,4 disubstituted (anti-) triazole formed in the cucurbituril cavity, but the rate of
reaction was accelerated approximately 105-fold over the non-templated reaction.
This result provided promising evidence that biological targets could also be used as
a template to promote cycloaddition reactions.
Figure 10: A) nonadecacyclic cage cucurbituril, B) proposed cross-sectional representation
of the cucurbituril-templated click reaction. Outlines drawn to van der Waals radii.
[76]
1.5.2 Acetylcholinesterase
The first successfully reported example of in situ click chemistry (ISCC)
came in 2002, published by the Sharpless group. Taking inspiration from the work
described by Mock, it was proposed that a protein binding pocket could be used as
the host or template to promote the click reaction for the best binding reactive
fragments.[77] Acetylcholinesterase (AChE), an enzyme which plays an important





provided an ideal model to develop ISCC. This was because AChE contains a
secondary “peripheral” binding pocket in close proximity to the substrate binding
site, Figure 11A. Proof of principal was described by using known inhibitors of each
binding pocket (Figure 11B); the tacrine motif, 7 and 8, binds to the active centre and
the phenanthridinium motif, 9 and 10, binds in the peripheral pocket.[77] Each motif
was functionalised with either azide or alkyne groups both on alkyl chains of varying
length. Incubation of AChE with this mixture of azides and alkynes led to the
identification of only one triazole product 11 from a possible 98 combinations.
Products were identified using desorption/ionisation on silicon mass spectrometry
(DIOS-MS) to detect triazole formation. The triazole product observed in the in situ
reaction had a Kd of 99 fM and could therefore be considered as irreversibly bound to
the enzyme during the course of the in situ experiment. As a result, the amount of
triazole that can be produced is limited to being no more than the amount of AChE
present in the reaction, as once the binding pocket has acted as a template it is then
blocked by the triazole product. To ensure the identification of any successful click
reactions the analysis technique was optimised, leading to the use of liquid
chromatography with mass spectrometry in selected ion monitoring (LC/MS-SIM)
mode. Products are identified based on their molecular weight and retention time.
Use of LC/MS-SIM identified three further triazoles 12, 13, 14, along with the
previously identified triazole 11 from the tacrine/phenanthridinium library, now
containing an additional fragment 9 (n = 5) with an alkyl chain length of five
carbons.[47] Reference samples of each triazole regioisomer observed in the ISCC
reaction were independently synthesised in order to determine which regioisomer
was formed in the presence of AChE. For all four triazoles it was found that the
syn-isomer was exclusively produced. The binding affinity for AChE for both
regioisomers was measured and, as expected, the syn-triazoles displayed much
stronger binding affinity, for AChE compared with the anti-triazoles, typically









































































11 Kd = 99 fM 12 Kd = 830 fM




Figure 11: A) diagram outlining the template effect of the enzyme binding pocket on the
tacrine and phenanthridinium fragments, B) ISCC library to find novel inhibitors of AChE.
A crystal structure of syn-11 bound to mouse AChE was obtained and
displayed the protein in a novel conformational form, never previously
characterised.[79] Furthermore the crystal structure revealed that the triazole ring
formed in the ISCC reaction also plays an important role in the binding of 11 through
hydrogen bonding and π-stacking interactions. The triazole ring was best located 
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approximately two methylene units from the tacrine fragment. Thus the
azide-decorated tacrine fragment with a linker of two methylene groups, 15, was
screened with a novel library of acetylene compounds, not previously known to bind
to AChE, to probe the peripheral binding site, Figure 12.[80] Two new triazole
products, 16 and 17, were detected using LC/MS-SIM and furthermore these triazole
inhibitors were selectively synthesised from a one pot mixture of several acetylene
compounds. Referencing with authentic samples of triazole products determined that
the reaction selectively produced the syn-triazole. Importantly, these triazole
products, detected using ISCC, had low femtomolar binding affinity for AChE.
Figure 12: A second ISCC library to find novel inhibitors of AChE.
1.5.3 Carbonic anhydrase II
With the success of AChE, the approach was applied to developing novel
inhibitors for carbonic anhydrase II (CAII).[81] An acetylenic benzenesulfonamide 18,
based on known inhibitors with nanomolar binding affinity was selected as a basis to
begin the screen of a library of azides, Figure 13. From a possible 24 triazole
products that could have been made, 11 triazoles were detected. All of these
compounds showed a greater binding affinity than that of the parent acetylene 18.
Several of the unsuccessful triazoles were also synthesised and their binding affinity
for CAII was measured. Six out of ten compounds that were not formed in the
presence of CAII still exhibited dissociation constants of less than 7.5 nM, which is
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comparable with those triazoles that were a hit in the ISCC reaction. This highlights
one drawback of the ISCC approach – the possibility of false negatives. If the alkyne
and azide groups are not bound within close proximity in just the right geometry then
the triazole will not form, even if the product itself has got good binding affinity.
Figure 13: ISCC library to find novel inhibitors of CAII.
1.5.4 HIV-1 protease
In both the cases of AChE and carbonic anhydrase II, the starting azide
and/or acetylene species already exhibited a high affinity for the target
(Ki < 37 nM).
[47, 77, 80, 81] ISCC has been applied to make HIV-1 protease inhibitors
from fragments with a low binding affinity.[82] Triazole 21 was a known nanomolar
inhibitor of HIV-1 protease, however the azide 19 and alkyne 20 fragments only
exhibited binding at micromolar quantities.
Figure 14: ISCC library to find novel inhibitors of HIV-1 protease.
Even with such weak binding, the triazole was not only formed in situ, but
was also selectively produced from a mixture of fragments, Figure 14. As a result of
the azide and acetylene fragments binding with a much weaker affinity, a higher
concentration had to be used in the ISCC reaction. This resulted in the observation of
trace amounts of triazole product forming in the background reaction. The triazole
product 21 with the best binding affinity was the only one that was amplified in the
presence of the enzyme template.
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1.5.5 DNA binding groove
Poulin-Kerstien and Dervan have shown that DNA can also be used to
template the click reaction.[83] Hairpin polyamides are made from three aromatic
amino acids, N-methylpyrrole, N-methylimidazole and N-methyl-3-hydroxypyrrole,
and are capable of binding to specific sequences of DNA.[84] In order to develop
polyamide compounds capable of recognizing longer sequences of DNA an ISCC
approach was utilized to couple together two polyamides that were each capable of
recognizing a five base pair sequence.[83] One polyamide was decorated with an
alkyne group with two different linker lengths 22a-b and the other polyamide was
functionalized with an azide group, again via two different linker lengths 23a-b.
Three DNA templates were utilized with zero (A), one (B) or two (C) base pairs
separating the polyamide binding sites. Only DNA template A, with no spacer
between binding sites, resulted in formation of triazole for each polyamide pairing,
as detected by HPLC and verified with MALDI-TOF MS, Figure 15. The length of
the linker between the azide/alkyne functionality and the polyamide affected the rate
of observed triazole formation. The introduction of base pair mismatches in the DNA
template sequence resulted in a dramatic decrease in the rate of triazole formation.
Figure 15: ISCC approach to designing novel linked hairpin polyamides capable of binding




In 2009, Omura et al. demonstrated the use of ISCC to identify a novel and
potent chitinase inhibitor.[85] Chitinases are the target for antifungal, insecticidal and
antiparasitic agents.[86] Azide fragment 26 was designed based on the natural cyclic
peptide Argifin, 25, which is known to demonstrate good chitinase inhibition.[87, 88]
This azide was subjected to an ISCC screen using a 71-member library of diverse
alkynes in the presence of three chitinases, Figure 16.[85] Only one alkyne, 27
resulted in the observation of a triazole product in the presence of the biological
template, with the triazole product 28 detected using LC/MS-SIM. Both the anti- and
syn- triazole regioisomers of this product were synthesised and their inhibitory
activity measured for each chitinase. The syn-triazole 28 displayed a 30-fold stronger
inhibition against Serrati marcescens Chitinase B, SmChiB, compared with the
starting azide and a 300-fold increase in potency over the natural product argifin 25.
The initial triazole detection conditions were unable to separate the two triazole
regioisomers so the reaction between azide 26 and alkyne 27 was repeated in the
presence of SmChiB with improved LC conditions allowing the observation of both
regioisomers. These results showed that whilst a small amount of the anti-isomer was
observed in the background reaction as well as in the presence of the chitinase, the
syn-isomer was only detected in the presence of chitinase, and the amount of product
observed was dependent on the amount of chitinase present.
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Figure 16: ISCC library based on argifin designed to identify novel chitinase inhibitors.
1.5.7 Protein-capture agents for carbonic anhydrase II
All of the previous examples of ISCC used a well defined biological
template, either an enzyme binding pocket or DNA binding groove. Heath and
co-workers have demonstrated that a well defined template is not a prerequisite for
ISCC in their design of novel protein-capture agents towards bovine and human
carbonic anhydrase II (b(h)CAII).[89] The work also further supports the argument
that the starting anchor fragment does not need to have a strong affinity for the
biological target itself. A one bead one compound (OBOC) library of heptapeptides
made from D-amino acids with a terminal D-propargylglycine were screened against
fluorescently-tagged bCAII. Hit beads were identified by the increased fluorescence
intensity and the heptapeptide sequence was determined by Edman degradation, as
shown in Figure 17, 1st ligand screen. The peptide 29 that was identified was then
used in a second screen of an OBOC library, this time decorated with an alkyne
group 29a, in the presence of bCAII. The heptapeptide 29 used as an anchor
fragment had approximately 500 M binding affinity for the protein. The second
ligand screen identified triazole product 30, which had a binding affinity of 3 M for
bCAII. The triazole 30a was utilized as the anchor ligand in a third ligand screen of
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the OBOC library, which identified triligand 31. The bistriazole 31 exhibited 64 nM
binding affinity for bCAII, however it was shown to have no effect on the activity of
bCAII proving that it was not binding in the active site of the protein. Another
significant achievement demonstrated in this work is that no knowledge of the
protein structure was required to develop a high affinity-binding ligand.
Figure 17: A solid phase ISCC approach to the discovery of protein capture agents for
b(h)CAII.
In 2010, Lee, Heath and co-workers reported a further advance in the
detection of protein-capture agents for CAII, by replacing the use of the Edman
degradation to identify the peptide sequence of successful beads with a
matrix-assisted laser desorption/ionisation tandem mass spectrometry
(MALDI-MS/MS) sequencing approach.[90] This new step alongside the ISCC screen
resulted in the identification of two novel biligand capture agents for bCAII.
1.5.8 Myelin-associated glycoprotein – combinatorial approach
with NMR spectroscopy
ISCC has been combined with NMR spectroscopy techniques to identify
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novel high affinity ligands for myelin-associated glycoprotein (MAG), a protein with
no available crystal structure.[91] With little information about the 3D structure of the
protein, NMR spectroscopy was used to identify small molecule fragments with
weak binding affinity for the MAG protein. A sialic acid derivative based on ligand
32 without the added acetylene linker, which was a known ligand of MAG was
tagged with a TEMPO spin label. This allowed fragments that bound to the protein in
close proximity to the sialic acid ligand to be identified by NMR techniques
monitoring paramagnetic relaxation effects. Fragment 33 was observed to be binding
in close proximity to the sialic acid ligand. These fragments were then utilized in an
ISCC approach to synthesise a novel biligand. The fragments were furnished with
acetylene and azide linkers, as demonstrated in Figure 18, and in the presence of the
MAG protein only one triazole product syn-34 was observed, exhibiting a binding
affinity of 2 M, which was a greater than 50-fold improvement in binding affinity
compared with the starting fragments. The ability of ISCC to successfully identify
novel triazole products from very weakly binding starting fragment was again
demonstrated.
Figure 18: ISCC library of fragments discovered by NMR techniques for the identification of
novel MAG protein biligands.
1.5.9 Mycobacterial monooxygenase EthR
Further to the observation by the Sharpless group that acetylcholinesterase
adopted a previously unseen conformation upon the binding of the syn-triazole
formed through an ISCC approach,[79] Willand, Deprez et al. have again
demonstrated the ability of ISCC to capture previously unknown protein
conformations.[92] They set up an ISCC screen to develop inhibitors for the
mycobacterial monooxygenase EthR. Starting from the scaffold azide 35, identified
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by X-ray crystallography, six batches of ten alkynes were screened in the presence of
biological target EthR. Only one triazole product was observed and this was
identified as being the anti-triazole 36, Figure 19. The triazole exhibited a 10-fold
increase in potency for EthR, but more importantly crystal structures of the triazole
bound to EthR revealed a novel protein conformation, with access to a previously
buried hydrophobic pocket. This highlights the ability of ISCC to not only identify



























35 IC50 = 7.4 M 36 IC50 = 580 nM
Figure 19: ISCC approach to discover novel inhibitors of EthR.
1.6 Summary – DCC versus kinetic TGS
The last ten years have seen a rapid increase in the use of TGS approaches in
the development of novel inhibitors. The leading light in terms of a thermodynamic
DCC approach is the reversible disulfide-forming reaction. The kinetic approach has
recently caught up with its thermodynamic counterpart with the introduction of the in
situ click reaction between an azide and terminal alkyne. Whilst these two reactions
have led the attack in understanding the power of TGS, researchers remain
committed to developing new connections to add to the, at present, small TGS
reaction pool. In addition to the lack of diverse reactions suitable for use with a
biological template, another notable limitation that both DCC and kinetic TGS
currently share is the problem of product detection and analysis. As the field of mass
spectrometry has developed to become more sensitive, the problems of product
detection in TGS have decreased. The introduction of LC/MS-SIM has provided a
great improvement to product detection in TGS.[47] Solid phase techniques have also
been employed in both DCC and ISCC approaches in a bid to further reduce the
problems associated with product identification.[14, 16, 22, 30, 89]
Efforts in TGS are now being directed towards coupling the strategy with
another area of drug discovery known as fragment-based drug design. In this
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approach, low molecular weight fragments are identified as possessing some binding
affinity for a given biological target and based on this knowledge larger lead
compounds are built up, Figure 20. Various fragment-based drug discovery
approaches have been developed over the last fifteen years and are well reviewed in
the literature.[7, 93-95] By coupling this approach with TGS, the fragments that have
been identified in the fragment-based approach can then be built up using a TGS
strategy.
Figure 20: Cartoon outlining the principles of fragment-based drug design.
The first reported case of fragment-based drug design was described by Fesik
and co-workers, who used NMR to identify fragments with binding affinity for the
target FK506 binding protein, a potent immunosuppressant.[96] 15N-HSQC NMR was
used to identify shifts in peaks characteristic of a binding event on the addition of
15N-labelled biological target to the fragment of interest. Fragments that bind to
adjacent sites within the protein are then coupled to create the final high-affinity
ligand. Drawbacks associated with this technique are that the protein target should be
less than 40 kDA, significant quantities of the 15N-labelled protein are required
(> 200 mg) and the fragment compounds must be soluble at high concentrations
(> 0.2 mM). NMR-based approaches have been further developed by the introduction
of a “spin label” onto a fragment with a known binding site.[97, 98] Fragments which
bind to an adjacent site will experience a paramagnetic relaxation enhancement
caused by the spin label which can be readily detected by NMR. Sensitivity is
improved using the spin label, which results in a reduction in the amount of protein
required (2 mg). This approach was successfully employed to identify fragments that
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bind to adjacent products in myelin-associated glycoprotein and these fragments
were subsequently linked using an ISCC strategy as described in section 1.5.8.[91]
A second approach used to identify fragments that bind to a biological target
is X-ray crystallography. X-ray crystallography gives the clearest picture of the
fragment binding to the target, allowing not only the discovery of the best fragments
but also the optimum location for the addition of the linker unit and further
information on the environment around the fragment to allow for extra development.
Researchers at Abbott Laboratories were the first group to report the successful use
of X-ray crystallography in the identification of a novel inhibitor for the anticancer
target urokinase.[99] Protein crystals were soaked in a mixture of fragment
compounds. Those fragments which bound to the protein were determined by
examining the shape of the electron density map. A hit was identified,
8-hydroxy-2-aminoquinoline, and the crystal structure showed that there was an
adjacent pocket that the fragment could be extended in to. The modification to
extend the fragment into this pocket resulted in a 1000-fold increase in potency (from
Ki = 56 to 0.37 M) over the original fragment. There are now several companies
using this technology to drive their drug discovery programmes including Abbott
Laboratories, Astex Therapeutics and Plexxikon. The inhibitors that have been
discovered by these companies are well reviewed in the literature.[7, 95]
Mass spectrometry, developed by Ibis Therapeutics,[100] and direct binding
assays at high concentration, developed by the Ellman group,[101] have also been
employed to identify binding fragments. Unlike the NMR and crystallography-based
approaches described above, mass spectrometry and binding assays do not give any
information about the binding mode of the fragment within the biological target.
All of the above approaches to fragment-based drug design utilise various
detection methods to identify the fragments with the best binding affinity for the
biological target. As the interactions between the small fragments and the biological
target are typically weak, large concentrations are required to ensure the detection of
any binding events. In response to this, Wells and co-workers developed a fragment
approach known as tethering.[102] Based on a similar concept to DCC, fragments are
“tethered” to the biological target via a reversible disulfide linkage with a cysteine
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residue located in close proximity to the binding pocket. The fragment with the best
fit for the binding pocket will form a disulfide bond with the cysteine thiol and can
then be detected at much lower concentrations, typically by mass spectrometry. A
cysteine residue can be introduced by site-directed mutagenesis if there is not a
naturally occurring cysteine residue located near the binding pocket. Some of these
fragment-based approaches, including tethering,[25, 26] X-ray crystallography,[27, 92]
and fragment-based NMR screening,[91] have already been successfully coupled with
DCC and ISCC to identify novel inhibitors.
The main difference between DCC and kinetic TGS is that DCC should
always result in the identification of the best binding compound from any given
library, even if this compound is not a highly potent inhibitor itself. Depending on
the choice of fragments in a kinetic TGS library, there can be a much smaller chance
of finding a hit; however this hit is much more likely to be a potent inhibitor. Kinetic
TGS has the added drawback that false negatives can occur. If the reactive functional
groups are not positioned in the correct orientation, despite a fragment binding to the
biological template, then the reaction cannot occur and the fragment will not be
identified as being a good inhibitor. Current literature suggests that neither approach
is significantly better than the other. The choice between the two comes down to the
ease with which a fragment library can be synthesized from the selected scaffold
fragment.
One area of TGS that remains relatively unexplored is the possibility of
synthesising multivalent ligands by having multiple reactive groups on one fragment
and therefore allowing the exploration of more chemical space in one TGS screen.
This thesis aims to explore the application of a multivalent approach to both DCC
and ISCC and compare the results observed from both systems.
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Chapter 2: A dynamic combinatorial chemistry
approach to identify novel bivalent inhibitors of
glutathione transferases
The first target-guided synthesis (TGS) method to be investigated was the
thermodynamic approach using dynamic combinatorial chemistry (DCC). The
biological templates that were selected were glutathione transferases.
2.1 Glutathione transferases
Glutathione transferases (GST) are a family of enzymes primarily responsible
for the conjugation of glutathione (γ-Glu-Cys-Gly, GSH) 2 to a number of substrates
in the cell.[1-6] This is the first step in the mercapturic acid pathway, a key pathway in
the metabolism of xenobiotic electrophiles.[7] Conjugate addition occurs between the
thiol of GSH and an electrophilic substrate. The conjugation of GSH is promoted
within two binding pockets in the enzyme; the glutathione binding region (“G-site”)
and the adjacent hydrophobic acceptor binding region (“H-site”), Figure 1.
Figure 1: Glutathione-conjugation to xenobiotics. Green = glutathione binding site.
Red = hydrophobic binding site.
GSTs can be separated into three different families; cytosolic, mitochondrial
and membrane-bound microsomal. The cytosolic family can be split into a further
seven classes; Alpha, Mu, Omega, Pi, Sigma, Theta and Zeta. The sequence identity
within a class is generally quite high at above 60%, but the sequence identity
between classes is much lower, at about 30 %. The GST family is extensively
reviewed in the literature.[2-6] The three most abundant mammalian classes are the
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alpha, mu and pi classes. Each class can be further sub-divided, with four subunits
identified in human for the Mu class (M1 - M4), four subunits in the Alpha class
(A1 - A4) and one subunit in the Pi class (P1). In all three classes the GST monomer
unit is split into two domains. The N-terminal domain 1 is highly conserved between
all of the cytosolic classes and forms the majority of the glutathione-binding G-site.
The C-terminal domain 2 provides the majority of the residues that make up the
hydrophobic pocket and is much less conserved between the mu, pi and alpha
classes. It is these differences that are responsible for the variation in substrate
specificity observed between the classes of GST. There are more structural features
that are unique to each class of GST. The Mu class GSTs have the ‘Mu loop’ which
results in a deeper active site cleft than those found in the Pi class.[8] Domain 2 of the
Alpha class contains an extra α-helix that folds onto the hydrophobic binding pocket, 
making it smaller and more hydrophobic than the H-site of the Pi and Mu class of
enzymes.[9] Representatives from all three classes have been selected to use as the
biological template in this DCC approach in an effort to probe isoform specificity.
The human form of the P1 subclass, hGSTP1-1, has been selected from the pi class,
the mouse form of the M1 subclass, mGSTM1-1, has been selected as a
representative of the mu class of GSTs and the mouse form of the A4 subclass,
mGSTA4-4 has been chosen from the alpha class. The helminth GST Schistosoma
japonica GST (SjGST) has also been selected as a fourth non-mammalian GST
isoform to investigate. The three-dimensional structure of SjGST most closely
resembles the Mu class of the mammalian GSTs and contains a shortened form of the




Figure 2: Three-dimensional structures of GST monomers. Unique structural features
located near the hydrophobic binding pocket, the Mu loop or extra α-helix, are represented in 
blue. a) SjGST (PDB: 1Y6E),
[13]
b) hGSTP1 (PDB: 1EOG),
[14]
c) mGSTM1 (generated with
the protein structure homology-modeling server SWISS-MODEL by Anne Caniard),
[15]
d) mGSTA4 (PDB: 1GUK).
[16]
To become catalytically active the GST monomers form non-covalently
bound homodimers. The active sites of each monomer lie at either end of a
solvent-accessible cleft, as demonstrated in Figure 3. The distance between the active
sites and the environment in the cleft vary between the GST classes.
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Figure 3: A) structure of hGSTM1-1 (PDB: 1XWK) with glutathione-conjugated xenobiotic
bound in each active site.
[17]
The grey and orange structures display the two monomer units.
The green compound is glutathione and the red compound is the xenobiotic, B) the same
structure illustrating the G-site in green and the H-site in red. The solvent-accessible cleft
between the two monomer active sites can clearly be seen. This figure was generated using
PyMOL by Anne Caniard.
[15]
GST activity is determined by measuring the rate of the conjugation of
glutathione to a universal substrate 1-chloro-2, 4-dinitrobenzene (CDNB), a substrate
known to bind to all GST isoforms.[7] The reaction proceeds via an SNAr
mechanism, forming an intermediate Meisenheimer complex, to yield the
glutathione-conjugated product, S-(2,4-dinitrophenyl)glutathione (DNP GSH) as
demonstrated in Scheme 1.[18] DNP GSH absorbs at 340 nm, allowing the rate of
product formation to be monitored using visible spectroscopy.




A secondary role for GSTs appears to be the cellular uptake and distribution
of large lipophilic molecules. These compounds, which include porphyrins, steroids
and fatty acids, typically contain large planar aromatic regions, often with anionic
functional groups. Such ligands are characterized by their display of
non-competitive inhibition of glutathione conjugation.[2] The site where these
compounds bind to GST has been labelled the ligandin binding site. There is much
debate over the location of the ligandin site and there is some suggestion that the
location is variable between GST isoforms. Evidence suggests that in the GSTP1-1
isoform it is adjacent to the hydrophobic binding pocket and some overlap between
the two sites can occur.[19] A crystal structure of the drug praziquantel bound to
SjGST demonstrates that the ligand binds in the inter-subunit cleft of the protein, as
shown in Figure 4.[11]
Figure 4: Crystal structure of SjGST dimer in complex with praziquantel (PDB: 1GTB).
[11]
One monomer unit = orange, second monomer unit = grey, praziquantel = pink. Glutathione
binding site is highlighted by the catalytic tyrosine residues (displayed in blue). This figure
was generated using PyMOL by Anne Caniard.
[15]
GSTs have become important drug targets in cancer therapy in recent years
after the observation of GST overexpression in cancer cell lines and the direct
correlation this has with increased resistance to chemotherapeutic drugs.[20-22] The
resistance is thought to be the result of two different responses of GSTs. The first is
that GSTs can be responsible for the metabolism of cancer drugs and their excretion
from the tumour cells.[23] The second response is as a result of the interaction of
GSTs in the mitogen-activated protein (MAP) kinase pathway. GSTP1-1 has been
shown to bind to and inhibit c-Jun NH2-terminal kinase (JNK), which plays an
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important role in proapoptotic signaling within the MAP kinase pathway.[20-22, 24]
Under oxidative or chemical stress GSTP1-1 dissociates from JNK, which is then
activated leading to the induction of apoptosis. JNK activation is required for a
number of anticancer drugs to have maximal cytotoxicity. GSTM1-1 has also been
identified as playing a role in the MAP kinase pathway.[25-27] GSTM1-1 binds to
apoptosis signal-regulating kinase 1 (ASK1), which is a MAP kinase kinase kinase
that activates both the JNK and p38 signalling pathways leading to apoptosis. As
with the GSTP1-JNK complex, GSTM1-1 acts as an inhibitor of ASK1, which
dissociates in response to cell stress resulting in the activation of ASK1.
Helminth GSTs are also important drug targets in parasitic diseases, such as
malaria and schistosomiasis. Schistosomal GSTs are believed to be responsible for
resistance to praziquantel, the major drug used to treat schistosomiasis.[5]
A number of different approaches have been used to design inhibitors for
GSTs and these have been well reviewed.[22, 28] Modifications of the glutathione
tripeptide typically result in a reduction in binding affinity, biological instability as a
drug-like compound and, because of the highly conserved nature of the glutathione
binding pocket, a lack of GST isoform specificity. A more successful example of a
glutathione analogue is the compound with the addition of an α-phenyl glycine 
residue, 37 designed by Telik Technologies, which was highly potent (Ki = 0.12 M)
and demonstrated good selectivity for GSTP1-1.[29] A second approach utilizes more
hydrophobic inhibitors designed to bind in the hydrophobic pocket, an approach that
has been utilized previously in the Greaney group to design novel inhibitors of the
H-site using DCC.[30, 31] Due to the large size of this binding pocket, this approach
can also prove to be problematic in finding isoform specificity. Other approaches to
GST inhibitor design include ligandin-type inhibitors and the use of pro-drugs
designed to take advantage of the catalytic activity of the GST to realease the active
drugs. These approaches have been well reviewed in the literature.[22, 28]
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Figure 5: Literature examples of GST inhibitors.
In 2003, the Atkins group first reported a bivalent approach to the design of
novel GST inhibitors.[32] The use of multivalent inhibitors that bind to multiple
binding sites on the biological target has been shown to increase binding affinity by
several orders of magnitude over the original monovalent ligands.[33] This is achieved
by reducing the entropic price associated with ligand binding. The cost of
translational entropy and rotational entropy is the same for binding of either one
monovalent ligand or one bivalent ligand; therefore the entropic cost of binding two
monovalent ligands is double the cost of binding one bivalent ligand. Careful design
of a rigid linking group with an optimised spacing to match the ligands to the binding
sites minimises the cost of a reduction in conformational entropy of the linking
group. The necessity for optimised spacing also results in ligands with high
selectivity for a given target.
The Atkins group took advantage of the dimeric nature of GSTs with the
solvent-accessible channel between the active sites of each monomer unit to design
bivalent inhibitors. Their strategy was to link two molecules of a known GST
inhibitor with a spacer designed to bind in the solvent-accessible cleft. The first
reported bivalent inhibitors used either an analogue of DNP GSH, the product of the
glutathione conjugation of the universal substrate CDNB, or uniblue A, an analogue
of cibacron blue as the anchor fragments.[32] Cibacron blue is a dye known to bind to
the H-site/ligandin pocket of GST. A small library of compounds was made using
three spacers of increasing length and, in the example using the DNP GSH analogue,
the binding data showed isoform specificity between A1 and P1 based on spacer
length (Figure 6). The longest spacer in the library demonstrated a 10-fold increase
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in binding affinity for GSTP1-1 over the GSTA1-1 isoform. This ligand also
exhibited a 100-fold increase in inhibitory activity over the monovalent reference,
highlighting the beneficial use of a multivalent approach.
Figure 6: Design of bivalent ligands based on the glutathione-conjugated product of CDNB
and the inhibitory activity of the ligands against GSTA1-1 and GSTP1-1.
The bivalent ligands with terminal uniblue A groups showed little binding
affinity for the Alpha GST but excellent affinity for GSTP1-1 with a 70-fold
improvement in binding affinity for the best binding bivalent compound 39b over the
monomer uniblue A, Figure 7. At the time of the article, the best binding ligand was







































































Figure 7: Design of bivalent ligands based on Uniblue A, an analogue of the GST ligandin
site binding dye Cibacron Blue, and the inhibitory activity of the ligands against GSTA1-1
and GSTP1-1.
The Atkins group later went on to report further bivalent inhibitors of GST
using ethacrynic acid as the anchor ligand.[34, 35] Ethacrynic acid is a non-specific
GST inhibitor that binds into the hydrophobic binding pocket. Isoform specificity
between GSTA1-1 and GSTP1-1 was achieved, firstly, by varying the length of the
spacer and secondly, by using a peptidic spacer to exploit the differences in the
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environment of the solvent-accessible cleft. In the first case, as demonstrated in
Figure 8A, the shorter spacer length favoured binding to GSTA1-1 but increasing the
length of the spacer improved the binding to GSTP1-1.[34] In the second case a
combinatorial library of peptide spacers was synthesized based on the design of 41 in
Figure 8B. Negatively charged or phenyl side groups on the spacer resulted in much
greater selectivity towards GSTA1-1, while hydrophobic groups showed an
improved affinity towards the GSTP1-1 isoform.[35] The spacer length resulted in
dramatic changes in binding affinity between compounds with a 30-fold difference
observed between 40a and 40b for GSTP1-1. The changes in side chain residue











































n = 2 IC50 13.7 nM 1022 nM
n = 7 IC50 52.1 nM 31.0 nM
GSTA1-1 GSTP1-1
IC50 5000 nM 4000 nM
Kd ~ 6000 nM 3300 nM
GSTA1-1 GSTP1-1
R1 = Phe, R2 = Asp Kd 9 nM 860 nM







Figure 8: Bivalent ligands of GST based on an ethacrynic acid anchor fragment.
A) Changes in binding affinity for GSTA1-1 and GSTP1-1 by varying spacer length.
B) Changes in binding affinity for GSTA1-1 and GSTP1-1 by varying the side chains of the
spacer.
The anchoring fragments at the terminus of each spacer, the differences in the
spacer length and, perhaps to a lesser extent, the environment of the
solvent-accessible cleft between GST isoforms clearly offer great potential to
develop novel isoform specific GST inhibitors. The design of the ligands, with two
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building blocks connected by a central spacer unit, offers an excellent opportunity to
utilise TGS techniques to investigate these three areas.
2.2 Design and synthesis of initial dynamic combinatorial
library
The reversible reaction that was chosen to create the linkage between the
H-site anchoring fragments and the spacer unit was the formation of acylhydrazones
from a hydrazide and an aldehyde species. The aniline-catalyzed acylhydrazone
reaction is a novel tool for biologically-templated DCC developed within the
Greaney group.[31] As described in the introduction, the use of aniline as a catalyst
allows equilibrium to be reached rapidly at pH 6 - 8, a pH window making the
reaction suitable for use with biological agents. The Greaney group developed a DCL
focusing on an aldehyde fragment based on DNP GSH (Figure 9B). This aldehyde
fragment (ALD01) is similar to the DNP GSH-based fragments used in the first
bivalent GST inhibitors described by Atkins 38 (Figure 9A).[32] Replacing the ester
link used in these inhibitors with an acylhydrazone group leads to a bivalent spacer
design synthesised from a library of bishydrazide spacers and the DNP GSH
analogue ALD01, as demonstrated in Figure 9C.
Figure 9: A) Literature example of bivalent ligand based on DNP GSH anchor.
[32]
B) DCL
designed in the Greaney group based on DNP GSH anchor fragment.
[31]
C) Proposed




Bishydrazide spacers were designed based on both the alkyl and peptidic
spacers used by Atkins.[32, 34, 35] The hydrazide functionality could be easily added to
the spacers via the condensation of hydrazine onto ester groups. With this in mind,








































































































Figure 10: Design of hydrazide spacer library and the esters from which they will be
synthesized.
The synthesis of hydrazide (HZD) spacers HZD02 to HZD04 is outlined in
Scheme 2. For HZD02, only one step was required, the hydrazine condensation onto
the commercially available ester dimethylisophthalate 42. Two steps were required
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for the synthesis of HZD03 and HZD04. The first step was the amide coupling of
alanine methyl ester 49 with the core dicarboxylic acid moiety 47 and 48. This was
followed by the condensation of hydrazine onto the ester group to yield the desired
bisacylhydrazide spacers.
Scheme 2: Synthesis of hydrazide spacer library: a; hydrazine hydrate (6 eq.) and methanol,
rt, overnight, b; alanine methyl ester (2 eq.), EDC.HCl (2.4 eq.), DMAP (0.4 eq.) and
chloroform, rt, overnight.
For the alkyl spacers, HZD01 was commercially available. The reaction to
yield HZD05 and HZD06 was again the straight forward hydrazine condensation on
to the ester group. The white solid products, however, were insoluble in most
common solvents. The solids were insoluble in water, DMSO and ethanol which
were the solvents that would be used in the DCC experiments. Because of this, these
two hydrazide spacers were abandoned.
2.2.1 Optimisation and identification of the initial dynamic
combinatorial library
The initial dynamic combinatorial library DCL01 took a mixture of four
hydrazide spacers, HZD01-04 with one aldehyde, ALD01 to yield a four member
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acylhydrazone library, as demonstrated in Figure 11. The acylhydrazone (HZN)
products have been labelled in the format HZNYY-XX-YY, where XX represents
the code for the hydrazide spacer and YY represents the code for the aldehyde at
each terminal position. As DCL01 only contains one aldehyde ALD01 in the
reaction mixture, the label takes the format HZN01-XX-01.
Figure 11: DCL01 – library set up between aldehyde ALD01 and hydrazide spacers
HZD01-HZD04.
The library was set up and monitored over several hours to determine when
equilibrium was reached. Figure 12 indicates that the equilibrium was reached within
8 hours in the presence of 5 mM aniline.
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Figure 12: HPLC trace showing the distribution of acylhydrazone products over time to
establish when equilibrium is reached. Experimental conditions: HZD01 to HZD04 (final
conc. = 60 M each, DMSO), ALD01 (60 M, water), aniline (5 mM, DMSO), DMSO (15 %
by vol.) and ammonium acetate buffer (1.3 mL, 100 mM, pH 6.4) mixed at room temperature.
10 L of sample injected directly onto HPLC column at several time points. Products
detected by UV at λ = 254 nm. HPLC gradient A (see chapter 5, section 5.2.1).
Peak 1 = HZN01-01-01, 2 = HZN01-04-01, 3 = HZN01-03-01, 4 = HZN01-02-01.
The order of elution was established in three ways. Firstly individual
mixtures were set up using one hydrazide with one aldehyde, as shown in Figure 13.
Secondly samples of the acylhydrazone products that were prepared and isolated in
the lab were run under the same chromatography conditions, see Appendix Figure 1.
Finally the mixture was run through LC/MS with the mass of the four product peaks
detected in selected ion monitoring (SIM) mode, see Appendix Figures 2-5.
1 2 3 4
Chapter 2
54
Figure 13: HPLC traces showing references to determine the products in the equilibrium
based on individual reactions between ALD01 and one hydrazide spacer. A) Full library of
ALD01 and HZD01 to HZD04, B) reaction between ALD01 and HZD01, C) reaction between
ALD01 and HZD02, D) reaction between ALD01 and HZD03. E) reaction between ALD01
and HZD04. Products are detected by UV detecting at λ = 254 nm. HPLC gradient A (see




The conditions of the DCL, in particular the optimum concentration of
aniline, were established previously in the lab.[31] In order to confirm that DCL01
was dynamic, the DCL was set up starting from one of the acylhydrazones
HZN01-04-01 and the other three hydrazide spacers HZD01 to HZD03. No free
aldehyde was added to the reaction mixture. If the DCL was truly dynamic, the same
product distribution should still be reached. Several days were needed to reach the
final equilibrium compared with the several hours it takes to reach equilibrium
starting with aldehyde and hydrazide. The peak corresponding to the starting
acylhydrazone HZN01-04-01 decreases over time, as shown in Figure 14 and after
ten days the formation of HZN01-01-01, HZN01-02-01 and HZN01-03-01 could be
clearly identified, however the final equilibrium had still not been achieved. A
possible explanation for this observation is described later in the chapter.
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Figure 14: HPLC traces showing time course data for DCL library starting from
HZN01-04-01 (peak 2) and HZD01, HZD02 and HZD03. A) Day 4, B) Day 6, C) Day 10.
Experimental conditions: HZD01 to HZD03 (final conc. = 60 M each, DMSO), HZD01-04-01
(60 M, water), aniline (5 mM, DMSO), DMSO (15 % by vol.) and ammonium acetate buffer
(1.3 mL, 100 mM, pH 6.4) mixed at room temperature. 10 L of sample injected directly onto
HPLC column at several time points. Products detected by UV at λ = 254 nm. HPLC gradient
A (see chapter 5, section 5.2.1). Peak 1 = HZN01-01-01, 2 = HZN01-04-01,
3 = HZN01-03-01, 4 = HZN01-02-01.
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With the equilibrium established and the products identified, the DCL was set
up in the presence of the biological template GST, using the isoform mGSTM1-1.
This was added both at the initial mixing of the library components and also after the
equilibrium was reached. Conditions were again chosen based on previous work in
the lab.[31] It was shown in this work that GST would remain active under the DCL
conditions and could tolerate 15 % by volume of DMSO and 5 mM aniline.
Figure 15: HPLC traces showing DCL01 in the absence and presence of the biological
template. Experimental conditions: HZD01 to HZD04 (final conc. = 60 M each, DMSO),
ALD01 (60 M, water), aniline (5 mM, DMSO), DMSO (15 % by vol.) and ammonium acetate
buffer (255 L, 100 mM, pH 6.4) mixed at room temperature. After 48 h, 10 L of sample
injected directly onto HPLC column. A) Blank equilibrium, B) mGSTM1-1 (final
conc. = 20 M) added initially, C) mGSTM1-1 (final conc. = 20 M) added at equilibrium.
Products detected by UV at λ = 254 nm. HPLC gradient A (see chapter 5, section 5.2.1).
Peak 1 = HZN01-01-01, 2 = HZN01-04-01, 3 = HZN01-03-01, 4 = HZN01-02-01.
In the presence of the biological template mGSTM1-1, a clear amplification
was observed over the background equilibrium, Figure 15. Comparison of the
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GST-templated reaction with the blank equilibrium showed a 2000 % increase in the
amplification of HZN01-03-01. A smaller amplification was also observed for
HZN01-04-01. The same amplification was observed whether the GST was added
initially or after the blank equilibrium had been reached, although it took a longer
time for the reaction to re-equilibrate in the latter case. The fact that the same final
equilibrium could be reached regardless of when the protein was added was further
proof that the library was dynamic. The same amplifications were observed when the
reaction was monitored using LC/MS in SIM mode detecting for bis acylhydrazone
product mass, see Appendix Figure 6.
2.2.2 Isoform specificity in the initial dynamic combinatorial
library
With the conditions for the protein-templated DCL established, four different




Figure 16: HPLC traces showing four hydrazide with one aldehyde DCL in presence of GST
isoforms. Experimental conditions: HZD01 to HZD04 (final conc. = 60 M each, DMSO),
ALD01 (60 M, water), aniline (5 mM, DMSO), DMSO (15 % by vol.) and ammonium acetate
buffer (255 L, 100 mM, pH 6.4) mixed at room temperature. After 48 h, 10 L of sample
injected directly onto HPLC column. A) blank equilibrium, B) mGSTM1-1 (final
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conc. = 20 M), C) hGSTP1-1 (final conc. = 20 M), D) SjGST (final conc. = 20 M),
E) mGSTA4-4 (final conc. = 20 M). Products detected by UV at λ = 254 nm. HPLC gradient
A (see chapter 5, section 5.2.1). Peak 1 = HZN01-01-01, 2 = HZN01-04-01, 3 = HZN01-03-

















blank mGSTM1-1 SjGST mGSTA4-4
Figure 17: Graphical representation of hydrazone product distribution in the presence of
different GST isoforms. Error bars represent standard deviation from two experiments.
The amplifications observed in the presence of SjGST followed the same
pattern as for mGSTM1-1 with acylhydrazone HZN01-03-01 giving the largest
amplification, although the amplification was less than in the presence of
mGSTM1-1. When mGSTA4-4 was added there appeared to be little observed
change to the equilibrium. The only significant amplification over the blank
equilibrium was for HZN01-02-01, but this was a much smaller amplification than
those observed with mGSTM1-1 and SjGST. The addition of hGSTP1-1 appeared to
disrupt the equilibrium without amplifying any of the bis acylhydrazone product
peaks. The baseline became much less well defined suggesting that it was actually
the monoacylhydrazone products that were favoured by the enzyme. The disruption
to the baseline made it very difficult to accurately measure the bis acylhydrazone
peak area, so no comparison with the blank equilibrium could be made. The
monoacylhydrazone products proved very difficult to observe under HPLC
conditions as they were often seen as broad peaks. The peaks marked with * on
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Figure 18 show the monoacylhydrazone peaks. Figure 18 also shows the appearance
of several new peaks marked with **. These peaks could not be identified as
anything in the reaction mixture and could indicate that the acylhydrazone spacers
were decomposing. It is unclear how the hGSTP1-1 could have done this. To further
investigate, these samples were run on LC/MS. Samples were monitored for the four
monoacylhydrazone mass peaks and also the four bis acylhydrazone peaks in SIM
mode, see Appendix Figure 7. This data confirmed that the monoacylhydrazones
were being amplified to a greater extent than any of the bis acylhydrazones by
hGSTP1-1 suggesting that the 3D structure of the spacer did not lie in the correct
orientation to bridge the space between the two active sites of the dimer. The new
peaks observed in the HPLC trace of the hGSTP1-1-templated DCL could not be
identified in the full mass scan of the same mixture as the DMSO masked the rest of
the spectrum.
Figure 18: HPLC trace of A) non-templated equilibrium of DCL01 and B) hGSTP1-1
templated DCL01. Products detected by UV at λ = 254 nm. HPLC gradient A (see chapter 5,
section 5.2.1). Peak 1 = HZN01-01-01, 2 = HZN01-04-01, 3 = HZN01-03-01,
4 = HZN01-02-01. * = monohydrazone, ** = unknown peak.
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2.2.3 Synthesis of DCL01 products
The four bis acylhydrazone products were synthesised by the reaction of
aldehyde ALD01 with hydrazide spacer HZD01 to HZD04 under acidic conditions.
The reaction was very straightforward, with the yellow product precipitating from
the solution. Characterisation of the products proved to be much more challenging.
The products were run through LC/MS which showed that they were pure and had
the expected mass for the bis acylhydrazone. The products were confirmed by high
resolution mass spectrometry as NMR data could not always be fully determined due
to problems with solubility of the acylhydrazones.
Scheme 3: Synthesis of acylhydrazone products from DCL01. a; glacial acetic acid (few
drops), water, rt, 30 min.
2.2.4 Binding data for DCL01 products
To confirm that the amplifications observed corresponded to the best




Table 1: Table of IC50 data of DCL01 products with different GST isoforms measured using















01-01-01 1.207 126.5 3.471  100
01-02-01 0.337 11.81 0.252  100
01-03-01 0.050 13.45 0.989  100
01-04-01 0.413 0.356 1.800  100
Aldehyde 01 341.7  500 265.6  500
Hydrazide 03  500  500 - -
The data correlated well with the amplifications observed in the DCL. In the
case of mGSTM1-1, the product with the greatest amplification was HZN01-03-01
and this gave almost 10-fold greater inhibition of GST activity over the other
acylhydrazone products. Gratifyingly, excellent isoform specificity was observed for
HZN01-03-01 for mGSTM1-1. HZN01-03-01 for mGSTM1-1 gave approximately
twenty-fold greater inhibitory activity over SjGST and 270-fold greater inhibitory
activity over hGSTP1-1. Interestingly, HZN01-04-01 also showed some
amplification in the DCL, however it appeared to have no greater inhibition of the
enzyme than HZN01-02-01. Additionally, when looking at the data for SjGST, the
inhibition data suggested that HZN01-02-01 was the best inhibitor, however in the
DCL the longer spacers HZN01-03-01 and HZN01-04-01 had a greater
amplification. The best IC50 value for hGSTP1-1 was for HZN01-04-01 with a value
similar to that for mGSTM1-1. The fact that HZN01-04-01 was the longest of the
spacers and only a small amplification of this product could be observed in the
HPLC trace might suggest that the spacers being used in the library were not long
enough to span the two active sites in hGSTP1-1. The bivalent spacers described by
the Atkins group provide further evidence that spacers of a longer length display
greater binding affinity for hGSTP1-1.[32, 34] This would explain why the mono
acylhydrazones were favoured, as the second aldehyde might not fit well into the
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solvent accessible cleft. For all GST isoforms there was a large increase in inhibitory
activity when the two units of the aldehyde ALD01 were connected by a spacer,
regardless of the length or shape of the spacer compared to the single aldehyde unit.
The inhibition data for mGSTA4-4 shows that the acylhydrazone products had little
effect on the enzyme activity, explaining the minimal effect the enzyme had on the
equilibrium of the DCL. This made the mGSTA4-4 isoform an excellent negative
control, showing that the change in the distribution of acylhydrazone products was
due to a specific binding site within the mGSTM1-1 isoform and not due to any
non-specific effects from the introduction of the hydrophobic protein to the DCL.
2.2.5 Controls for protein-templated DCL01
As the most successful of the isoforms used, further controls were set up to
confirm the amplification observed with mGSTM1-1. In the presence of bovine
serum albumin (BSA) a protein without the binding pockets found in GSTs, no
amplification was observed, Figure 19B.
Figure 19: HPLC traces of DCL01 in the presence of control protein BSA. Experimental
conditions: HZD01 to HZD04 (final conc. = 60 M each, DMSO), ALD01 (60 M, water),
aniline (5 mM, DMSO), DMSO (15 % by vol.) and ammonium acetate buffer (255 L,
100 mM, pH 6.4) mixed at room temperature. After 48 h, 10 L of sample injected directly
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onto HPLC column. A) blank equilibrium, B) BSA (final conc. = 20 M), C) mGSTM1-1 (final
conc. = 20 M). Products detected by UV at λ = 254 nm. HPLC gradient A (see chapter 5,
section 5.2.1). Peak 1 = HZN01-01-01, 2 = HZN01-04-01, 3 = HZN01-03-01,
4 = HZN01-02-01.
To determine where exactly in the binding pocket of mGSTM1-1 the
acylhydrazone product was binding, the DCLs were set up in the presence of a
variety of known GST inhibitors which bind in different areas of the hydrophobic
binding pocket.
Figure 20: Known inhibitors and substrates of GST used to block the binding pocket in
DCL01.
Benzyl isothiocyanate (BITC) binds in the H-site of GSTs and is also known
to covalently modify the active site. It has a different, distinct binding site to the
substrate CDNB.[36] Sulfasalazine also binds in the H-site and is a competitive
inhibitor of CDNB.[19] The crystal structure of sulfasalzine bound to hGSTP1-1 also
shows that the pyridinyl ring binds in a shallow pocket on the surface of the protein.
Ethacrynic acid is a non-specific inhibitor of GSTs, which binds in the H-site. There
is evidence that ethacrynic acid can bind in more than one orientation in the binding
pocket.[37, 38] The final two compounds selected were the universal substrate, CDNB
and the glutathione-conjugated product of CDNB, DNP GSH. DNP GSH is believed
to bind in a different position to CDNB within the H-pocket.[19] Cibacron blue, a dye,
which also binds to the ligandin site of GSTs,[19] was found to disrupt the background

































no inhibitor BITC Sulfasalazine Ethacrynic Acid DNP GSH CDNB
Figure 21: Graphical representation of the effect on DCL01 of added inhibitors of GST. Bars
represent the % difference in the peak area over the blank equilibrium. Error bars represent
standard deviation from two experiments. The data for the reaction with the addition of
CDNB is the result of only one experiment.
Although none of the inhibitors completely reduced the amplification, the
best effects were seen with DNP GSH. Adding increasing amounts of DNP GSH
showed a dose-dependent response on the reduction of the amplification.
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Figure 22: HPLC traces of DCL01 in the presence of increasing concentrations of GST
conjugation product DNP GSH. Experimental conditions: HZD01 to HZD04 (final
conc. = 60 M each, DMSO), ALD01 (60 M, water), aniline (5 mM, DMSO), DMSO (15 %
by vol.) and ammonium acetate buffer (255 L, 100 mM, pH 6.4) mixed at room temperature.
After 48 h, 10 L of sample injected directly onto HPLC column. A) blank equilibrium,
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B) mGSTM1-1 (final conc. = 20 M), C) mGSTM1-1 (final conc. = 20 M) + 200 M DNP
GSH, D) mGSTM1-1 (final conc. = 20 M) + 400 M DNP GSH, E) mGSTM1-1 (final
conc. = 20 M) + 600 M DNP GSH. Products are detected by UV at λ = 254 nm. HPLC
gradient A (see chapter 5, section 5.2.1). Peak 1 = HZN01-01-01, 2 = HZN01-04-01,

















blank mGSTM1-1 200 uM DNP GSH
400 uM DNP GSH 600 uM DNP GSH
Figure 23: Graphical representation of the effect on DCL01 of increasing concentrations of
GSDNB. Error bars represent standard deviation from two experiments.
The result of using these inhibitors suggested that the acylhydrazone products
were binding in the active site of the GST. There must be a very specific binding
orientation for the bivalent acylhydrazones within the H-site as the addition of
CDNB, sulfasalazine or ethacrynic acid did not prevent amplification of the DCL.
The H-site is a very large, promiscuous pocket. Work studying the binding of CDNB
during the conjugation reaction has shown that in the transition state the phenyl ring
of CDNB binds with two ring stacking interactions in the H-site from the side-chains
of Phe8 and Tyr108. This is known as the “in” binding mode. When glutathione is
conjugated to CDNB the phenyl ring undergoes a twist and loses one of these
interactions, leaving just the interaction with Tyr108. The phenyl ring is then
positioned along the edge of the hydrophobic pocket in the “out” binding mode. This
change in binding mode has been observed for both the rat and human form of
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GSTM1-1 and the human form of GSTP1-1 and is demonstrated for the hGSTM1-1
isoform in Figure 24.[17, 19, 39, 40]
Figure 24: Overlay of the crystal structures of hGSTM1-1 with the transition state analogue
1-(S-glutathionyl)-2,4,6-trinitrocyclohexadienate anion (Yellow, PDB: 2F3M) and with the
conjugate product DNP GSH (Red, PDB: 1XWK). Figure taken from Patskovsky et al.
[17]
The
twist of the phenyl ring is highlighted with an arrow.
The bivalent acylhydrazone compounds appear to be binding in the “out”
mode, as it was only DNP GSH that reduced amplification in the DCL. The results
from the DCL suggest that there is space within the H-site for a new molecule of
CDNB to bind before the conjugated product leaves the enzyme, as CDNB does not
block the amplification in the DCL. There is some precedence for inhibitors binding
in the H-site, without being competitive inhibitors of CDNB.[19, 28, 41]
2.2.6 Further binding studies for DCL01 products - competition
assay and isothermal titration calorimetry
A competition assay between CDNB and the three best binding
acylhydrazones HZN01-02-01, HZN01-03-01 and HZN01-04-01 was set up and the
results showed that the acylhydrazones were noncompetitive partial inhibitors of
CDNB, Figure 25. This result provided further evidence that the acylhydrazone




Figure 25: Michaelis-Menten plot and Lineweaver-Burk plot for HZN01-03-01 with
mGSTM1-1. Data best fit to noncompetitive (partial) equation. Standard error as a result of 3
repeat experiments.
Isothermal titration calorimetry (ITC) was used to determine the binding
stoichiometry of the best acylhydrazone HZN01-03-01, as shown in Figure 26. The
results gave a binding stoichiometry of 0.4 with respect to the GSTM1 monomer
concentration, confirming that the spacer was binding across the dimer GST.
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Figure 26: ITC data for HZN01-03-01 with mGSTM1-1. Top panels show the heat effects
associated with the injection of ligand into the cell containing GST. Bottom panels show the
binding isotherm, generated from the integrated heats in the top panel, and the best fitted
curves.
In an interesting aside, the ITC data also showed that the dilution of ligand
into buffer was an endothermic process. This indicated that there was a degree of
hydrogen bonding between the acylhydrazone ligands, which was disrupted upon
dilution. This did not seem to affect the inhibition capability of the ligand. An
overlay of the trace for ligand into buffer over ligand into protein clearly showed that
the endothermic reaction of the ligand dilution was a separate event to ligand binding
to protein, Figure 27. When the energy changes associated with the ligand binding to

















changes associated with the ligand dilution. This phenomenon was also observed for
the bivalent compounds with glutathione at the terminal described by the Atkins
group.[32]
Figure 27: Overlay of the raw transpose from the ITC data for HZN01-03-01 with
mGSTM1-1 showing the heat effects associated with the injection of ligand into buffer and
the heat effects associated with the injection of ligand into GST (labelled).
The Cheng-Prusoff equation, Equation 1, describes the relationship between
the inhibition constant, (Ki) and the IC50 value for a substrate.
[42]
Ki = IC50
1 + ([S] / KM)
Equation 1: Cheng-Prusoff equation. [S] = concentration of substrate.
According to the Cheng-Prusoff equation, in the case of noncompetitive
inhibitors, IC50 = Ki.
[42] The data for HZN01-03-01 and HZN01-04-01 in Table 2 fit
this equation, confirming the observation that the acylhydrazone compounds were





Table 2: Binding data for the products of DCL01 with mGSTM1-1. Standard error shown for
Ki data taken from 3 replicates.
Acylhydrazone IC50 (nM) Ki (nM) Kd (nM)
01-01-01 1207 - -
01-02-01 337 646  80.7 525
01-03-01 50 61  4.1 107
01-04-01 413 634  23.8 -
2.3 Problems with HZN01-02-01
Perhaps the most surprising result was the binding data for the shortest
acylhydrazone HZN01-02-01. This spacer should not be long enough to span the
distance between the two active sites within the GST dimer, yet the IC50 value was
very favourable when compared with other monovalent GST inhibitors based on a
glutathione conjugated aromatic scaffold. A DCL has previously been set up in the
Greaney lab, based on ALD01 with a library of aromatic hydrazides designed to
explore the hydrophobic binding pocket.[31] The best of the compounds from the
library 4 and 5 had IC50 values of 22 M for SjGST and 57 M for hGSTP1-1
respectively, as shown in Figure 28. This is a five-fold reduction in inhibition for
hGSTP1-1 and a ten-fold reduction for SjGST when compared to bivalent inhibitor
HZN01-02-01. In the case of mGSTM1-1 the compounds in the library showed little
inhibitory effect with the IC50 for all compounds being greater than 100 M. The
monovalent acylhydrazones were competitive inhibitors of CDNB, however the bis
acylhydrazone HZN01-02-01 was a noncompetitive inhibitor of CDNB. Molecular
docking studies of the monovalent compounds suggest that they bind into the
hydrophobic pocket, explaining why they are competitive inhibitors. The fact that
HZN01-02-01 was noncompetitive indicated that the compound was pointing out




Figure 28: Comparison of binding data for competitive mono acylhydrazone GST inhibitors 4
and 5 and bis acylhydrazone HZN01-02-01 for three GST isoforms.
ITC was used to determine whether, due to the short spacer length, two
molecules were in fact binding to the GST dimer; one in each active site, with the
rest of the molecule found in the solvent accessible cleft.
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Figure 29: ITC data for HZN01-02-01 with mGSTM1-1. Top panels show the heat effects
associated with the injection of ligand into the cell containing GST. Bottom panels show the
binding isotherm, generated from the integrated heats in the top panel, and the best fitted
curves.
The stoichiometry of binding with respect to the monomer gave a value of
0.7, Figure 29. This did not give a clear indication of how the compound was binding
to GST. The ITC data again showed that the mixing of the ligand into buffer was an
endothermic process. A greater energy change was observed with this process than
when HZN01-03-01 was diluted. An interesting observation for HZN01-02-01 and
also HZN01-01-01 at high concentrations in DMSO was that a gel formed. It seems

















glutathione species, causing the formation of a polymeric species. This happened
much more readily in the case of the flexible linear spacer HZN01-01-01 and the
short rigid spacer HZN01-02-01. In the same compounds without glutathione present
at the terminal, gels no longer formed. This observation could explain some of the
anomalous results associated with HZN01-02-01. This could explain why the
binding data for HZN01-02-01 did not always complement the amplifications
observed in the protein-templated DCL. It also explains why it took a longer time
period for the DCL to re-equilibrate when one or more of the acylhydrazone products
were present from the beginning.
In the ITC data for HZN01-02-01, an extra endothermic event occurred once
the protein was saturated with ligand and the event cannot be explained by ligand
dilution into buffer. This can be seen at a molar ratio of approximately 1.5 in Figure
29 or at approximately 50 minutes in Figure 30. An explanation for this observation
is yet to be established.
Figure 30: Overlay of the raw transpose from the ITC data for HZN01-02-01 with
mGSTM1-1. Green trace shows the heat effects associated with the injection of ligand into
buffer. Blue line shows the heat effects associated with the injection of ligand into GST.




2.4 Increasing complexity within the dynamic combinatorial
library
With the initial DCL set up and best inhibitor identified, the complexity of
the library was increased. As the design of the library was based on bivalent spacers,
with two reactive hydrazide groups per molecule, the introduction of multiple
aldehydes to the group would greatly increase the complexity of the library with the
possible formation of both homo-spacers and hetero-spacers. The addition of one
more aldehyde to the initial library would increase the number of bis acylhydrazone
products from four to twelve. The addition of a third aldehyde would increase the
number of bis acylhydrazone products to twentyfour from only seven starting
fragments. A second dynamic combinatorial library DCL02 was set up using the
same four hydrazide spacers with three aldehydes. The aldehyde analogue of CDNB
ALD02, with a chlorine para to the aldehyde and the aldehyde ALD03 with only the
meta nitro group present and hydrogen in the para position were added to ALD01.
These aldehydes were selected to study the binding effect of the glutathione species
on the anchoring fragment. Again, the acylhydrazone products have been labelled in
the format HZN(YY)1-XX-(YY)2, where XX represents the code for the hydrazide
spacer and YY represents the code for the aldehyde at each terminal position. For
example the product resulting from the reaction of hydrazide HZD02 with ALD01 at
one end and ALD03 at the other end would be labelled HZN01-02-03.
Figure 31: DCL02 with an increased aldehyde library.
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The new library was set up under the same conditions as the previous
DCL01. The introduction of the two more hydrophobic aldehydes ALD02 and
ALD03 led to insoluble acylhydrazone products. The concentrations of the library
members had to be reduced to overcome these solubility issues. Furthermore with the
added complexity in the DCL, better chromatographic separation was required. The
use of a second column on the HPLC led to much better separation.
Figure 32: HPLC trace for DCL02. Peak numbers 1-21 are described in Table 3.
Experimental conditions: HZD01 to HZD04 (final conc. = 80 M each, DMSO), ALD01
(80 M, water), ALD02 and ALD03 (final conc. = 80 M each, DMSO) aniline (5 mM,
DMSO), DMSO (15 % by vol.) and ammonium acetate buffer (255 L, 100 mM, pH 6.4)
mixed at room temperature. After 48 h, 10 L of sample injected directly onto HPLC column.
Products are detected by UV at λ = 254 nm. HPLC gradient A (see chapter 5, section 5.2.1).
The peaks in DCL02, Figure 32, were identified by a deconvolution of the
library, using mixtures of one hydrazide with one, two or three aldehydes and one
aldehyde with one, two, three or four hydrazides. The HPLC traces can be seen in the
Appendix, Section 6.1.2, Figures 8-13. The peaks have been described in Table 3.























































2.4.1 Exploring isoform specificity with DCL02
The background library was set up along with mixtures containing one each
of the four GST isoforms.
Chapter 2
82
Figure 33: HPLC traces of DCL02 reaction of HZD01-HZD04 with ALD01-AL03 in the
presence of different GST isoforms. Experimental conditions: HZD01 to HZD04 (final
conc. = 80 M each, DMSO), ALD01 (80 M, water), ALD02 and ALD03 (final
conc. = 80 M each, DMSO) aniline (5 mM, DMSO), DMSO (15 % by vol.) and ammonium
acetate buffer (255 L mL, 100 mM, pH 6.4) mixed at room temperature. After 48 h, 10 L of
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sample injected directly onto HPLC column. A) blank equilibrium, B) mGSTM1-1 (final
conc. = 20 M), C) hGSTP1-1 (final conc. = 20 M), D) SjGST (final conc. = 20 M),
E) mGSTA4-4 (final conc. = 20 M). Peak numbers 1-21 are described in Table 3. Products






























Figure 34: Graphical representation of DCL02 in the presence of different GST isoforms.
Bars represent % difference of peak area over blank equilibrium. Peak numbers 1-21 are
described in Table 3. Error bars represent standard deviation over two experiments.
Again the peak showing the largest amplification was the acylhydrazone
HZN01-03-01. Several smaller amplifications were also observed corresponding to
acylhydrazones containing the hydrazide spacer HZD02, the shortest of the spacers.
For the SjGST isoform several peaks were amplified to a similar extent over the
blank equilibrium. With the exception of HZN01-03-01, all of the other
amplifications were due to acylhydrazones containing the hydrazide spacer HZD02.
As with the smaller DCL library DCL01, adding hGSTP1-1 resulted in the
destruction of the products containing both terminal units from ALD01. The other
components in the library appeared to remain unaffected by the presence of
hGSTP1-1, with no change in the equilibrium observed. The only amplifications
observed in the presence of mGSTA4-4 were for acylhydrazones containing the
hydrazide spacer HZD02, the shortest of the hydrazide spacers.
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2.4.2 Control experiments for DCL02
Control experiments were again set up to confirm that the amplifications that
were observed were due to a templative effect from the GST active site. The addition
of bovine serum albumin had little effect on the equilibrium of the DCL, Figure 35.
Figure 35: HPLC traces of DCL02 in the presence of control protein BSA. Experimental
conditions: HZD01 to HZD04 (final conc. = 80 M each, DMSO), ALD01 (80 M, water),
ALD02 and ALD03 (final conc. = 80 M each, DMSO) aniline (5 mM, DMSO), DMSO (15 %
by vol.) and ammonium acetate buffer (255 L, 100 mM, pH 6.4) mixed at room temperature.
After 48 h, 10 L of sample injected directly onto HPLC column. A) blank equilibrium,
B) BSA (final conc. = 20 M), C) mGSTM1-1 (final conc. = 20 M). Products are detected by
UV at λ = 254 nm. HPLC gradient A (see chapter 5, section 5.2.1).
The glutathione-conjugated CDNB substrate, DNP GSH was again used to
block the binding pocket, to prevent amplification of the DCL.
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Figure 36: HPLC traces of DCL02 in the presence of increasing concentrations of DNP
GSH. Experimental conditions: HZD01 to HZD04 (final conc. = 80 M each, DMSO), ALD01
(80 M, water), ALD02 and ALD03 (final conc. = 80 M each, DMSO) aniline (5 mM,
DMSO), DMSO (15 % by vol.) and ammonium acetate buffer (255 L, 100 mM, pH 6.4)
mixed at room temperature. After 48 h, 10 L of sample injected directly onto HPLC column.
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A) blank equilibrium, B) mGSTM1-1 (final conc. = 20 M) + 0 M DNP GSH, C) mGSTM1-1
(final conc. = 20 M) + 200 M DNP GSH, D) mGSTM1-1 (final conc. = 20 M) + 400 M
DNP GSH, E) mGSTM1-1 (final conc. = 20 M) + 600 M DNP GSH. Products are detected



























mGSTM1-1 200 uM DNP GSH 400 uM DNP GSH 600 uM DNP GSH
Figure 37: Graphical representation of DCL02 in the presence of increasing concentrations
of DNP GSH. Bars represent % difference of peak area over blank equilibrium. Peak
numbers 1-21 are described in Table 3. Error bars represent standard deviation over two
experiments.
The addition of DNP GSH to block the binding pocket produced a
dose-dependent decrease in the amplification of HZN01-03-01, peak number 3 and
HZN01-04-01, peak number 2. Surprisingly the amplification of peak numbers 11,
14, 17 and 21 corresponding to acylhydrazones not containing terminal glutathione
remained unaffected by the addition of DNP GSH. It could indicate that the
important interaction that was being blocked for the cases containing ALD01 was the
binding of the glutathione species. To see if those compounds not containing
glutathione were binding in a different location within the enzyme, other inhibitors,
such as ethacrynic acid and CDNB, were also added to the DCL. Unfortunately the
inhibitors eluted in the middle of the library of bis acylhydrazones making it very
difficult to compare the GST-templated library with the blank. As was seen in
DCL01, these inhibitors did not appear to prevent the amplifications observed in the
Chapter 2
87
protein-templated library for those products that were not masked in the HPLC trace,
suggesting that these compounds might not be binding in the H-site at all.
2.4.3 Synthesis and binding data for homodimers from DCL02
The homodimers made from ALD02 and ALD03 were synthesised using the
same chemistry as in the synthesis of HZN01-01-01 to HZN01-04-01, Scheme 4.
Scheme 4: Synthesis of homo acylhydrazone products from DCL02. a; glacial acetic acid
(few drops), water/ethanol 1:1, rt, 30 min.
The IC50 values for these compounds were determined using the CDNB
assay.[7] As shown in Table 4, the removal of glutathione from the products resulted
in a 100-fold decrease in inhibition for the longer spacers HZD03 and HZD04,
demonstrating the importance of glutathione for binding affinity. The loss of
glutathione for the shortest spacer HZD02 was much better tolerated, with only a
two-fold reduction in inhibition. This also suggests that these compounds were
binding in a different way to the longer spacers.
Table 4: IC50 data for homo acylhydrazone spacers with mGSTM1-1. Data acquired using















 -  500
HZD01 1.21 - -
HZD02 0.337 2.02 3.38
HZD03 0.050 9.32 106.4
HZD04 0.413 49.89  100
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HZN02-02-02, the most potent bivalent inhibitor without glutathione, was
run in the CDNB competition assay. This compound was also a noncompetitive
partial inhibitor with respect to CDNB. The Ki value was 1.98 M  0.47. This again
fit with the Cheng-Prusoff equation IC50 = Ki in the case of noncompetitive
inhibitors.[42]
2.5 Conclusion and future work
The possibilities of DCC have clearly been demonstrated with the
identification of a novel isoform specific bivalent inhibitor of mGSTM1-1. The
power of DCC has been shown, not only in its primary goal of identifying novel
inhibitors from weakly binding fragments, but also with the insight offered into the
mode of binding by the careful use of “inhibitors” to block the amplification of
library members. It has also been shown that DCC is capable of coping with the
increased complexity of bivalent inhibitors.
Bis acylhydrazone HZN01-03-01 has been identified as a novel inhibitor for
mGSTM1-1, with an IC50 value of 50 nM. The design of GST inhibitors described in
the literature has primarily focussed on ligands for the GSTP1-1 isoform because of
the associations between GSTP1-1 and cancer. The dye cibacron blue is the most
potent inhibitor of GSTM1-1 known to date and has an IC50 of 50 nM for the human
isoform and 700 nM for the mouse isoform, which is used in this study.[2] Bis
acylhydrazone HZN01-03-01 exhibits a 14-fold increase in inhibitory activity over
the best literature example, cibacron blue. HZN01-03-01 also shows excellent
isoform specificity for the Mu isoform of GST over several other isoforms studied, a
20-fold increase in inhibitory activity is observed for mGSTM1-1 over SjGST. The
best example of isoform specificity towards GSTM1-1 described in the literature is
from Kunze and Heps.[43] They report an analogue of glutathione with a phosphono
group replacing the cysteine side chain, which has an IC50 value of 4.7 M for
hGSTM1-1 and only a 3-fold increase in potency over hGSTP1-1 and hGSTA1-1.
The isoform selectivity demonstrated by the bis acylhydrazone HZN01-03-01
may be explained by looking at the 3D structural differences between the GST
isoforms, which have been described in detail in section 2.1. The Mu isoform
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contains a mu loop, which creates a deeper solvent-accessible cleft between the
binding pockets of each monomer unit.[8] This deeper cavity could present more
space for the acylhydrazone spacer to bind. The Alpha class contains an additional
alpha helix, which fits partially into the solvent-accessible cleft and makes the
hydrophobic pocket smaller.[9] This reduction in space could explain why the
acylhydrazone compounds had no inhibitory activity with mGSTA4-4. The Pi class
of GST does not contain the Mu loop or the extra alpha helix so the space available
lies somewhere between the Mu isoform and the Alpha isoform. The binding affinity
of the acylhydrazones for hGSTP1-1 was also between the Mu isoform and the
Alpha isoform (13.45 M for hGSTP1-1 compared with 50 nM for mGSTM1-1 and
> 100 M for mGSTA4-4 for HZN01-03-01), providing evidence that the available
space within the H-site and into the solvent-accessible cleft is playing an important
role in recognition for the acylhydrazones. The SjGST isoform most closely
resembles the Mu isoform and contains a shortened version of the Mu loop.[10-12] The
acylhydrazones also show reasonable, although reduced, inhibition for SjGST
compared with inhibition for mGSTM1-1. Several other factors may also play an
important role in the spacer selection, including the distance between binding
pockets and the polarity of the residues lining the solvent-accessible cleft. The
isoform specificity gained by using the bivalent spacers could be further probed by
increasing the size of the hydrazide library. The bivalent compounds described by the
Atkins group suggested that increasing spacer length resulted in an increase in
affinity for hGSTP1-1, so adding longer hydrazide spacers to the library may result
in the identification of hGSTP1-1 isoform specific ligands.[32, 34]
The careful selection of inhibitor compounds used to block the GST binding
pockets during the DCC reaction led to the conclusion that the bivalent
acylhydrazones were binding in the “out” mode within the hydrophobic binding
pocket. This was further confirmed by the observation that the bivalent compounds
were noncompetitive inhibitors with respect to CDNB. The presence of glutathione
at the terminal of each spacer was of particular importance for binding affinity for
the longer spacers HZN01-03-01 and HZN01-04-01. The glutathione was less
important for products made from HZD02. All products made from HZD02 with any
of the three aldehydes at the end gave amplifications in the GST-templated reaction.
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These results may indicate that these smaller compounds are binding in a different
location in the GST protein, perhaps in the solvent-accessible cleft as observed with
the binding of praziquantel to SjGST.[11] A possible way to determine this would be
to repeat the inhibitor-blocked DCC reactions using a larger library of ligands, such
as bromosulfophthalein or praziquantel that bind in the ligandin site or the
solvent-accessible cleft, and observing the effects on the library amplification. A
crystal structure of the bivalent ligand bound to GST would be most desirable to
confirm the binding mode of the acylhydrazones and particularly to confirm if those
products made from HZD02 are binding in a different way. Molecular modelling is
currently being employed, in collaboration with Iain McNae of the Walkinshaw
group, to determine the possible binding modes of the bivalent compounds within the
GST dimer.
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Chapter 3: An in situ click chemistry approach to
identify novel bivalent inhibitors of glutathione
transferases
3.1 Introduction
A second approach to target-guided synthesis (TGS) is to use reactions that
function under kinetic control. This approach makes use of irreversible reactions that
will be selectively promoted by the introduction of a biological template, which can
bring reactive species in close proximity allowing the reaction to occur (Figure 1).[1-3]
Figure 1: A cartoon diagram outlining the kinetic approach to target-guided synthesis using
the Huisgen 1, 3 dipolar cycloaddition reaction.
A number of reactions used in this approach have been described in the
introduction of this thesis. Of the reactions discussed, by far the most successful is
the Huisgen 1, 3 dipolar cycloaddition reaction or as it is more commonly known the
“click” reaction. A click reaction is a reaction that is reliable, selective and efficient.
Sharpless et al. have outlined a series of rules to define a click reaction as a reaction
that “must be modular, wide in scope, give very high yields, generate only inoffensive
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byproducts that can be removed by nonchromatographic methods, and be
stereospecific.”[4] The 1, 3 dipolar cycloaddition reaction between an azide and a
terminal alkyne is atom efficient, producing no by-products, and bio-orthogonal,
preventing side reactions with the biological template. The copper (I) catalysed
reaction to yield the anti (1,4-substituted) triazole was introduced by the Meldal
group in the solid phase synthesis of peptidotriazoles and further developed by
Sharpless and Fokin to be utilized with a broad spectrum of reactants.[5, 6] While the
copper (I) catalysed reaction is commonly used in a wide range of chemistries,[7-10]
the uncatalysed reaction is typically extremely slow. As described in the
introduction, Sharpless and co-workers have shown that in the presence of a
biological template the click reaction can be accelerated if the reactants have a good
fit within the template.[11] This acceleration in rate allows the products to be detected
over any background reaction.
3.2 Designing the in situ click chemistry library – a triazole as
a peptide mimic
In order to compare the thermodynamic approach to TGS with the kinetic
approach, an in situ click chemistry (ISCC) library was designed to develop novel
inhibitors of glutathione transferase (GST). Inspiration was again taken from the
bivalent inhibitors described by Atkins et al., which included inhibitors designed
with a peptidic spacer 41, Figure 2.[12-14]
Figure 2: Bivalent inhibitors of GST designed by Atkins and co-workers.
There is precedent in the literature for replacing an amide bond with a
disubstituted triazole ring.[15, 16] The 1,4-substituted triazole mimics the Z-amide
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bond, with similar atom placement and electronic properties, as detailed in Figure 3.
The lone pair found on the 3-nitrogen mimics the carbonyl oxygen of the amide
bond, the polarised C(5)-H bond is able to act as a hydrogen bond donor in the same
way as the amide N-H bond, and finally the carbonyl carbon is mimicked by the
electrophilic and polarised 4-carbon in the triazole. Structurally, the triazole unit
contains an extra atom between the substituents giving an overall increased distance
of approximately 1.1 Å.
Figure 3: A diagram to show the similarities between a peptide bond and a 1,4 -disubstituted
triazole.
Brik and co-workers have developed novel HIV-1 protease inhibitors
containing a triazole species.[15] Crystal structures of these inhibitors showed that the
triazole was interacting with the protease, via hydrogen bonding, in the same way as








Figure 4: Peptide mimics of HIV-1 protease inhibitors. A) HIV-1 protease inhibitor
Amprenavir and the triazole analogue AB2, B) Crystal structure of AB2 bound into the active
site of HIV-1 protease. The position of Amprenavir is shown with the carbon atoms in green.
Key hydrogen bonds to a structural water molecule and the main chain of the protease are
shown with black lines. Crystal structure taken from paper by Brik et al.
[15]
Van Maarseveen and co-workers successfully replaced amide bonds in the
cyclic peptide tyrosinase inhibitor cyclo-[Pro-Val-Pro-Tyr] 50 with a 1,4-substituted
triazole, as demonstrated in Figure 5.[16] These compounds, with a triazole as a
peptide bond mimic, not only match the inhibitory activity of the original cyclic
peptide, but in two examples, 51 and 52, actually show a three-fold increase in
activity with IC50 values of 0.5 mM and 0.6 mM compared with an IC50 value of














































































Figure 5: The naturally occurring cyclotetrapeptide cyclo-[Pro-Tyr-Pro-Val] a potent
tyrosinase inhibitor and three triazole analogues with one or two amide bonds replaced by
1,4 substituted triazoles. Tyrosinase activity for the cyclopeptide and three triazole
analogues is included.
[16, 17]
Bivalent compound 41, designed by Atkins et al., contains two amide bonds
on either side of a central ring that could be potentially replaced by a triazole.[14] The
amide bonds, highlighted in yellow, in Figure 6 were selected as target-bonds to be
modified. This would provide a connection between the central spacer unit, which
bridges the space between the active sites of each monomer unit of GST, and the
terminal unit that would anchor in the hydrophobic binding pocket (H-site) of GST.
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Disconnection of the triazole to the starting azide and alkyne led to a bisazide spacer









































































GST inhibitor Spacer GST inhibitor
41
Figure 6: Design of ISCC fragments based on known bivalent inhibitors.
[14]
3.2.1 Synthesis of the azide spacer library
A small library of six azide spacers was synthesised, including a range of four
different lengths (4-8 carbons) and two different side chains (glycine or valine). The
valine side chain was selected as this was present in one of the most potent inhibitors
for hGSTP1-1 identified by Atkins et al. with a Kd of 204 nM  21.
[14] The synthesis
of the spacers was carried out in two uncomplicated steps. In the initial step azide
formation was realised by the reaction of imidazole sulfonyl azide in a diazotransfer
reaction, as described by Goddard-Berger.[18] This was followed by a straightforward
EDC-coupling to a central amine unit, Scheme 1.
Chapter 3
99
Scheme 1: Synthesis of azide spacers. a) 0.01 eq CuSO4.5H2O, 2.2 eq K2CO3, methanol, rt,
18 h. b) 1.2 eq EDC.HCl, 0.2 eq DMAP, dichloromethane, rt, 18 h.
3.2.2 Design and synthesis of a small alkyne library
For the preliminary research into the ISCC conditions required for this
system, a small library of four alkyne fragments was designed based on known
inhibitors or substrates of GST. The first two alkynes were based on
1-chloro-2,4-dinitrobenzene, CDNB the universal substrate for GST.[19, 20] The nitro
group para to the chloride was replaced with carboxylic acid 54 and this group
coupled with propargylamine 55 using EDC.HCl to generate the first alkyne ALK01.
The second alkyne in the library, alkyne ALK02, was generated by conjugation of
glutathione to alkyne ALK01. These alkynes closely resemble the aldehyde
compounds used in the DCL described in the previous chapter. A third alkyne
ALK03 was synthesised from known GST inhibitor ethacrynic acid 56.[20] This was
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again achieved via EDC-coupling of the carboxylic acid group of ethacrynic acid
with propargylamine 55. A final alkyne ALK04, based on naphthalene, was added to
the library and was selected as a more general group to bind in the hydrophobic
pocket of the active site. Naphthalene is also known to be metabolised by GSTs.[21]
Naphthalene-2-carboxylic acid 57 was coupled to propargyl alcohol 58 to generate
alkyne ALK04.
Scheme 2: Synthesis of the initial alkyne library ALK01-ALK04. a) 1.2 eq EDC.HCl, 0.2 eq
DMAP, dichloromethane, room temperature, 18 h. b) 1 eq reduced glutathione, 1 eq sodium
carbonate, 1:1 water/acetonitrile, room temperature, 48 h.
3.3 The initial in situ click chemistry reaction
The preliminary ISCC reaction was set up using the six member azide spacer
library with each of the four alkynes.
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Scheme 3: ISCC reaction using azide spacer library and alkynes ALK01 to ALK04.
Triazoles detected by LC/MS-SIM in the ISCC reaction are also shown, TZ03a-01 and
TZ04a-01. a) AZ (250 M), ALK (250 M), hGSTP1-1 or mGSTM1-1 or BSA (15 M), 15 %
DMSO, 10 mM ammonium acetate buffer, pH 7.0, 7 d, 25 °C.
Each reaction contained one azide spacer with one alkyne. Two isoforms of
GST, hGSTP1-1 and mGSTM1-1, were initially chosen to be investigated.
hGSTP1-1 was one of the isoforms used by Atkins and co-workers in their search for
bivalent inhibitors and mGSTM1-1 was the most successful isomer used in the DCL
work described in the previous chapter.[12-14] Control reactions containing bovine
serum albumin, BSA, a control protein, were set up in tandem with the
GST-catalysed reactions in order to measure any background triazole formation or
any non-specific protein effects.
Fragments were added in large excess of the enzyme concentration
(ca. 250 M fragment / 15 M enzyme), as is common in literature examples for
fragments with low or unknown binding affinity for the target.[22] An enzyme
concentration of 15 M was chosen to maximise the formation of triazole product to
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ensure detection of the product. Reactions were set up and incubated at 25 C; for
seven days, after which time the reactions were quenched with methanol in order to
remove the enzyme. Samples were then run on liquid chromatography mass
spectrometry (LC/MS) in selected ion monitoring (SIM) mode. SIM mode was
necessary to provide the required sensitivity to identify the product peaks as they
would be at such small concentrations within the mixture. For each sample, the
monotriazole and bistriazole product masses were scanned. Small scale thermal
reactions between each alkyne and azide pairing were also set up to provide a
reference sample for analysis.
Figure 7: LC/MS-SIM traces for the ISCC reaction between ALK04 and AZ01 and reference
traces. A) reference from the thermal reaction between ALK04 and AZ01, B) ISCC reaction
between ALK04 and AZ01 in the presence of hGSTP1-1, C) ISCC reaction between ALK04
and AZ01 in the presence of mGSTM1-1, D) ISCC reaction between ALK04 and AZ01 in the
presence of BSA. ISCC reaction conditions: Azide (250 M final conc.), Alkyne (250 M final
conc.), DMSO (15 % by vol.), GST/BSA (15 M final conc.) and ammonium acetate buffer (to
total reaction volume of 300 L, 10 mM, pH 7.0) mixed at room temperature. After 7 days,
200 L of reaction quenched in 400 L methanol, filtered and 10 L injected onto LC/MS.
Products detected in SIM mode monitoring for [M + H]
+





monotriazole and bistriazole products. Plots show TIC for selected ions versus retention time
using gradient B or C depending on the products being measured (see Chapter 5, Section
5.2.2, Table 1).
An example of the LC/MS-SIM traces obtained for the reactions between
ALK04 and AZ01 are shown in Figure 7. The increase in triazole formation in the
presence of GST over the control reaction was calculated by dividing the peak area
for the product in the presence of GST by the peak area for the product formed in the
control. It is this ratio that is reported in subsequent ISCC reactions throughout this
chapter.
Table 1: Results of the first ISCC screen between the azide spacer library and ALK03 or
ALK 04 in the presence of hGSTP1-1 or mGSTM1-1. Data shows the ratio of the amount of
monotriazole formed in the presence of GST over the amount of monotriazole formed in the
presence of BSA, therefore a value of 1 represents no difference in triazole formation










AZ01 1.4 1.5 2.7 2.6
AZ02 NT NT 1 1
AZ03 1 1 1 1
AZ04 1 1 1 1
AZ05 1 1 1 1
AZ06 NT NT 1 1
For both of the alkyne fragments based on CDNB, ALK01 and ALK02, no
product peaks were observed. For the ethacrynic acid based alkyne, ALK03 and the
naphthalene based alkyne, ALK04 peaks corresponding to the monotriazole products
were observed in all but two examples, AZ02 or AZ06 with ALK03. However in the
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case of only one azide spacer was the amount of triazole observed in the
GST-catalysed reaction higher than that of the control reaction. For both ALK03 and
ALK04, this spacer was AZ01, the spacer with the valine side-chain. It was
interesting to note that despite spacer AZ02 being the same length as AZ01, no
increase in triazole formation was observed over the control BSA reaction. This
suggested that the additional hydrophobic bulk of the valine side-chain was required
to gain enough binding affinity for GST. The formation of the bistriazole product
was not observed in any of the reactions.
The observation that the monotriazole product formed in the presence of BSA
was unexpected and could be due to product forming in the background reaction. In
most examples of ISCC, background reactions are not observed. An exception is
Sharpless’ report on novel HIV protease inhibitors using ISCC where background
reaction could be observed.[22] The concentration of the alkyne and azide reacting
fragments in Sharpless’ report was much larger than had previously been used in
ISCC as the reacting fragments had much weaker binding affinity for the biological
target than in previous examples. It was proposed that the use of higher
concentrations was the reason for the observation of product in the background
reaction. The same high concentrations were used in the ISCC reactions described in
this chapter and this could be why the product was seen in the control. A second
possibility is that the product was not formed in the background, but was formed due
to a non-specific effect from the presence of the hydrophobic environment of the
protein in the reaction. This is discussed later in the chapter. Although the
amplification in monotriazole formation was not very large in the presence of GST
(1.4 – 2.7 times greater), the reactions between AZ01 with ALK03 and AZ01 with
ALK04 were investigated further. There were several conditions in the ISCC
reaction which needed optimizing and these are discussed below. For the
optimization of the reaction only one GST isoform was used; hGSTP1-1 was
selected as similar peptidic bivalent inhibitors 41 were known to bind with this
isoform.[14] It was also important to determine the cause of the triazole formation in
the presence of BSA, in particular, the background reaction needed to be studied in
the absence of any protein.
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3.3.1 Optimising the ISCC reaction - the volume of DMSO.
A volume of 15 % DMSO in buffer was initially chosen for the ISCC
reaction as this value was known to be suitable to maintain the activity of the GST
enzyme.[23] This volume had been previously used in DCC experiments within the
Greaney group and the activity of the enzyme was unaffected for 48 hours. The ISCC
reaction was incubated for up to seven days so the activity of hGSTP1-1, stored in
15% DMSO under the ISCC reaction conditions of 25 °C in ammonium acetate


























control 1 hour 2 days 4 days 7 days background
Figure 8: A graph to show the activity of hGSTP1-1 stored in 15 % DMSO over time. Activity
is measured by monitoring the rate of formation of the glutathione conjugation product DNP
GSH. Plot shows the peak area of GSH DNP, as measured using LC/MS-SIM (monitoring for
the mass of DNP GSH), against the time of the reaction.
There was little effect on the activity of the enzyme up to four days after
incubation of hGSTP1-1 in 15 % DMSO. After day four the activity started to
decline, however after seven days the enzyme still had some activity, as evidenced in
Figure 8.
The use of relatively large hydrophobic ligands resulted in some solubility
issues at the higher concentrations (> 250 M) desired for the initial ISCC screens.
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The effects of increasing the percentage of DMSO on the enzyme activity were



























control 15% DMSO 20% DMSO 25% DMSO background
Figure 9: A graph to show the activity of hGSTP1-1 stored for seven days in increasing
volumes of DMSO. Activity is measured by monitoring the rate of formation of the glutathione
conjugation product DNP GSH. Plot shows the peak area of GSH DNP, as measured using
LC/MS-SIM (monitoring for the mass of DNP GSH), against the time of the reaction.
The increase in the % volume of DMSO used resulted in a loss of activity of
the enzyme, as shown in Figure 9. These increases in DMSO did not yield a notable
improvement to the solubility of the azide and alkyne fragments, so the % volume of
DMSO used was kept at 15 %.
3.3.2 Optimising the ISCC reaction – the time of the reaction
The initial assay was incubated for seven days to ensure that for any hits there
would be enough triazole formed to be detected. The results of the hGSTP1-1
activity over time experiments would suggest that activity begins to decline after four
days. Time course experiments were set up to monitor both the enzyme-templated
















































































Figure 10: ISCC reaction monitored over time. Graphs show the ratio of triazole observed in
the presence of hGSTP1-1 over the background reaction. Graph A) ALK03 + AZ01,
Graph B) ALK 04 + AZ01. ISCC reaction conditions: Azide (250 M final conc.), Alkyne (250
M final conc.), DMSO (15 % by vol.), GST (15 M final conc.) and ammonium acetate
buffer (to total reaction volume of 1.5 mL, 10 mM, pH 7.0) mixed at room temperature. Over
several time points, 200 L of reaction quenched in 400 L methanol, filtered and 10 L
injected onto LC/MS using gradient B or C depending on the products being measured (see
Chapter 5, Section 5.2.2, Table 1). Products detected in SIM mode monitoring for [M + H]
+
and [M + Na]
+
mass peaks for monotriazole and bistriazole products.
Both the reactions of ALK03 with AZ01 and ALK04 with AZ01 were
monitored over a seven day period with the results shown in Figure 10. The reaction





amplification of the monotriazole product after one day (over four times greater),
with the ratio over the background increasing to 11:1 over the next six days. In the
example using ALK03 with AZ01 the ratio between the protein-templated reaction
and the background did not give a significant increase until seven days, when a ratio
of 4:1 was achieved. This result indicated that despite a reduction in the activity of



























































Figure 11: ISCC reaction monitored over time. Graphs show the peak area of the
monotriazole products observed in the presence of hGSTP1-1 and in the background
reaction. Graph A) ALK03 + AZ01. Graph B) ALK 04 + AZ01. ISCC reaction conditions:





final conc.) and ammonium acetate buffer (to total reaction volume of 1.5 mL, 10 mM,
pH 7.0) mixed at room temperature. Over several time points, 200 L of reaction quenched
in 400 L methanol, filtered and 10 L injected onto LC/MS using gradient B or C depending
on the products being measured (see Chapter 5, Section 5.2.2, Table 1). Products detected
in SIM mode monitoring for [M + H]
+
and [M + Na]
+
mass peaks for monotriazole and
bistriazole products.
Another key point taken from the time course experiment was the observation
of triazole in the background reaction, with no protein present. Figure 11 shows the
peak area for the monotriazole products, TZ03a-01 and TZ04a-01 for both the
background reaction and the reaction with hGSTP1-1. Interestingly the triazole was
observed in the background reaction after only one minute though the concentration
did not increase with time after this. This might suggest that there was an impurity in
the reaction with the same retention time as the product, although it would also have
to have the same mass as the product as the reaction was being monitored in the SIM
mode. The individual components of the reaction mixture were all run through the
LC/MS on the same gradient looking for the mass of the monotriazole product to try
to determine the cause of any impurity present. The peak corresponding to the
monotriazole was not observed in any of these separate components. It is unlikely for
a different impurity to be present in each reaction, especially if each of those
impurities has the same mass and retention time as the corresponding monotriazole.
This means that the most likely explanation was that the peak was due to the
presence of the monotriazole. The monotriazole must be forming upon mixing of the
reaction components or alternatively whilst loading the reaction mixture onto the
LC/MS column. Either way this small amount of background reaction seems to be
unavoidable.
3.3.3 Optimising the ISCC reaction – fragment concentration
One possible way to reduce the background reaction was to reduce the
concentration of the reacting fragments; the azide and the alkyne species. It was
hoped that by making the reaction more dilute, the background reaction would fall
below the detection limits of the LC/MS. Of course the reduction of the reacting
fragments may also reduce the amount of triazole formed in the presence of the GST















































Alkyne = 50 uM Alkyne = 100 uM Alkyne = 250 uM
Figure 12: ISCC reaction monitored with different concentrations of azide AZ01 and alkyne
ALK04. Graph A) the ratio of triazole observed in the presence of hGSTP1-1 over the
background reaction. Error bars represent standard deviation. Graph B and C) the peak
area of the monotriazole products observed in the presence of hGSTP1-1 and in the
background reaction for two separate assays with identical reaction conditions showing the
variation observed in the peak area of the triazole product. ISCC reaction conditions: Azide
(50/100/250 M final conc.), Alkyne (50/100/250 M final conc.), DMSO (15 % by vol.), GST
(15 M final conc.) and ammonium acetate buffer (to total reaction volume of 0.5 mL, 10 mM,



































































Alkyne = 50 uM, background Alkyne = 50 uM, hGSTP1-1
Alkyne = 100 uM, background Alkyne = 100 uM, hGSTP1-1





methanol, filtered and 10 L injected onto LC/MS using gradient C (see Chapter 5, Section
5.2.2). Products detected in SIM mode monitoring for [M + H]
+
and [M + Na]
+
mass peaks for
monotriazole and bistriazole products.
The reaction between ALK04 and AZ01 was studied over a range of alkyne
and azide concentrations, from 50 M to 250 M. The ratio of monotriazole
TZ04a-01 observed in the presence of hGSTP1-1 over the background reaction is
shown in Figure 12A. A ratio of two or above was only observed for concentrations
of azide at 100 M and higher. The concentration of alkyne used made little
difference on the ratio of product observed. The peak areas of TZ04a-01 are shown
in Figure 12B and C and suggest that the higher concentrations of the fragments
would ensure more reliable product detection. The lower concentration resulted in
very small peaks, which would increase the error when calculating the ratio between
the peaks. It was disappointing to see that despite repeating the reaction several
times, the higher ratios that had been observed in the time course experiments could
not be repeated. Another issue became apparent when analysing the peak areas in
Figure 12B and C, Graph B and C show the peak areas observed in repeat
experiments. The conditions of the reaction were identical, with the only difference
being the date that they were monitored on the LC/MS. For the reaction with 250 M
concentration for both fragments the peak area for the reaction in the presence of
hGSTP1-1 is four times greater in experiment B compared to experiment C. This
observation was noted many times during the course of this work and seemed to be a
limitation with the ionization of the mass spectrometer. When samples with known
concentrations were run on the LC/MS on different days the peak area for the
product was seen to vary by large amounts (60x103 in experiment B and 15x103 in
experiment C). Importantly however, the ratio between the background and the
reaction containing the protein was unaffected between the two experiments even
though the size of the peak area changed drastically. It became clear during the
optimization reactions that while the peak areas could not be compared between
experiments monitored days apart, those monitored on the same day could be reliably
compared. For all subsequent reactions, any ratios that are quoted were calculated
from reactions run at the same time and repeat results were calculated from taking
the average of the ratio and not the average of the peak areas.
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3.3.4 Optimising the ISCC reaction – enzyme concentration
The final variable investigated was the concentration of enzyme used. Both
the reactions of AZ01 with ALK03 and AZ01 with ALK04 were studied and the
results are shown in Figure 13.
Figure 13: ISCC reaction with varying concentrations of hGSTP1-1. Graphs show the ratio
of triazole observed in the presence of hGSTP1-1 over the background reaction.
Graph A; ALK03 + AZ01. Graph B; ALK 04 + AZ01. ISCC reaction conditions: Azide (250
M final conc.), Alkyne (250 M final conc.), DMSO (15 % by vol.), GST (1/5/15/20/35/50 M
final conc.) and ammonium acetate buffer (to total reaction volume of 0.8 mL, 10 mM,
pH 7.0) mixed at room temperature. After 7 days, 200 L of reaction quenched in 400 L
methanol, filtered and 10 L injected onto LC/MS using gradient B or C depending on the
products being measured (see Chapter 5, Section 5.2.2, Table 1). Products detected in SIM
mode monitoring for [M + H]
+
and [M + Na]
+
mass peaks for monotriazole and bistriazole
products.
The results for the reaction with ALK03 suggested that an increase in protein
resulted in a decrease in triazole formation. This could be because the protein
becomes unstable at higher concentrations. Worryingly, in the reaction between
ALK04 and AZ01, there was little amplification in the formation of triazole in the
presence of hGSTP1-1 regardless of the concentration used. This is unexpected as
ratios up to 12:1 had been previously observed under the same conditions. This
might indicate that in some reactions the enzyme is losing its activity or structure.
For each ISCC reaction set up subsequently, a sample of the enzyme was set up
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concentration of DMSO. The activity of the enzyme was monitored at the same time
as the ISCC reaction was quenched and analysed.
3.4 The optimised ISCC reaction for AZ01 with ALK03 and
ALK04
After studying the variables in the ISCC reaction, the initial conditions
seemed to be suitable so no changes were made to the original conditions for
subsequent reactions. A more important point arose during the optimisation
experiments with the inconsistent results of the protein-templated reaction. Values
for the ratio between the protein-containing reaction and the background varied from
one to twelve. These reactions were repeated several times to gain a reliable value for
the amplification in triazole formed in the presence of the protein. The reaction was










































Figure 14: ISCC reaction for the reaction between AZ01 and ALK03 and the reaction
between AZ01 and ALK04 in the presence of various isoforms of GST. Graph shows the
ratio of triazole observed in the presence of GST over the background reaction. Error bars
represent standard deviation. ISCC reaction conditions: Azide (250 M final conc.), Alkyne
(250 M final conc.), DMSO (15 % by vol.), GST (15 M final conc.) and ammonium acetate
buffer (to total reaction volume of 0.3 mL, 10 mM, pH 7.0) mixed at room temperature. After
7 days, 200 L of reaction quenched in 400 L methanol, filtered and 10 L injected onto
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LC/MS using gradient B or C depending on the products being measured (see Chapter 5,





mass peaks for monotriazole and bistriazole products.
All of the reactions, both for ALK03 and ALK04, and for all three GST
isoforms resulted in an increase in monotriazole in the presence of GST compared
with the background reaction with the exception of the reaction between ALK03 and
AZ01 in the presence of mGSTM1-1. The error bars showing the standard deviation
for the results were very large showing the unreliability of this reaction. As has been
previously discussed, there are only two examples in the literature where the
background click reaction is observed. The first was in an article describing ISCC
approaches to discovering HIV-1 protease inhibitors.[22] In this article there is no
statistical value stated to quantify a hit from the reaction. Any hit is described as
being an amplification in the amount of triazole product observed over the
background reaction. The second example is the ISCC identification of Chitinase
inhibitors.[24] In this case however, one triazole regioisomer, the anti-triazole, is
observed in the background but it is the other regioisomer, the syn-isomer, which is
observed in the templated reaction, with no increase in formation of the anti-triazole
over the background reaction. Work published by Xiangdong Hu et al. may provide a
guideline to the statistical values that constitute a protein-templated hit.[25] In their
work Hu and co-workers use the reaction between sulfonyl azides and thio acids in a
target-guided approach to develop novel Bcl-XL inhibitors. Unlike the 1,4 dipolar
cycloaddition reaction, a background reaction is always observed. A ratio of 4:1
increase in product formation in the presence of the protein template over a control
was used to determine a hit in this example. Though this is for a different reaction,
the ratio was calculated in part to eliminate the errors associated with the detection
technique of LC/MS in SIM mode, the same detection method that was employed in
this work. Certainly a ratio below 2:1 could not indicate a hit in this assay based on
the changes in peak area observed for samples of known concentrations run on the
LC/MS in SIM mode. Further controls were set up to try to build up a clearer picture
of what was happening with the ISCC reaction.
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3.4.1 Further controls for the ISCC reaction between AZ01 and
ALK03 or ALK04
An amplification of triazole formation was being observed in the presence of
enzyme over the background reaction. It now had to be proven that it was the
enzyme’s active site templating the click reaction rather than a non-specific
hydrophobic effect from the enzyme. Two types of controls were used. The first was
to replace the GST protein with a non-specific protein, in this case BSA, in a repeat
of the initial ISCC reactions run to improve the reliability of the observed





































Figure 15: ISCC reaction for the reaction between AZ01 and ALK03 and the reaction
between AZ01 and ALK04 in the presence of various isoforms of GST compared with the
reaction in the presence of BSA. Graph shows the ratio of triazole observed in the presence
of GST over the BSA reaction. Error bars represent standard deviation. ISCC reaction
conditions: Azide (250 M final conc.), Alkyne (250 M final conc.), DMSO (15 % by vol.),
GST/BSA (15 M final conc.) and ammonium acetate buffer (to total reaction volume of
0.3 mL, 10 mM, pH 7.0) mixed at room temperature. After 7 days, 200 L of reaction
quenched in 400 L methanol, filtered and 10 L injected onto LC/MS using gradient B or C
depending on the products being measured (see Chapter 5, Section 5.2.2, Table 1).
Products detected in SIM mode monitoring for [M + H]
+
and [M + Na]
+
mass peaks for
monotriazole and bistriazole products.
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The results of the increase in triazole observed in the presence of GST over
BSA are shown in Figure 15. Disappointingly in the reaction between AZ01 and
ALK03, there was little amplification in the amount of triazole TZ03a-01 observed
in the presence of all three GST isoforms compared with BSA. This would suggest
that the amplification that was observed over the background reaction was the result
of a non-specific effect due to the presence of a protein in the reaction mixture. The
results were more interesting for the reaction between AZ01 and ALK04. The
formation of TZ04s-01 was more than double in the presence of either hGSTP1-1 or
SjGST compared with BSA and four times greater in the presence of mGSTM1-1
than in the presence of BSA. Unlike the previous reactions it was the 1,5 triazole that
showed a greater increase in amplification as opposed to the 1,4 triazole. The error
bars in the data comparing the GST reaction with the BSA reaction were very large
so this result could be misleading.
The second control utilised a known inhibitor of GST to block the binding
pocket and thus prevent any templating effects from the binding pocket. As described
previously in chapter 2, the hydrophobic pocket in GST is large and promiscuous.
Not all of the inhibitors of GST were able to block the amplifications observed in the
DCC reaction; therefore DNP GSH was selected as this had demonstrated the best
effect on blocking the DCL described in chapter 2. Ethacrynic acid was also used as
an inhibitor in the ISCC reaction as ALK03 is synthesised from ethacrynic acid so it








































hGSTP1-1 + Ethacrynic acid hGSTP1-1 + DNP GSH mGSTM1-1 + DNP GSH
Figure 16: ISCC reaction for the reaction between AZ01 and ALK03 and the reaction
between AZ01 and ALK04 in the presence of hGSTP1-1 or mGSTM1-1 with the addition of
GST inhibitors ethacrynic acid and DNP GSH. Graph shows the ratio of triazole observed in
the presence of GST over the reactions in the presence of GST + inhibitor. Error bars
represent standard deviation. ISCC reaction conditions: Azide (250 M final conc.), Alkyne
(250 M final conc.), DMSO (15 % by vol.), inhibitor (500 M final conc.) GST (15 M final
conc.) and ammonium acetate buffer (to total reaction volume of 0.3 mL, 10 mM, pH 7.0)
mixed at room temperature. After 7 days, 200 L of reaction quenched in 400 L methanol,
filtered and 10 L injected onto LC/MS using gradient B or C depending on the products
being measured (see Chapter 5, Section 5.2.2, Table 1). Products detected in SIM mode
monitoring for [M + H]
+
and [M + Na]
+
mass peaks for monotriazole and bistriazole products.
The introduction of inhibitors to block the binding pockets generally had little
effect on the amount of triazole forming. The inhibitor that might be expected to
block the GST-templated triazole formation is the glutathione conjugate of the
substrate CDNB, labelled DNP GSH, but as Figure 16 highlights there was no
amplification above 2:1. This result adds support to the argument that the
amplifications in the triazole formation that were observed in the presence of GST
over the background were as a result of a non-specific effect.
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3.4.2 Synthesis and binding studies of the triazole products
observed in the ISCC reaction
The results of the control reactions were unclear, but seemed to be suggesting
that the increase of triazole production in the presence of GST was as a result of a
non-specific effect and not by the GST acting as a template in the reaction. To try to
gain a better understanding of the results seen in the ISCC reaction, the monotriazole
products that were observed were synthesised with a view to measuring their binding
affinity for GST. The reaction was carried out in one step, using copper (I) iodide to
synthesise the 1,4 triazole, Scheme 4. Both the monotriazole and bistriazole products
were synthesised in one pot by reacting the bisazide and alkyne in a one to one ratio,
Scheme 4. The products were easily separated by column chromatography. As a
result of the observation using the BSA control that the 1,5 triazole TZ04s-01 was
preferentially synthesized in the presence of GST, this triazole was also synthesized




Scheme 4: Synthesis of mono- and bistriazoles from ALK03 and ALK04 with AZ01. a) 1:1
ratio of alkyne to azide, 0.2 eq copper (I) iodide, acetonitrile, rt, 18 h. b) 1:1 ratio of alkyne to
azide, 0.1 eq Cp*RuCl(PPh3)2, dioxane, 60°C, under N2 atmosphere, 18 h.
With the monotriazoles in hand, their binding affinity for all of the GST




Table 2: IC50 values for the alkynes monitored and the triazole products detected in the
ISCC reaction. Data calculated using the CDNB binding assay. Results were calculated from








ALK03 27.2 1.1 10.5
TZ03a-01 29.6 0.14 7.97
ALK04 ≥ 100 ≥ 100 -
TZ04a-01 ≥ 100 129.3 ≥ 100 
TZ04s-01 - ≥ 50 -
TZ03a-01 showed good inhibitory activity for GST, particularly for the M1
isoform. This might be expected, as the product was based on ethacrynic acid, a
known inhibitor of GSTs. There is a 10-fold increase in binding affinity for
mGSTM1-1 by adding the azide spacer AZ01 to alkyne ALK03. In the case of
hGSTP1-1 and SjGST there was no gain in binding affinity by addition of the spacer
AZ01 to ALK03. This suggests that the spacer unit was accessing a binding site
present in the mGSTM1-1 isoform that was absent in the hGSTP1-1 or SjGST
isoforms. Both alkyne ALK04 and the monotriazole product TZ04a-01 have little
binding affinity for any of the GST isoforms with IC50 values greater than 100 M.
This failure to correlate inhibitory activity with the small amplifications observed in
the ISCC reaction suggests that it was unlikely that the triazole was formed by a
genuine templative effect from the hydrophobic binding pocket of GST. This
provides evidence that the increase in triazole formation in the presence of GST over
the controls used must be greater than 4:1 for the ISCC reaction to identify a hit.
3.5 Increasing the alkyne library
The inhibition data for the products resulting from the reaction between
AZ01 and ALK03/ALK04 did not match the results seen in the ISCC reaction. To
further explore the relationship between ISCC and inhibitory activity, the alkyne
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library was expanded to study the role of this fragment in the in situ reaction.
Scheme 5: Synthesis of extended alkyne library. a) 1.2 eq EDC.HCl, 0.2 eq DMAP,
dichloromethane, rt, 18 h. b) 1.5 eq DIPEA, acetonitrile, 60 °C, 18 h.
Two more alkynes were synthesized based on CDNB, varying the length of
the alkyne linker, ALK05 and the position on the benzyl ring, ALK06. Another
naphthyl alkyne was synthesized, this time with the alkyne added in the one position
of the naphthalene ring, ALK07. Three more alkynes were synthesized in one step;
ALK08 and ALK09 were again made via the EDC-coupling of
3,5-dimethoxybenzoic acid 62 with propargyl alcohol 58 or butyne-3-ol 63. ALK10
was made by an SN2 reaction of propargyl bromide 65 to benzoxazoline 64. The
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library was made up to twenty members by commercially available alkynes.
Scheme 6: Alkyne library
3.5.1 ISCC reaction with AZ01 and the 20-member alkyne library
This alkyne library was set up under the ISCC conditions with the azide
spacer AZ01. One alkyne was added per reaction. Each combination was set up in
duplicate; one reaction contained hGSTP1-1 whilst the other reaction was kept blank,
with no protein added, in order to monitor the background reaction.
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Scheme 7: ISCC screen using AZ01 and alkyne library. Alkynes resulting in the triazole
product being observed in the reaction are highlighted in red. a) AZ01 (250 M), ALK
(250 M), hGSTP1-1 (15 M), 15 % DMSO, 10 mM ammonium acetate buffer, pH 7.0, 7 d,
25 °C.
The results indicated that triazole product was formed in the presence of
protein with four alkynes, the two alkynes that had previously been studied ALK03
and ALK04, and two further alkynes ALK07 and ALK08. Triazole product was also
detected in the background reaction, but at a much smaller quantity than in the











































Figure 17: ISCC reaction between AZ01 and ALK07 and between AZ01 and ALK08 in the
presence hGSTP1-1. Graph shows the ratio of triazole observed in the presence of
hGSTP1-1 over the background reaction and over the reaction containing BSA. Error bars
represent standard deviation. ISCC reaction conditions: Azide (250 M final conc.), Alkyne
(250 M final conc.), DMSO (15 % by vol.), GST/BSA (15 M final conc.) and ammonium
acetate buffer (to total reaction volume of 0.3 mL, 10 mM, pH 7.0) mixed at room
temperature. After 7 days, 200 L of reaction quenched in 400 L methanol, filtered and
10 L injected onto LC/MS using gradient B or C depending on the products being measured
(see Chapter 5, Section 5.2.2, Table 1). Products detected in SIM mode monitoring for
[M + H]
+
and [M + Na]
+
mass peaks for monotriazole and bistriazole products.
The successful combinations were repeated in the presence of BSA. In all
cases, the amount of triazole formed was very similar in the presence of BSA or
GST. This would indicate that the effect was down to the hydrophobic environment
of the protein in the reaction solution, rather than a specific templative effect from
the binding pocket of GST. What seems strange with this proposal was that only four
of the alkynes reacted with the azide but for sixteen of the alkynes, no triazole
formed. There appeared to be no trend within the successful alkynes to distinguish
them from those that did not react. Many of the alkynes contained an aromatic ring.
There were library members containing alkynes linked by an amide or ester to the
aromatic ring that reacted and others that did not react. There was no observable
common feature present amongst the alkynes that reacted in the presence of protein
and those that did not.
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3.6 Investigating the sensitivity of LC/MS-SIM
It was assumed with the LC/MS-SIM detection method that all of the triazole
products would ionise to a similar extent, but it could have been that some hits were
not detected because the products were not as easily ionised as others. To check this,
the triazole products of ALK18, which were not detected in the ISCC reaction, were
synthesized using copper (I) catalysis (Scheme 8).
Scheme 8: Synthesis of TZ18a-01 and TZ18a-01-18a. a) 1:1 ratio of alkyne to azide,
0.2 eq copper (I) iodide, acetonitrile, rt, 18 h.
The MS detection for these compounds was then compared with those for the
products of the reaction with ALK04, one of the compounds that was detected
during the ISCC reaction, section 3.4. The ionisation for AZ01, ALK04 and ALK18,
and their respective monotriazole products, TZ04a-01 and TZ18a-01, and bistriazole



















































AZ01 ALK04 TZ04a-01 TZ04a-01-04a ALK18 TZ18a-01 TZ18a-01-18a
Figure 18: Graphs to show the LC/MS-SIM response to AZ01, ALK04, ALK18 and the
triazole products from these fragments. Graph B is a zoomed in version of graph A
highlighting the concentration range of 100 nM to 10 M. Concentration (along x axis) is the
concentration of the analysed compound under the same conditions as the in situ click
reactions, prior to dilution and injection onto LC/MS as per the in situ click reaction
conditions. Peak area (along y axis) is the peak area for the total ion count of ions at the
selected mass of the product being analysed.
As shown in Figure 18 neither of the alkyne fragments (blue and red squares)





low micromolar concentrations. All of the triazole products were more easily
detected than the azide spacer. Pleasingly, the triazoles (blue triangle and cross) that
were not observed in the ISCC reaction, TZ18a-01 and TZ18a-01-18a, ionized to a
greater extent than those triazoles (red triangle and cross) that were observed in the
ISCC reaction. This confirms that should a triazole be formed, whether it was just the
background reaction or as a result of the presence of protein in the reaction mixture,
then it would be detected under the LC/MS-SIM conditions utilised in the reaction.
3.7 Binding data of triazole TZ18a-01, a triazole not formed in
the ISCC reaction
Having synthesised the monotriazole TZ18a-01, which was not observed in
the ISCC reaction, this monotriazole was run in the CDNB assay to measure its
binding affinity for GST. This could then be compared with the binding data for
TZ03a-01 and TZ04a-01, the triazoles that were observed in the ISCC reaction. The
binding affinity of TZ18a-01 was only measured for mGSTM1-1, the GST isoform
for which the monotriazoles previously tested had shown the best inhibition.
Table 3: A table showing the IC50 values for monotriazoles measured in the CDNB assay.
Values are calculated from three separate assays. Raw data described in experimental
chapter.
Triazole IC50 (M) mGSTM1-1 Observed in ISCC reaction
TZ03a-01 0.138 
TZ04a-01 129.3 
TZ18a-01  100 x
The inhibitory activity for TZ04a-01, which was observed in the ISCC
reaction, was very small (129.3 M) and showed very little difference to that for
TZ18a-01 (> 100 M). This provides further evidence to suggest that the triazoles
observed in the ISCC reaction were forming due to a non-specific hydrophobic effect
from the presence of the protein in the solution and not from a template effect from
the binding pocket of the protein. The IC50 value of TZ03a-01 was 1000-fold better
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than the negative control triazole TZ18a-01. This result might suggest that
TZ03a-01 would prove to be a hit in the ISCC reaction, however the ratios in the
amount of triazole formed in the presence of GST over BSA were very similar for
both TZ03a-01 and TZ04a-01. The binding data suggested that it was very unlikely
that TZ04a-01 was forming as a result of a templative effect from the GST, therefore
this would suggest that TZ03a-01 was still forming as a result of a non-specific
effect.
The ISCC reaction failed to yield any positive hits that involved double
cycloaddition with both azide groups on the spacer. This is perhaps not surprising as
it would require three weakly binding fragments to be brought together in the
protein’s active site and this may be beyond the scope of this particular set of ISCC
reactions, or even any ISCC approach.
In particular, the bisazide spacers were very weakly binding, as they would
bind in the solvent-accessible cleft and not in a well defined binding pocket. In order
to add some binding affinity to the spacers, a monoazide compound with one of the
alkyne fragments already attached to the spacer was selected to trial in the ISCC
reactions. The monoazide that was selected was TZ03a-01 as this had by far the best
binding affinity for GST.
3.8 In situ click chemistry screen of TZ03a-01 with alkyne
library
An initial screen of TZ03a-01 with the 20-member alkyne library and
hGSTP1-1 as the protein template highlighted three combinations in which triazole
formation was observed. These were the reactions with ALK03, ALK04 and




Scheme 9: ISCC screen using TZ03a-01 and alkyne library. Alkynes resulting in the triazole
product being observed in the reaction are highlighted in red. a) TZ03a-01 (50 M),
ALK (250 M), hGSTP1-1 (15 M), 15 % DMSO, 10 mM ammonium acetate buffer, pH 7.0,
7 d, 25 °C.
The reactions with ALK03 and ALK04 were further investigated with four
different GST isoforms to see if amplification of triazole production above the





































hGSTP1-1 v background hGSTP1-1 v BSA
mGSTM1-1 v background mGSTM1-1 v BSA
sjGST v background sjGST v BSA
mGSTA4-4 v background mGSTA4-4 v BSA
Figure 19: ISCC reaction between TZ03a-01 and ALK03 and between TZ03a-01 and
ALK04 in the presence of various isoforms of GST. Graph shows the ratio of triazole
observed in the presence of GST over two controls; the background reaction (block colour)
and in the presence of BSA (diagonal stripe). Error bars represent standard deviation. For
mGSTM1-1 and mGSTA4-4 only one peak observed. ISCC reaction conditions: Azide
(50 M final conc.), Alkyne (250 M final conc.), DMSO (15 % by vol.), GST/BSA (15 M
final conc.) and ammonium acetate buffer (to total reaction volume of 0.3 mL, 10 mM,
pH 7.0) mixed at room temperature. After 7 days, 200 L of reaction quenched in 400 L
methanol, filtered and 10 L injected onto LC/MS using gradient B or C depending on the
products being measured (see Chapter 5, Section 5.2.2, Table 1). Products detected in SIM
mode monitoring for [M + H]
+
and [M + Na]
+
mass peaks for monotriazole and bistriazole
products.
Surprisingly, rather than seeing an increase in triazole production in the
presence of protein or even a 1:1 ratio indicating that it was only the background
reaction being observed, the amount of triazole produced was reduced when
compared with the background reaction, Figure 19. The greatest reduction was in the
presence of mGSTM1-1 and hGSTP1-1.
The amount of triazole produced was also compared with the reaction in the
presence of control protein, BSA. Again, the amount of triazole produced in the
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presence of mGSTM1-1 was greatly reduced in comparison with the reaction in the
presence of BSA, Figure 19. The other three GST isoforms had a close to 1:1 ratio
with BSA.
The bistriazole product TZ03a-01-03a had been synthesized previously,
Scheme 4. The bistriazole product TZ03a-01-04a was synthesized from the copper
(I) iodide catalysed reaction between TZ04a-01 and ALK03, Scheme 10.
Scheme 10: Synthesis of TZ03a-01-04a. a) 0.2 eq copper (I) iodide, acetonitrile, rt, 18 h.
The inhibitory activity of both 1,4 triazole products, along with the starting
azide and alkynes were measured using the CDNB assay to try to elucidate the
results observed in the ISCC reaction.
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Table 4: A table showing the IC50 values for starting fragments and triazole products
observed in the ISCC screen with TZ03a-01 measured using the CDNB assay. Values are
calculated from three separate assays. Raw data described in experimental chapter.










TZ03a-01 29.64 0.138 7.97 ≥ 100 
ALK03 27.18 1.101 10.49 ≥ 100 
TZ03a-01-03a 7.56 0.0038 0.014 ≥ 100 
ALK04 ≥100 ≥ 100 - -
TZ03a-01-04a 24.45 0.055 13.08 ≥ 100 
The results from the CDNB binding assay identified a very potent inhibitor
for both mGSTM1-1 and SjGST in the bivalent triazole TZ03a-01-03a, the triazole
based on known inhibitor ethacrynic acid (IC50 = 4 nM (mGSTM1-1) and 14 nM
(SjGST)). This result, along with that for SjGST, highlights the power of the bivalent
approach. In the example of mGSTM1-1, two monovalent inhibitors with IC50 values
of 0.1 and 1.0 M have combined to make a bivalent inhibitor with low nanomolar
activity. Even in the case of hGSTP1-1, an improvement in binding affinity was
observed with the bivalent triazole.
These results suggest that the ISCC reaction could work for TZ03a-01 with
ALK03. However, the results from the ISCC reaction were clearly negative with
triazole formation actually being reduced relative to the control. This decrease might
have been occurring because the azide and alkyne fragments were binding to the
GST, reducing the concentration of those fragments participating in the background
reaction, but being unable themselves to undergo triazole formation. A noted
disadvantage of the ISCC approach is that false negatives can and do occur.[27] This
happens when the fragments bind in the enzyme in such a way that the reactive
alkyne and azide groups are held at too great a distance apart and so the reaction
cannot proceed, despite the fact that the final triazole product also binds well. This
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could explain why the ISCC reaction was not working in this case. Another possible
explanation for not seeing any amplification of the tight binding bistriazole product
in situ was because the template binding pocket was symmetrical but the fragments
were asymmetrical. One of the fragments may have been acting as a self inhibitor by
binding in both halves of the GST binding pocket, so that azide plus azide or alkyne
plus alkyne was present in the binding pocket and therefore no reaction could
happen.
While TZ03a-01-03a was the most potent ligand, TZ03a-01-04a gave the
highest GST isoform specificity, with an IC50 value 200 times greater for
mGSTM1-1 than for any other GST isoform that was tested. The addition of the
naphthyl alkyne ALK04 had little effect on the binding affinity of the monotriazole
TZ03a-01 towards hGSTP1-1 or SjGST. This would suggest that these examples
should not work in the ISCC reaction.
3.9 ISCC screen of TZ04a-01 with alkyne library using
mGSTM1-1
The ISCC reaction using the monoazide TZ03a-01 was clearly not working
to produce products templated by GST, so a second monoazide TZ04a-01 was
selected to try in the ISCC reaction. TZ04a-01 had much weaker binding affinity
towards GST compared with TZ03a-01, which would reduce the possibility of the
monoazide acting as a self-inhibitor. TZ04a-01 was screened with the 20-member
alkyne library in the ISCC reaction, under the same conditions as those described
previously except for a reduction in the concentration of the azide to 50 M due to
solubility problems. The screen was performed with mGSTM1-1 as the monoazide
displayed a slightly more favourable activity for this isoform and because this
isoform had produced the best results in the DCC approach. The resultant
LC/MS-SIM traces were compared to the background reaction in the absence of
protein, see appendix for traces.
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Scheme 11: ISCC screen using TZ04a-01 and alkyne library. Alkynes resulting in the
triazole product being observed in the reaction are highlighted in red. a) TZ04a-01 (50 M),
ALK (250 M), hGSTP1-1 (15 M), 15 % DMSO, 10 mM ammonium acetate buffer, pH 7.0,
7 d, 25 °C.
From the 20-member library of alkynes, seven reactions resulted in peaks
corresponding to expected triazole products. These products were confirmed by
references from both the copper (I)-catalysed or Ru-catalysed reactions and via the
thermal reaction. Four of the alkynes were the same as those forming triazole with
the bisazide AZ01 (section 3.5.1). These were ALK03, ALK04, ALK07 and
ALK08. The further three alkynes were ALK01, ALK09 and ALK11. ALK01 was
based on known substrate CDNB. ALK09 was the same as one of the original hits,
ALK08, except for an extra carbon in the alkyne linker. ALK11 was another
fragment containing a naphthyl group. In all of the examples, except for those
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containing ALK08 and ALK09, the two triazole regioisomers, the anti (1,4) and the
syn (1,5) triazole, could be separated on the LC/MS. The enzyme-templated reaction
produced both triazole regioisomers in every example with the 1,4-triazole being the
major isomer. This was unexpected as the confined spatial arrangement of the active
























































1, 5 triazole 1, 4 triazole Both regioisomers
Figure 20: ISCC reaction between TZ04a-01 and alkyne ‘hits’ in the presence of
mGSTM1-1. Graph shows the ratio of triazole observed in the presence of GST over the
background reaction. Data calculated from the ratio between the average value of the peak
area for product formed in the presence of mGSTM1-1 and the average value for the peak
area for product formed in the background reaction. ISCC reaction conditions: Azide (50 M
final conc.), Alkyne (250 M final conc.), DMSO (15 % by vol.), GST (15 M final conc.) and
ammonium acetate buffer (to total reaction volume of 0.3 mL, 10 mM, pH 7.0) mixed at room
temperature. After 7 days, 200 L of reaction quenched in 400 L methanol, filtered and
10 L injected onto LC/MS using gradient B or C depending on the products being measured
(see Chapter 5, Section 5.2.2, Table 1). Products detected in SIM mode monitoring for
[M + H]
+
and [M + Na]
+
mass peaks for monotriazole and bistriazole products.
The comparison between the enzyme-containing reaction and the background
was only undertaken between averages of the peak areas observed for the triazole
products and not from an average of the ratios of reactions monitored on the same
day. As described in section 3.8, comparison between reactions monitored at
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different times resulted in less reliable results, however the important points to take
from this experiment, Figure 20, are that the seven triazoles were observed. The
alkyne based on the known inhibitor ethacrynic acid, ALK03, resulted in a
significant increase in triazole formation in the presence of mGSTM1-1. There was a
much greater increase in the formation of the 1,4 regioisomer over the 1,5 triazole
product. Five of these triazoles would qualify as hits using the guideline 4:1 ratio.
TZ04a-01-01a/s and TZ04a-01-09a/s would not qualify as being hits for
mGSTM1-1.
3.9.1 ISCC screen of AZ04a-01 with alkyne ‘hits’ using
mGSTM1-1 – further controls
The seven combinations which produced triazoles were subjected to the same
















































1, 5 triazole 1, 4 triazole Both regioisomers
Figure 21: ISCC reaction between TZ04a-01 and alkyne ‘hits’ in the presence of
mGSTM1-1. Graph shows the ratio of triazole observed in the presence of GST over the
reaction in the presence of BSA. Error bars represent standard deviation. ISCC reaction
conditions: Azide (50 M final conc.), Alkyne (250 M final conc.), DMSO (15 % by vol.),
GST/BSA (15 M final conc.) and ammonium acetate buffer (to total reaction volume of
0.3 mL, 10 mM, pH 7.0) mixed at room temperature. After 7 days, 200 L of reaction
quenched in 400 L methanol, filtered and 10 L injected onto LC/MS using gradient B or C
depending on the products being measured (see Chapter 5, Section 5.2.2, Table 1).
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Products detected in SIM mode monitoring for [M + H]
+
and [M + Na]
+
mass peaks for
monotriazole and bistriazole products.
Comparison of the reactions in the presence of mGSTM1-1 with the reactions
in the presence of BSA resulted in one reaction forming 12 times the amount of
triazole, TZ04a-01-08a/s, than in the presence of BSA, Figure 21. Three more
triazoles, TZ04a-01-04a/s, TZ04a-01-07s and TZ04a-01-09a/s, were observed at
the proposed 4:1 ratio in favour of the mGSTM1-1 reaction. Only one reaction, for
the production of TZ04a-01-01a/s, resulted in no increase at all in triazole formation
between the mGSTM1-1 reaction and the BSA control. This matched the results seen


















































Figure 22: ISCC reaction between TZ04a-01 and alkyne ‘hits’ in the presence of
mGSTM1-1. Graph shows the ratio of triazole observed in the presence of mGSTM1-1 over
the reaction in the presence of other GST isoforms. Error bars represent standard deviation.
ISCC reaction conditions: Azide (50 M final conc.), Alkyne (250 M final conc.), DMSO
(15 % by vol.), GST (15 M final conc.) and ammonium acetate buffer (to total reaction
volume of 0.3 mL, 10 mM, pH 7.0) mixed at room temperature. After 7 days, 200 L of
reaction quenched in 400 L methanol, filtered and 10 L injected onto LC/MS using
gradient B or C depending on the products being measured (see Chapter 5, Section 5.2.2,
Table 1). Products detected in SIM mode monitoring for [M + H]
+
and [M + Na]
+
mass peaks
for monotriazole and bistriazole products.
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When the reaction in the presence of mGSTM1-1 was compared with other
GST isoforms the general trend was that mGSTM1-1 resulted in the greatest amount
of triazole formation, Figure 22. The greatest difference between the amounts of
triazole observed was between mGSTM1-1 and mGSTA4-4, with typically three
times as much triazole forming in the presence of mGSTM1-1. On average twice as
much triazole was observed in the reaction with mGSTM1-1 compared with the
reaction with hGSTP1-1. The reaction in the presence of SjGST produced triazole in
the most similar amounts to mGSTM1-1. These observations with the different GST
isoforms follow the same pattern as in the DCLs described in the previous chapter.
SjGST is most similar to mGSTM1-1 in its three dimensional structure and this could
explain why the amount of triazole observed was very similar for mGSTM1-1 and
SjGST.[28-30]
The final control was to use a known inhibitor of mGSTM1-1 to block the
binding pocket. If it was the binding pocket that was templating the click reaction
then blocking it should prevent the click reaction. The same approach was used in the
previous chapter to prove the amplification in the DCL was being templated by the
GST binding pocket. Problems arose with this approach as the hydrophobic binding
pocket of GST is so large and not very well defined.[20, 31-34] As the expected binding
orientation of the spacers was not known, a range of GST inhibitors were used as
controls.
Figure 23: Known inhibitors of GST.
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As described in detail in chapter 2.6, BITC, ethacrynic acid and DNP GSH all
bind in different orientations within the hydrophobic binding pocket.[35-38]
Sulfasalazine binds in the hydrophobic binding pocket, but it also extends out into a
further shallow pocket on the protein surface.[38] Cibacron blue binds in the ligandin
binding site.[38] In the example of the DCL the only compound that blocked the
amplification was DNP GSH. If the triazole compounds are binding in the same
orientation as the acylhydrazone compounds described in chapter 2, it would be

























































1, 5 triazole 1, 4 triazole Both regioisomers
Figure 24: ISCC reaction between TZ04a-01 and alkyne ‘hits’ in the presence of
mGSTM1-1. Graph shows the ratio of triazole observed in the presence of mGSTM1-1 over
the reaction in the presence of mGSTM1-1 plus GST inhibitor, DNP GSH. ISCC reaction
conditions: Azide (50 M final conc.), Alkyne (250 M final conc.), GSH DNP (500 M final
conc.) DMSO (15 % by vol.), GST (15 M final conc.) and ammonium acetate buffer (to total
reaction volume of 0.3 mL, 10 mM, pH 7.0) mixed at room temperature. After 7 days, 200 L
of reaction quenched in 400 L methanol, filtered and 10 L injected onto LC/MS using
gradient B or C depending on the products being measured (see Chapter 5, Section 5.2.2,
Table 1). Products detected in SIM mode monitoring for [M + H]
+
and [M + Na]
+
mass peaks
for monotriazole and bistriazole products.
The full range of GST inhibitors was screened to block both the hydrophobic
and ligandin binding pockets within mGSTM1-1. The results showed no effect on the
triazole production with the exception of DNP GSH. These results are displayed in
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Figure 24. Even with this inhibitor only two reactions, TZ04a-01-04a/s and
TZ04a-01-09a/s, showed an increase in product formation in the presence of the free
protein over the protein which was blocked with DNP GSH. Only one of these,
TZ04a-01-04a/s gave an increase greater than 4:1. This data suggested, perhaps with
the exception of TZ04a-01-04a/s, that it was not the hydrophobic binding pocket that
was the site for the triazole synthesis.
3.10 Summary of the ISCC reaction between TZ04a-01 and
alkyne ‘hits’ with mGSTM1-1 and comparison with the binding
data for the triazole products
After trying several different controls no clear pattern emerged. The results
from all of the control experiments have been summarized in Table 5. The ratio of
the mGSTM1-1 value over the control has been listed and those that gave a value of




Table 5: A summary of the results from the ISCC reaction between TZ04a-01 and the alkyne
‘hits’, with mGSTM1-1. Data is tabulated by control reactions, with values quoted being the
ratio of triazole formed in the presence of mGSTM1-1 over the control. A tick indicates a ratio
above four. NT = no triazole observed. - = no reaction performed. The final column shows
the IC50 values measured using the CDNB assay. Values are calculated from three separate
assays. Raw data described in experimental chapter.





AZ04a-01 - - - - 129.3
TZ04a-01-01s 0.8 X 1 X - - -
TZ04a-01-01a 0.8 X 1 X - - 7.8
TZ04a-01-03s 110 3 X 4 (A4) 1 X -
TZ04a-01-03a 20 2 X 5 (A4) 1 X 0.055
TZ04a-01-04s 4  4  3 (A4) X 5  16.9
TZ04a-01-04a 4  4  X 3 X 13.2
TZ04a-01-07s 12  4  3 (A4) X 2 X 3.8
TZ04a-01-07a 8  3 X 3 (A4) X 2 X 25.5
TZ04a-01-08s 4  13 3 (A4) X 1 X 62.1
TZ04a-01-08a 4  13 3 (A4) X 1 X 33.9
TZ04a-01-09s 0.4 X 4  X 3 X 64.9
TZ04a-01-09a 0.4 X 4  X 3 X 29.6
TZ04a-01-11s 23  2 X X 1 X 35.1
TZ04a-01-11a 10  2 X X 2 X 9.7
TZ04a-01-10a NT NT NT NT 38.8
TZ04a-01-18a NT NT NT NT 30.5
The results from the first two control reactions comparing the GST-templated
reaction with the background reaction and the reaction in the presence of BSA,
Table 5 column 2 and 3, show whether or not there was a specific feature of the GST
enzyme that was promoting the cycloaddition reaction. The reaction between
monoazide Tz04a-01 and alkynes ALK04, ALK07 and ALK08 gave significant
amplifications over both of these control reactions clearly indicating that a distinct
region of GST was responsible for accelerating the click reaction. The
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GST-templated reaction between monoazide TZ04a-01 and alkynes ALK03 and
ALK11 resulted in extremely large amplifications (greater than 10:1) in triazole
formation over the background reaction, however a much less substantial increase,
lower than the suggested 4:1 ratio, was observed over the BSA reaction.
A degree of improvement was observed in the formation of triazole in the
presence of mGSTM1-1 over the other GST isoforms for these reactions, although
never above a ratio of 4:1. The comparison between GST isoforms could only serve
to indicate if the template-effect was as a result of a specific binding pocket on one
isoform over the others. Smaller differences in triazole formation suggest that the
binding site acting as the template is present in all of the GST isoforms and the small
amplifications are as a result of subtle changes within this binding site between
isoforms. The results of using the various GST inhibitors to block the hydrophobic
binding pocket and the ligandin site had demonstrated that it was unlikely that it was
these sites that were responsible for templating the click reaction.
To gain a better insight into the binding of the triazoles with mGSTM1-1,
their inhibitory activity was measured in the CDNB assay. The IC50 values have been
listed in Table 5. All of the triazoles showed an improvement in the inhibitory
activity over the starting azide AZ04a-01. The products from the reactions that
appeared to be amplified by the presence of GST (TZ04a-01-03a/s,
TZ04a-01-04a/s, TZ04a-01-07a/s, TZ04a-01-08a/s and TZ04a-01-11a/s) displayed
activities from 0.055 M to 62.1 M, a 1000-fold range. This is a large span of
results, which appears to contradict the observations of the ISCC reactions. Two
control triazoles not observed in the ISCC reaction, TZ04a-01-10a and
TZ04a-01-18a, were also run in the CDNB assay and gave IC50 values of 39 and
31 M respectively, values that fall within the range observed for the ISCC hits. One
explanation is that these two products happen to be false negatives in the ISCC
reaction. Alternatively, and perhaps more likely, a three to four-fold improvement in
activity for the ditriazole compound compared with the monotriazole precursor
signifies a model that is not templated by the enzyme and those products that did
show an increase in triazole formation are proof that the ratio used to determine a hit
in ISCC needs to be re-evaluated.
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While the inhibitory activity of a compound is not a direct measure of its
binding affinity for the enzyme, it seems unlikely in this case that some of the
compounds bind with good inhibitory activity and other compounds based on the
same spacer design bind elsewhere on the enzyme, to exhibit good binding affinity
but display little effect on the catalytic turnover. Perhaps the only explanation could
be that the spacers bind into the solvent-accessible cleft, as designed, but the terminal
groups bind at different angles, so that some bind into an area that can affect the
enzymatic activity (possibly the hydrophobic pocket), while others bind in a different
area, perhaps similar to the shallow secondary pocket where sulfasalazine is known
to bind.[38] The only way to prove these theories is to firstly determine the binding
affinity each ditriazole product exhibits towards GST and compare these values with
the data collected from the ISCC reactions. This can be achieved by using a
technique such as isothermal titration calorimetry (ITC) or surface plasmon
resonance (SPR). Secondly, getting crystal structures of the triazole products bound
to the GST would explain how and where on the enzyme the template reaction was
occurring. Alternatively, molecular modelling could be used to determine how these
ditriazoles are likely to be binding to the GST dimers.
As previously mentioned in chapter 2.1, GSTM1-1 has been shown to bind to
apoptosis signal-regulating kinase 1 (ASK1).[39-41] This mitogen-activated protein
kinase kinase kinase plays a crucial role in cytokine- and stress-induced apoptosis in
the cell. It is the C-terminal area of GSTM1-1 that binds to ASK1. It could be this
site that was responsible for templating the click reaction observed in the ISCC
reactions. It has also been shown that the interaction of GSTM1-1 with ASK1 is
independent of the glutathione-conjugating activity of GSTM1-1.[39] This could
explain why the bistriazole products that appeared to be amplified in the presence of
mGSTM1-1 did not have good inhibition of the glutathione-conjugating activity
measured in the CDNB assay.
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3.11 Summary of the ISCC reaction between TZ04a-01 and
alkyne ‘hits’ with hGSTP1-1 and comparison with the binding
data for the product triazoles
As the original library was designed from bivalent inhibitors of hGSTP1-1,
this GST isoform was also used in the ISCC reaction between TZ04a-01 and the
20-member alkyne. The product formation in the presence of hGSTP1-1 was
compared with the control reactions, data in Appendix, Section 6.3. A summary of
these reactions has been collated in Table 6. The ratio of the hGSTP1-1 value over
the control has been listed and those that gave a value of four or above have been
marked with a tick to provisionally indicate a hit in the reaction.
The results obtained correlated well with those results described for the
reactions using the mGSTM1-1 isoform. The same five reactions, between
TZ04a-01 and alkynes ALK03, ALK04, ALK07, ALK08 and ALK11, resulted in
large amplifications (greater than 4:1 increase) in triazole formation observed over
the background and BSA control reactions, again indicating that a specific site on
hGSTP1-1 was responsible for accelerating the rate of triazole synthesis. Some
amplification was observed over other GST isoforms, typically SjGST and
mGSTA4-4, although this was not true in every example. In this case, no decrease in
triazole formation was observed with the use of any of the library of known GST
inhibitors previously described. This provides evidence that it was not the




Table 6: A summary of the results from the ISCC reaction between TZ04a-01 and the alkyne
‘hits’, with hGSTP1-1. Data is tabulated by control reactions, with values quoted being the
ratio of triazole formed in the presence of hGSTP1-1 over the control. A tick indicates a ratio
above four. NT = no triazole observed. - = no reaction performed. The final column shows
the IC50 values measured using the CDNB assay. Values are calculated from three separate
assays. Raw data described in experimental chapter.
Triazole Background BSA Isoforms Inhibitors IC50 M
AZ04a-01 - - - - ≥ 100 
TZ04a-01-01s 7  1 X - X -
TZ04a-01-01a 7  2 X - X -
TZ04a-01-03s 62 2 X 4 (A4) X -
TZ04a-01-03a 53 2 X 5 (A4) X 24.5
TZ04a-01-04s 4  3 X X X 140.6
TZ04a-01-04a 4  4  X X 166.6
TZ04a-01-07s 7  9  7 (A4) X 56.0
TZ04a-01-07a 6  5  5 (A4) X 55.2
TZ04a-01-08s 7  8  5 (Sj) X -
TZ04a-01-08a 7  8  5 (Sj) X -
TZ04a-01-09s 2 X 5  X 3 (CB) -
TZ04a-01-09a 2 X 5  X 3 (CB) -
TZ04a-01-11s 10 3 X X X -
TZ04a-01-11a 3 X 2 X X X -
TZ04a-01-10a NT NT NT NT 36.7
TZ04a-01-18a NT NT NT NT 2.2
The inhibitory activity of a selection of ligands was again determined and has
been detailed in Table 6, column 6. The data showed that overall the ditriazole
spacers were weaker inhibitors of hGSTP1-1 compared to mGSTM1-1. The best
inhibitors of hGSTP1-1 were actually the two triazole compounds that were not
observed in the ISCC reactions. Unless these are examples of false negative results,
the triazoles with amplified formation in the presence of hGSTP1-1 must not be
templated in a site that affects the enzyme activity, a theory supported by the lack of
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an effect on triazole formation by the addition of known GST inhibitors to the
GST-templated ISCC reaction. As well as its role in detoxification in the cell,
hGSTP1-1 has also been shown to have antiapoptotic activity via a protein-protein
interaction with c-Jun NH2-terminal kinase (JNK), which is a key regulator of
apoptosis within the cell.[42-45] GSTP1-1 is known to bind to JNK in the C-terminal
region of the protein. It is the same region that contributes to the shaping of the
hydrophobic binding pocket. It could be that it was the site of the protein-protein
interaction that was templating the click reaction in the ISCC reactions.
3.12 Implications for ISCC as an approach for TGS
ISCC screens based on three different azide scaffolds have been studied in
this chapter and a number of weaknesses have been exposed. The use of a diazide
spacer resulted in the observation of monotriazole products in four examples. The
average amplification of triazole formation in the presence of GST over the controls
was a 4:1 ratio or less. The inhibitory activity of these monotriazoles suggested that
the small amplifications observed in the ISCC reaction were not as a result of a
specific template effect of the target protein, demonstrating that a minimum of a 4:1
increase in triazole is desired to define an in situ hit.
The optimization reactions highlighted a number of inconsistencies with the
observed amount of triazole formed in a reaction. The presence of a background
reaction made this problematic in comparing the relative amounts of triazole forming
in each reaction. As discussed, more recent examples of ISCC in the literature have
reported the observation of the background click reaction.[22, 24] As with this work,
these were examples in which relatively weak-binding fragments were utilised in the
ISCC library and so higher concentrations were required in the ISCC reaction, which
seems to be the cause of the observed background reaction. If ISCC is going to be
used as a valid and consistent tool in drug discovery, then it is reasonable to expect
that weakly-binding fragments will be employed regularly, so suitable guidelines to
define a ‘hit’ need to be determined. Clearly if the quantification of an in situ hit is
going to be based on an amplification of product formation over a background
reaction then the calculation of the amount of product observed needs to be both
accurate and reliable. The results observed in this work suggested the ionisation of
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compounds in the LC/MS was unreliable over long time periods. While reactions run
on the same day could be reasonably compared, reactions run weeks apart could not
be. It would be recommended to introduce an internal standard to the sample prior to
monitoring on the LC/MS, which would then allow the concentration of triazole to
be calculated from the peak areas observed.
The second azide scaffold to be studied, the monoazide based on the original
diazide spacer with ethacrynic acid attached at one end, highlighted another
drawback of ISCC, the problem of false negatives. For the reaction between the
monoazide and the alkyne-derivatised ethacrynic acid, a 100-fold increase in the IC50
value of the product over the monoazide was observed, yet the triazole formation
observed in the GST-templated reaction was reduced compared with the background
reaction. These observations could imply that a degree of flexibility is essential
between the fragments and the reactive functional groups. The central spacer unit had
a peptide backbone which could reduce the flexibility of movement of the reactive
azide and alkyne functional groups. Future work could involve redesigning the
fragment libraries to introduce more flexibility, e.g. by removing the peptidic spacer
and/or changing from two triazole connections to one 66, as shown in Scheme 12.
The azide and alkyne functionality could then be linked to the ligand, which is
designed to dock in the hydrophobic binding pocket, by a more flexible alkyl or
polyethylene glycol (PEG) chain 67 and 68. This approach, however, is vulnerable to
problems with self-inhibition due to the symmetrical binding pockets of the GST as
the template, but may give some indication of the amount of flexibility required by
fragments used in ISCC.
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Scheme 12: A scheme to outline the potential for adding more flexibility into the spacer
design to aid the ISCC approach.
The final azide scaffold analysed, the monoazide with a terminal naphthyl
group, identified several products that were showing large amplifications in triazole
formation as a result of a specific template effect from the GST proteins. The use of
known GST inhibitors and the lack of correlation between the inhibitory activity of
those triazoles amplified by the GST suggested that it was not the hydrophobic
binding pocket that was acting as the template, despite the original library being
designed to span the two H-sites located in the GST dimer. As discussed previously,
it is now important to get a direct measure of the binding affinity of these triazoles
with the GST proteins. Even without the binding affinity the results of the inhibitory
activity reveal another potential limitation to ISCC as a drug discovery technique.
This ISCC library was designed, based on limited structural knowledge, to identify
novel GST inhibitors. The results of the final ISCC screen indicated several hits and
while these may still demonstrate good binding affinity for GST, some of them did
not display good inhibition of GST. One of the advantages of ISCC over traditional
drug discovery approaches is that it should not require much, if any structural
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information about the biological target. The results from this ISCC screen clearly
demonstrate the importance of the control reaction in which the target binding site is
blocked with a known inhibitor, to reveal the exact location within the biological
target that is templating the click reaction. The large, flexible hydrophobic binding
site of GST has made this control reaction very difficult in this work. The ability to
perform this control reaction is an important consideration in the future selection of
biological targets to investigate with an ISCC approach.
3.13 Inconsistencies in the ISCC reaction
An unexpected observation in the ISCC reaction was the formation of both
triazole regioisomers. The restricted three dimensional structure of the binding
pocket of the biological template should direct the synthesis of only one regioisomer.
Indeed in all previous literature reports of ISCC, a single triazole regioisomer is
observed. In an article by Omura and co-workers, using ISCC to identify novel
chitinase inhibitors, the second regioisomer was observed in the background
reaction; however this product showed no amplification in the presence of the
biological target.[24] In the ISCC reactions described in this thesis, both regioisomers
are observed in the background and are shown to be amplified in the presence of
GST. While this is a novel observation in ISCC, it is important to note that inhibitory
activity of both regioisomers was similar, with typically only a 2-fold difference in
inhibition, suggesting the GST protein is tolerant of both triazoles. Again, obtaining
an image of how the ligands are binding to GST, either by molecular modelling or
X-ray crystallography, will explain this observation.
A second point to consider from the ISCC screens, is that the same four
alkynes (ALK03, ALK04, ALK07 and ALK08) are always observed to form
triazole, with a further three related alkynes (ALK01, ALK09 and ALK11)
producing triazole in the final ISCC screen with the naphthyl monoazide TZ04a-01.
The remaining 13 alkynes do not result in triazole formation even in the background
reaction. This might suggest a source of metal catalyst is present in these alkyne
samples which is responsible for the click reaction. The metal trace can only be
present in the alkyne samples or triazole would be observed for every reaction. The
observation of both triazole regioisomers means that a trace amount of both copper
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and ruthenium must be present in these samples if they are the cause of the click
reaction. While this seems unlikely, the alkyne samples could be analysed for trace
copper and ruthenium.
3.14 Implications for multivalent drug design
The ditriazole products were poorly water soluble, which made them
unsuitable for assays to measure their binding affinity for GST. The inhibitory
activity of the triazoles could only be determined by using 15 % DMSO to solubilise
the ligands in the CDNB activity assay. The hydrophobic nature of these ligands
highlights a drawback in the multivalent approach to drug discovery, which becomes
limited by the size and hydrophobicity of the molecules that are designed. The
library fragments also had limited solubility in the reaction buffer, which resulted in
the reactions being performed at almost saturated conditions to try to obtain the
maximum amount of triazole being produced in the protein-templated reaction. It
would perhaps help the ISCC reaction if the water solubility of the reacting
fragments was increased.
The best area for the introduction of some hydrophilic groups would appear
to be the peptidic spacer as this is binding in the solvent-accessible cleft, and might
be expected to be more tolerant to the introduction of added functionality. The two
areas that could be modified are the side chain of the peptide backbone, marked A in
Scheme 13. Alternatively hydrophilic groups could be introduced onto the central
phenyl ring of the spacer, marked B in Scheme 13. These modifications could be
investigated using the ISCC reaction, to see if the increased solubility results in
clearer results from the reaction. The identification of the novel bivalent inhibitors
TZ03a-01-03a and TZ03a-01-04a, combined with the lack of success with the ISCC
reaction for the GST target so far, may warrant a more traditional approach by
synthesis of a combinatorial library in the lab, followed by biological testing. The
synthesis of analogues of the symmetrical inhibitor TZ03a-01-03a could be achieved
in three simple steps using reliable chemistry already demonstrated in this chapter.
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Scheme 13: A scheme to outline the potential for adding more water soluble groups to
bivalent product TZ03a-01-03a. A) Sites A and B highlight the positions on TZ03a-01-03a
that could be modified to add hydrophilic groups, B) A scheme to outline a simple three step
procedure to synthesize analogues of TZ03a-01-03a. a) diazotransfer step, b) amide
coupling step, c) Cu (I) catalysed click reaction step.
3.15 Conclusions and future work
Two novel bivalent inhibitors of GST with low nanomolar inhibitory activity
have been identified in this work.
Chapter 3
152
Figure 25: Two novel bivalent GST inhibitors TZ03a-01-03a and TZ03a-01-04a and their
IC50 binding data for four GST isoforms determined using the CDNB binding assay.
TZ03a-01-03a is a bivalent compound linking together two ethacrynic acid
moieties with a triazolopeptide spacer. The compound had excellent binding affinity
for both mGSTM1-1 and SjGST, with IC50 values of 4 nM and 14 nM respectively.
This is the most potent GSTM1-1 inhibitor reported to date (previous best is cibacron
blue, IC50 = 700 nM for mGSTM1-1).
[20] TZ03a-01-04a linked one ethacrynic acid
group with a naphthyl group utilizing the same triazolopeptide spacer. This
compound was highly isoform selective for mGSTM1-1 over three other GST
isoforms tested, hGSTP1-1, mGSTA4-4 and SjGST, with an IC50 value 200 times
greater for mGSTM1-1 than for any other isoform. This is unprecedented selectivity
for GSTM1-1, with the previous best selectivity exhibited being a 3-fold increase in
potency for a glutathione analogue over GSTP1-1 and GSTA1-1.[46] Whilst these
ditriazole compounds were discovered as part of an ISCC approach, the




As has already been discussed, the immediate work that is required is the
measurement of the binding affinity of the observed ditriazoles for GST, either by
SPR or ITC. Unfortunately the poor water solubility of these ligands makes this very
difficult to achieve and so the hydrophilicity of these triazoles needs to be improved.
Obtaining a crystal structure of a ditriazole product bound to GST or alternatively the
use of molecular modelling is also important to understand where the spacers are
binding on the protein. The reactions in which triazoles are observed need to be
analysed to ensure there is no trace of copper (I) or ruthenium present, which might
promote triazole synthesis.
In summary, a new ISCC screen has been developed to investigate novel
bivalent inhibitors of GST. The results from the ISCC reactions have highlighted
some potential problems with the ISCC approach to target-guided synthesis,
including difficulties when the background reaction is observed, the possibility of
false negatives and the need for flexibility of the reactive functional groups in the
fragment library design. The results from the ISCC reaction suggested that several
examples were being specifically amplified in the presence of one or more isoforms
of GST over the background and the control protein reactions. The evidence
indicated that the hydrophobic pocket of GST, which was the expected site of
binding, was not the template for the increase in triazole formation. Work now needs
to be done to identify the binding site on GST for the bistriazole compounds. In the
course of the project two of the bistriazole compounds synthesized, TZ03a-01-03a
and TZ03a-01-04a, were found to be potent inhibitors of mGSTM1-1 and in the
latter case, TZ03a-01-04a, highly isoform specific.
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Three novel, potent, bivalent GST inhibitors have been reported in this thesis.
The linkers were based on a design first described by Atkins and co-workers, which
connected two substrates that demonstrated binding affinity for the hydrophobic
binding pocket of GST with a central linker unit, as outlined in Figure 1.
Figure 1: Three novel bivalent GST inhibitors HZN01-03-01, TZ03a-01-03a and
TZ03a-01-04a and their IC50 binding data for four GST isoforms.
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The first potent inhibitor described in this thesis linked two molecules of
DNP GSH using an acylhydrazone linkage. The best inhibitor HZN01-03-01
exhibited an IC50 value of 50 nM towards mGSTM1-1, which was a 20-fold
improvement in inhibition over any other GST isoform tested. The other two
inhibitors were designed based on a triazole connection; a symmetrical ligand
TZ03a-01-03a connecting two molecules of ethacrynic acid and an asymmetrical
ligand TZ03a-01-04a connecting a molecule of ethacrynic acid with a naphthalene
species. The symmetrical ligand TZ03a-01-03a is the most potent inhibitor of
GSTM1-1 reported to date with an IC50 of 5 nM. The asymmetrical ligand
TZ03a-01-04a (IC50 = 55 nM for GSTM1-1) offers excellent isoform specific with a
200-fold improvement in inhibitory activity for GSTM1-1 over SjGST, hGSTP1-1
and mGSTA4-4.
The acylhydrazone ligand HZN01-03-01 was discovered using a DCC
approach, employing aniline-catalysed acylhydrazone formation as the reversible
reaction. Acylhydrazone linker HZN01-03-01 was selectively amplified in the
presence of a GST from a library composing of four bis hydrazide linkers and three
aldehyde fragments. The amplifications observed in the DCL correlated well with the
binding data for the product compounds.
A second TGS approach has also been established using in situ click
chemistry (ISCC) to try to identify novel GST inhibitors. This approach proved to be
much more complicated than using DCC. In a direct comparison with the DCC
approach, attempts to synthesise the symmetrical ditriazole ligand TZ03a-01-03a
from a bis azide linker AZ01 and two alkyne fragments in the presence of the GST
template proved to be unsuccessful. There was evidence of the formation of the
monotriazole product TZ03a-01 but the observation of the background reaction in
the absence of GST made the interpretation of this data difficult. Some amplification
in monotriazole product was observed in the presence of GST for several alkynes,
however these amplifications did not correlate with the inhibitory activity of the
monotriazole products. Attempts to synthesise TZ03a-01-03a from the monoazide
TZ03a-01 in the presence of GST were also unsuccessful, with no increase in
product formation observed in the presence of GST over the background. The
inhibitory activity of the ditriazole product showed a significant improvement over
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the starting azide and alkyne fragments (35-fold improvement over azide) suggesting
that an in situ hit should be observed. The failure to template the click reaction in this
example may be because a symmetrical template was being used with asymmetric
reactive fragments. Replacing the ethacrynic acid-tagged azide with a less potent
azide TZ04a-01 resulted in the formation of several triazole products being
amplified in the presence of GST, but again the inhibitory activity of these
compounds did not correspond with the observed amplifications. This result suggests
that a different binding site on the GST could be responsible for templating the click
reaction and work is now been done to identify where these ligands could be binding
to GST. The primary goal of identifying novel inhibitors through the use of ISCC has
failed. The binding affinity of these ligands for GST needs to be calculated to find
out if, as the ISCC data suggests, the ligands are binding to a different site, not
associated with the enzyme’s activity.
This work has identified several drawbacks to the use of ISCC as a tool in
drug design, which need to be addressed. The major problem that was encountered
during the ISCC screens was the observation of the background reaction. The ISCC
approach was originally hailed a successful reaction for kinetic TGS as no
background reaction was observed, however as ISCC has been applied to more
ambitious targets, so more weakly binding fragments have been employed. Because
of the weak binding affinity of the azide and alkyne fragments, much greater
concentrations are required in the ISCC reaction and this seems to be the cause for
observing the background reaction. Clearly for ISCC to be a useful technique the use
of weakly binding fragments will be a necessity and therefore a clear set of rules
defining how much amplification in triazole formation results in a hit need to be
established. To avoid the problems associated with defining a hit, it might be
advisable to pursue the use of ISCC with a solid phase approach; that is to
immobilise the protein template on a solid support which would allow any triazole
products formed in the template to be easily separated from the reaction mixture and
identified, thus negating the problems observed with comparisons to the background
reaction.
One of the aims of this thesis was to compare the thermodynamic TGS
approach with the kinetic TGS approach using a difficult protein target whilst also
Chapter 4
160
employing a multicomponent reaction. With respect to this DCC has clearly proved
to be a much more suitable approach, identifying novel inhibitors from a three
component reaction. The confusing results observed in the ISCC reactions indicate
that there are limitations to the biological targets that can be used with ISCC.
The advantages of a multivalent approach to drug discovery have clearly been
demonstrated within this thesis. Linking two molecules of the substrate product
DNP GSH to synthesise HZN01-03-01 resulted in a 6800-fold increase in inhibition
of mGSTM1-1 (IC50 of DNP GSH-aldehyde ALD01 = 340 M, IC50 of
HZN01-03-01 = 50 nM). The potency of ethacrynic acid for mGSTM1-1 was
improved 250-fold by linking two molecules together to yield TZ03a-01-03a (IC50
of alkyne-functionalised ethacrynic acid ALK03 = 1.1 M, IC50 of
TZ03a-01-03a = 4 nM).
Atkins utilised the idea of multivalency to overcome the challenge of
designing isoform specific inhibitors of GST and demonstrated this in the design of
specific inhibitors of GSTA1-1 and GSTP1-1. This thesis has now reported specific
inhibitors of GSTM1-1, a target in anti-cancer therapy, and demonstrated the ease
with which a DCC approach can be used to identify these inhibitors based on a
similar motif to the Atkins inhibitors (ligand-linker-ligand). This design can easily be
exploited by varying both the ligands used and the length of the linkers to identify
more new isoform specific GST inhibitors.
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Chapter 5 Experimental Data
5.1 Product synthesis and characterisation
5.1.1 General methods
1H and 13C NMR spectra were recorded on a Brüker AVA500 (500 MHz)
instrument. All NMR spectra were referenced internally to residual protio solvent
(1H) or solvent (13C) resonances and are reported relative to tetramethylsilane
(δ = 0 ppm). Chemical shifts are quoted in δ (ppm) and coupling constants in Hertz. 
Electrospray high resolution mass spectrometry was performed by the EPSRC
National Mass Spectrometry Service Centre, Swansea, using a Thermofisher LTQ
Orbitrap XL mass spectrometer. The data is recorded as the ionisation method
followed by the calculated and measured masses. Liquid chromatography low
resolution mass spectrometry was performed on an Agilent 1200 series LC-MS and
recorded as the calculated and measured masses followed by the LC purity measured
by the UV spectrum (at 254 nm) and finally the retention time (with gradient
described in section 5.2.2). Infrared spectra were obtained using a Shimadzu FT-IR
Affinity-1 spectrophotometer or a JASCO FT/IR-460 using sodium chloride disks.
[α]D values were calculated using an AA-55 Series Automatic Polarimeter. Melting
points are uncorrected. TLC was performed on Merck 60F254 silica plates and
visualised by UV light and/or anisaldehyde or potassium permanganate stains. All
chemicals were purchased from a chemical supplier and used as received.
5.1.2 Synthesis of compounds described in Chapter 2
Hydrazides
HZD02 Isophthalic acid dihydrazide
Dimethylisophthalate (1.0 g, 5.2 mmol) was dissolved in dry methanol
(25 mL). Hydrazine hydrate (2.3 mL, 30.9 mmol) was added and the reaction was
stirred at room temperature overnight. The resulting precipitate was collected by
filtration and the white solid was washed with methanol (3 x 25 mL). The final
product was obtained as a white solid in 98 % yield. Mass = 1.0 g.
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1H NMR (500 MHz, d6-DMSO) δ 9.82 (s, 2H, NH), 8.26 (t, J = 1.6 Hz, 1H, ArH),
7.91 (dd, J = 7.7, 1.8 Hz, 2H, ArH), 7.52 (t, J = 7.7 Hz, 1H, ArH), 4.53 (s, 4H, NH2);
13C NMR (126 MHz, d6-DMSO) δ 165.5 (C=O), 133.6 (ArC-C), 129.3 (ArC-H),
128.5 (ArC-H), 126.1 (ArC-H); IR (film) 3287, 1657, 1620, 1587, 1522, 1479, 1321,
1308, 1109 cm-1.
The spectroscopic data is in agreement with that previously reported.[1]
Isophthalic acid alanine methyl ester
To a solution of isophthalic acid (897 mg, 5.4 mmol) in chloroform (50 mL),
L-alanine methyl ester (1.5 g, 10.8 mmol) and DMAP (269 mg, 2.2 mmol) were
added at 0 °C. After 10 minutes of stirring EDC.HCl (2.53 g, 13.2 mmol) was added.
The reaction was stirred overnight at room temperature. The reaction mixture was
quenched with water (100 mL), extracted with chloroform (50 mL) and washed with
water (3 x 100mL). The organic layer was dried (MgSO4), filtered and concentrated
under reduced pressure. The product was purified by flash column chromatography,
eluting with ethyl acetate (100 %) to yield a white solid, yield = 53 %. Mass =
963 mg.
1H NMR (500 MHz, CDCl3) δ 8.16 (t, J = 1.5 Hz, 1H, ArH), 7.88 (dd, J = 7.7, 1.7
Hz, 2H, ArH), 7.42 (t, J = 7.6 Hz, 1H, ArH), 7.07 (d, J = 7.1 Hz, 2H, NH),
4.87 – 4.71 (m, 2H, CHCH3), 3.77 (s, 6H, OCH3), 1.51 (d, J = 7.3 Hz, 6H, CH3CH);
13C NMR (126 MHz, CDCl3) δ 173.9 (C=O), 166.3 (C=O), 134.3 (ArC-C), 130.6
(ArC-H), 129.2 (ArC-H), 125.5 (ArC-H), 52.8 (OCH3), 48.8 (CHCH3), 18.5
(CH3-CH); HRMS (ESI+) calcd for C16H21O6N2 [M + H]
+ 337.1394, found
337.1397; IR (film) 3321, 1742, 1636, 1522, 1454, 1207, 1175, 1156 cm-1; MP
125 – 127 °C; [α]D = + 60.0 (c = 0.5 in CHCl3).
HZD03 Isophthalic acid alanine dihydrazide
Isophthalic acid alanine methyl ester (500 mg, 1.5 mmol) was dissolved in
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dry methanol (20 mL). Hydrazine hydrate (0.68 mL, 8.9 mmol) was added and the
reaction was stirred at room temperature overnight. The resulting precipitate was
collected by filtration and the white solid was washed with methanol (3 x 20 mL).
The final product was obtained as a white solid in 74 % yield. Mass = 370 mg.
1H NMR (500 MHz, d6-DMSO) δ 9.19 (s, 2H, NH), 8.57 (d, J = 7.6 Hz, 2H, NH),
8.35 (t, J = 1.7 Hz, 1H, ArH), 8.01 (dd, J = 7.7, 1.7 Hz, 2H, ArH), 7.54 (t, J = 7.7
Hz, 1H, ArH), 4.54 – 4.43 (m, 2H, CHCH3), 4.22 (s, 4H, NH2), 1.33 (d, J = 7.2 Hz,
6H, CH3CH);
13C NMR (126 MHz, d6-DMSO) δ 171.6 (C=O), 165.6 (C=O), 134.1
(ArC-C), 130.3 (ArC-H), 128.1 (ArC-H), 126.8 (ArC-H), 47.8 (CHCH3), 18.2
(CH3-CH); HRMS (ESI+) calcd for C14H21O4N6 [M + H]
+ 337.1619, found
337.1616; IR (film) 3291, 1645, 1634, 1607, 1559, 1526, 1271, 1258 cm-1; MP
228 – 232 °C; [α]D = + 33.3 (c = 0.57 in H2O).
1,3-phenylenediacetic acid alanine methyl ester
To a solution of 1,3-diphenylenediacetic acid (1.0 g, 5.4 mmol) in chloroform
(50 mL), alanine methyl ester (1.5 g, 10.8 mmol) and DMAP (269 mg, 2.2 mmol)
were added at 0 °C. After 10 minutes of stirring EDC.HCl (2.5 g,
13.2 mmol) was added. The reaction was stirred overnight at room temperature. The
reaction mixture was quenched with water (100 mL), extracted with chloroform
(50 mL) and washed with water (3 x 100mL). The organic layer was dried (MgSO4),
filtered and concentrated under reduced pressure. The product was purified by flash
column chromatography, eluting with ethyl acetate (100 %) to yield a white solid,
yield = 48 %. Mass = 953 mg.
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.30 (m, 1H, ArH), 7.22 – 7.16 (m, 3H, ArH),
6.05 (d, J = 6.8 Hz, 2H, NH), 4.60 – 4.52 (m, 2H, CHCH3), 3.68 (s, 6H, OCH3), 3.56
(s, 4H, CH2C(=O)), 1.33 (d, J = 7.3 Hz, 6H, CH3CH);
13C NMR (126 MHz, CDCl3)
δ 173.6 (C=O), 170.5 (C=O), 135.5 (ArC-C), 130.6 (ArC-H), 129.8 (ArC-H), 128.6
(ArC-H), 52.7 (OCH3), 48.3 (CHCH3), 43.6 (CH2), 18.4 (CH3CH); HRMS (ESI+)
calcd for C18H25O6N2 [M + H]
+ 365.1707, found 365.1709; IR (film) 3304, 1749,
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1738, 1640, 1530, 1437, 1358, 1211, 1165, 1148 cm-1; MP 141 – 144 °C;
[α]D = + 30.0 (c = 0.5 in CHCl3).
HZD04 1,3-phenylenediacetic acid alanine hydrazide
1,3-phenylenediacetic acid alanine methyl ester (500 mg, 1.4 mmol) was
dissolved in dry methanol (20 mL). Hydrazine hydrate (0.6 mL, 8.2 mmol) was
added and the reaction was stirred at room temperature overnight. The resulting
precipitate was collected by filtration and the white solid was washed with methanol
(3 x 20 mL). The final product was obtained as a white solid in 68 % yield. Mass =
339 mg.
1H NMR (500 MHz, d6-DMSO) δ 9.10 (s, 2H, NH), 8.23 (d, J = 7.8 Hz, 2H, NH),
7.22 – 7.15 (m, 1H, ArH), 7.14 – 7.07 (m, 3H, ArH), 4.31 – 4.12 (m, 6H, CHCH3
and NH2), 3.41 (d, J = 2.0 Hz, 4H, CH2C(=O)), 1.17 (d, J = 7.1 Hz, 6H, CH3CH);
13C NMR (126 MHz, d6-DMSO) δ 171.5 (C=O), 169.6 (C=O), 136.2 (ArC-C), 129.9
(ArC-H), 127.9 (ArC-H), 127.0 (ArC-H), 46.8 (CHCH3), 41.9 (CH2), 18.7
(CH3CH); HRMS (ESI+) calcd for C16H25O4N6 [M + H]
+ 365.1932, found 365.1941;
IR (film) 3291, 1661, 1620, 1539, 1441, 1418, 1354, 1240 cm-1; MP 214 – 218 °C;
[α]D = - 40.9 (c = 0.44 in DMSO).
Aldehyde


















Commercially available bishydrazide HZD01 (50 mg, 0.3 mmol) and
aldehyde ALD01 (262 mg, 0.6 mmol) were dissolved in water (5 mL). A few drops
of glacial acetic acid were added to the stirred mixture until a yellow precipitate was
observed. The solid was collected by filtration and washed with ice cold ether (2 x
10 mL). The solid was resuspended in water and lyophilised. The final product was
obtained as a yellow solid in 58 % yield. Mass = 175 mg.
1H NMR could not be determined due to poor solubility of sample. HRMS (ESI–)
calcd for C40H48O18N12S2 [M – 2H]
2- 524.1331, found 524.1346; HPLC (UV λ = 254 
nm, Gradient A (section 5.2.1)) purity > 95 %, retention time 16.6 min; IR (film)
1643, 1607, 1514, 1400, 1337, 1221, 1107 cm-1; MP decomposition observed > 200
°C.
HZN01-02-01
Bishydrazide HZD02 (50 mg, 0.3 mmol) and aldehyde ALD01 (235 mg,
0.5 mmol) were dissolved in water (5 mL). A few drops of glacial acetic acid were
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added to the stirred mixture until a yellow precipitate was observed. The solid was
collected by filtration and washed with ice cold ether (2 x 10 mL). The solid was
resuspended in water and lyophilised. The final product was obtained as a yellow
solid in 71 % yield. Mass = 195 mg.
1H NMR could not be determined due to poor solubility of sample. LC/MS mass
calcd for C42H47O18N12S2 [M + H]
+ 1071.2, found 1071.0; HPLC (UV λ = 254 nm, 
Gradient A (section 5.2.1)) purity > 95 %, retention time 19.4 min; IR (film) 1643,




































Bishydrazide HZD03 (100 mg, 0.3 mmol) and aldehyde ALD01 (271 mg,
0.6 mmol) were dissolved in water (10 mL). A few drops of glacial acetic acid were
added to the stirred mixture until a yellow precipitate was observed. The solid was
collected by filtration and washed with ice cold ether (2 x 10 mL). The solid was
resuspended in water and lyophilised. The final product was obtained as a yellow
solid in 24 % yield. Mass = 87 mg.
1H NMR (500 MHz, d6-DMSO) δ 12.00 – 11.81 (m, 1H), 11.71 – 11.52 (m, 1H), 
9.02 – 8.86 (m, 1H), 8.86 – 8.61 (m, 4H), 8.51 – 8.37 (m, 3H), 8.36 – 8.30 (m, 1H),
8.18 – 7.94 (m, 5H), 7.80 (m, 3H), 7.66 – 7.50 (m, 1H), 5.45 – 5.26 (m, 1H),
4.64 – 4.45 (m, 3H), 3.84 – 2.86 (m, 13H), 2.40 – 2.20 (m, 3H), 2.04 – 1.71 (m, 4H),
1.44 (t, J = 7.8 Hz, 4H), 1.23 (s, 3H). HRMS (ESI+) calcd for C48H57O20N14S2
[M + H]+ 1213.3309, found 1213.3286; HPLC (UV λ = 254 nm, Gradient A (section 
5.2.1)) purity > 95 %, retention time 18.5 min; IR (film) 1643, 1609, 1514, 1398,




Bishydrazide HZD04 (50 mg, 0.1 mmol) and aldehyde ALD01 (125 mg,
0.3 mmol) were dissolved in water (15 mL). A few drops of glacial acetic acid were
added to the stirred mixture until a yellow precipitate was observed. The solid was
collected by filtration and washed with ice cold ether (2 x 10 mL). The solid was
resuspended in water and lyophilised. The final product was obtained as a yellow
solid in 44 % yield. Mass = 75 mg.
1H NMR (500 MHz, d6-DMSO) δ 11.81 (d, J = 45.4 Hz, 1H), 11.61 (s, 1H), 8.81 (s,
2H), 8.65 (s, 2H), 8.60 – 8.52 (m, 1H), 8.44 (s, 1H), 8.41 – 8.32 (m, 2H), 8.27 (d,
J = 11.2 Hz, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.96 (d, J = 7.5 Hz, 2H), 7.83 – 7.68 (m,
2H), 7.24 – 7.05 (m, 4H), 5.19 – 5.07 (m, 1H), 4.61 – 4.51 (m, 2H), 4.39 – 4.28 (m,
1H), 3.79 – 3.66 (m, 5H), 3.58 – 3.30 (m, 9H), 3.30 – 3.14 (m, 4H), 2.32 (s, 4H),
2.02 – 1.78 (m, 4H), 1.36 (m, 6H). HRMS (ESI+) calcd for C50H61O20N14S2
[M + H]+ 1241.3622, found 1241.3596; HPLC (UV λ = 254 nm, Gradient A (section 
5.2.1)) purity > 95 %, retention time 17.5 min; IR (film) 1641, 1609, 1516, 1398,
1337, 1227, 1107 cm-1; MP decomposition observed > 200 °C.
HZN02-02-02
Bishydrazide HZD02 (50 mg, 0.3 mmol) and aldehyde ALD02 (96 mg,
0.5 mmol) were dissolved in an ethanol/water mix (10 mL, 1:1). A few drops of
glacial acetic acid were added to the stirred mixture until a precipitate was observed.
The solid was collected by filtration and washed with ice cold ether (2 x 10 mL). The
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solid was resuspended in water and lyophilised. The final product was obtained as a
white solid in 79 % yield. Mass = 107 mg.
1H NMR (500 MHz, d6-DMSO) δ 12.35 (s, 2H, NH), 8.54 (s, 2H, CH=N), 8.49 (s,
1H, ArH), 8.42 (s, 2H, ArH), 8.16 (d, J = 7.5 Hz, 2H, ArH), 8.09 (d, J = 8.3 Hz, 2H,
ArH), 7.89 (d, J = 8.4 Hz, 2H, ArH), 7.74 (t, J = 7.6 Hz, 1H, ArH); 13C NMR
(126 MHz, d6-DMSO) δ 191.3, 163.3, 148.4, 145.2, 136.2, 135.4, 134.0, 133.9, 
133.3, 132.7, 132.1, 131.6, 129.4, 127.7, 126.7, 126.4, 124.1; LC/MS mass calcd for
C22H15O6N6Cl2 [M + H]
+ 529.1, found 529.0; HPLC (UV λ = 254 nm, Gradient A 
(section 5.2.1)) purity > 95 %, retention time 34.2 min; IR (film) 3190, 3028, 1659,
1605, 1557, 1535, 1343, 1304, 1277, 1256, 1225, 1171, 1125 cm-1.
HZN02-03-02
Bishydrazide HZD03 (50 mg, 0.15 mmol) and aldehyde ALD02 (55 mg,
0.3 mmol) were dissolved in an ethanol/water mix (10 mL, 1:1). A few drops of
glacial acetic acid were added to the stirred mixture until a precipitate was observed.
The solid was collected by filtration and washed with ice cold ether (2 x 10 mL). The
solid was resuspended in water and lyophilised. The final product was obtained as a
white solid in 64 % yield. Mass = 64 mg.
1H NMR (500 MHz, d6-DMSO) δ 11.88 (s, 1H, NH), 11.67 (s, 1H, NH), 8.87 – 8.80
(m, 1H, CH=N), 8.80 (dd, J = 6.9, 5.0 Hz, 1H, CH=N), 8.44 – 8.34 (m, 3H, ArH),
8.33 (s, 1H, NH), 8.10 – 7.97 (m, 5H, 4 x ArH and 1 x NH), 7.84 (dd, J = 8.4,
3.5 Hz, 2H, ArH), 7.62 – 7.53 (m, 1H, ArH), 5.41 – 5.30 (m, 1H, CHCH3),
4.61 – 4.51 (m, 1H, CHCH3), 1.43 (dd, J = 7.0, 5.3 Hz, 6H, CH3CH);
13C NMR (126
MHz, d6-DMSO) δ 174.0, 169.5, 166.0, 165.7, 148.1, 147.9, 143.5, 140.0, 135.0, 
134.9, 134.2, 134.0, 132.2, 132.1, 131.4, 131.1, 130.3, 128.2, 126.9, 125.7, 125.3,
123.6, 123.3, 48.6, 46.3, 17.5, 16.7; HRMS (ESI+) calcd for C28H28O8N9Cl2
[M + NH4]
+ 688.1432, found 688.1424; HPLC (UV λ = 254 nm, Gradient A (section 
5.2.1)) purity > 95 %, retention time 33.5 min; IR (film) 3300, 3071, 1682, 1645,
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1532, 1478, 1348, 1258, 1233, 1130 cm-1;  MP 198 – 204 °C; [α]D = + 216.6 (c = 0.3
in 2:1 CHCl3 / DMSO).
HZN02-04-02
Bishydrazide HZD04 (50 mg, 0.1 mmol) and aldehyde ALD02 (51 mg,
0.3 mmol) were dissolved in an ethanol/water mix (10 mL, 1:1). A few drops of
glacial acetic acid were added to the stirred mixture until a precipitate was observed.
The solid was collected by filtration and washed with ice cold ether (2 x 10 mL). The
solid was resuspended in water and lyophilised. The final product was obtained as a
white solid in 76 % yield. Mass = 73 mg.
1H NMR (500 MHz, d6-DMSO) δ 11.81 (s, 1H, NH), 11.63 (s, 1H, NH), 8.54 – 8.46
(m, 1H, CH=N), 8.44 – 8.39 (m, 1H, CH=N), 8.37 – 8.30 (m, 2H, ArH), 8.26 (s, 1H,
NH), 8.07 – 7.92 (m, 3H, 2 x ArH and 1 x NH), 7.84 (dd, J = 8.4, 3.9 Hz, 1H, ArH),
7.79 (d, J = 8.4 Hz, 1H, ArH), 7.25 – 7.05 (m, 4H, ArH), 5.13 (dq, J = 7.8, 7.1 Hz,
1H, CHCH3), 4.34 (dq, J = 7.8, 7.1 Hz, 1H, CHCH3), 3.51 – 3.39 (m, 4H, CH2),
1.28 (d, J = 7.2 Hz, 6H, CH3CH);
13C NMR (126 MHz, d6-DMSO) δ 174.6, 170.5, 
170.1, 169.9, 148.5, 148.3, 144.0, 140.4, 136.5, 135.4, 135.3, 132.6, 132.5, 132.0,
131.5, 130.3, 128.4, 127.4, 126.2, 125.7, 124.0, 123.7, 48.1, 45.72, 42.3, 42.2, 18.4,
17.6; LC/MS mass calcd for C30H29O8N8Cl2 [M + H]
+ 699.1, found 699.2; HPLC
(UV λ = 254 nm, Gradient A (section 5.2.1)) purity > 95 %, retention time 33.0 min; 
IR (film) 3269, 3063, 2976, 1678, 1645, 1609, 1532, 1449, 1397, 1354, 1263, 1132
cm-1.
HZN03-02-03
Bishydrazide HZD02 (50 mg, 0.3 mmol) and aldehyde ALD03 (78 mg,
0.6 mmol) were dissolved in an ethanol/water mix (10 mL, 1:1). A few drops of
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glacial acetic acid were added to the stirred mixture until a precipitate was observed.
The solid was collected by filtration and washed with ice cold ether (2 x 10 mL). The
solid was resuspended in water and lyophilised. The final product was obtained as a
white solid in 46 % yield. Mass = 55 mg.
1H NMR (500 MHz, d6-DMSO) δ 12.33 (s, 2H, NH), 8.62 (s, 2H, CH=N or ArH),
8.60 (s, 2H, CH=N or ArH), 8.51 (s, 1H, ArH), 8.30 (d, J = 7.6 Hz, 2H, ArH),
8.23 – 8.14 (m, 4H, ArH), 7.83 – 7.72 (m, 3H, ArH); 13C NMR (126 MHz,
d6-DMSO) δ 163.3, 148.7, 146.3, 136.6, 134.0, 131.6, 131.0, 129.4, 127.6, 124.9, 
121.5; LC/MS mass calcd for C22H17O6N6 [M + H]
+ 461.1, found 461.1; HPLC (UV
λ = 254 nm, Gradient A (section 5.2.1)) purity > 95 %, retention time 29.6 min; IR 
(film) 3181, 3017, 1665, 1649, 1564, 1524, 1350, 1306, 1273, 1169 cm-1.
HZN03-03-03
Bishydrazide HZD03 (50 mg, 0.15 mmol) and aldehyde ALD03 (45 mg,
0.30 mmol) were dissolved in an ethanol/water mix (10 mL, 1:1). A few drops of
glacial acetic acid were added to the stirred mixture until a precipitate was observed.
The solid was collected by filtration and washed with ice cold ether (2 x 10 mL). The
solid was resuspended in water and lyophilised. The final product was obtained as a
white solid in 70 % yield. Mass = 62 mg.
1H NMR (500 MHz, d6-DMSO) δ 11.88 (s, 1H, NH), 11.67 (s, 1H, NH), 8.88 (t,
J = 6.0 Hz, 1H, CH=N), 8.78 (dd, J = 7.2, 3.3 Hz, 1H, CH=N), 8.53 (s, 1H, ArH),
8.50 (s, 1H, ArH), 8.43 (t, J = 6.8 Hz, 1H, ArH), 8.40 (s, 1H, NH), 8.26 (d,
J = 8.1 Hz, 2H, ArH), 8.20 – 8.12 (m, 3H, ArH and NH), 8.10 – 8.04 (m, 2H, ArH),
7.75 (td, J = 8.0, 1.8 Hz, 2H, ArH), 7.64 – 7.55 (m, 1H, ArH), 5.39 (dq, J = 8.4,
7.3 Hz, 1H, CHCH3), 4.59 (dq, J = 8.4, 7.3 Hz, 1H, CHCH3), 1.46 (dd, J = 13.1,
7.2 Hz, 6H, CH3CH);
13C NMR (126 MHz, d6-DMSO) δ 174.5, 169.9, 166.5, 
166.2, 148.8, 148.7, 145.0, 141.6, 136.7, 136.5, 134.7, 134.5, 133.7, 133.2, 130.9,
130.8, 128.7, 127.4, 124.7, 124.6, 121.5, 49.1, 46.7, 18.0, 17.2; LC/MS mass calcd
for C28H27O8N8 [M + H]
+ 603.2, found 603.2; HPLC (UV λ = 254 nm, Gradient A 
(section 5.2.1)) purity > 95 %, retention time 29.0 min; IR (film) 3225, 3075, 1682,
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1632, 1570, 1530,1350, 1242 cm-1.
HZN03-04-03
Bishydrazide HZD04 (50 mg, 0.15 mmol) and aldehyde ALD03 (42 mg,
0.3 mmol) were dissolved in an ethanol/water mix (10 mL, 1:1). A few drops of
glacial acetic acid were added to the stirred mixture until a precipitate was observed.
The solid was collected by filtration and washed with ice cold ether (2 x 10 mL). The
solid was resuspended in water and lyophilised. The final product was obtained as a
white solid in 45 % yield. Mass = 39 mg.
1H NMR (500 MHz, d6-DMSO) δ 11.77 (s, 1H, NH), 11.59 (s, 1H, NH), 8.55 – 8.47
(m, 2H, CH=N and ArH), 8.45 – 8.38 (m, 2H, CH=N and ArH), 8.32 (s, 1H, NH),
8.28 – 8.20 (m, 2H, ArH), 8.15 – 8.07 (m, 3H, ArH and NH), 7.79 – 7.66 (m, 2H,
ArH), 7.26 – 7.06 (m, 4H, ArH), 5.16 (dq, J = 7.6, 7.2 Hz, 1H, CHCH3), 4.36 (dq,
J = 7.6, 7.2 Hz, 1H, CHCH3), 3.53 – 3.38 (m, 4H, CH2), 1.31 (dd, J = 11.0, 7.1 Hz,
6H, CH3CH);
13C NMR (126 MHz, d6-DMSO) δ 174.5, 170.5, 170.1, 169.8, 148.7, 
148.7, 145.0, 141.5, 136.6, 136.6, 136.4, 133.7, 133.1, 130.8, 130.3, 128.4, 127.5,
127.4, 124.7, 124.5, 121.5, 48.1, 45.7, 42.3, 42.2, 18.5, 17.6; LC/MS mass calcd for
C30H31O8N8 [M + H]
+ 631.2, found 631.2; HPLC (UV λ = 254 nm, Gradient A 
(section 5.2.1)) purity > 95 %, retention time 28.0 min; IR (film) 3262, 3208, 3065,
1686, 1668, 1647, 1528, 1348, 1234 cm-1.
5.1.3 Synthesis of compounds described in Chapter 3
Azide linker library
Imidazole sulfonylazide
Sulfuryl chloride (16 mL, 200 mol) was added drop-wise to an ice-cooled
suspension of sodium azide (13.0 g, 200 mmol) in acetonitrile (200 mL). The
reaction mixture was stirred at room temperature overnight. Imidazole (25.9 g,
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380 mmol) was added portion-wise to the ice-cooled reaction mixture. The resulting
slurry was stirred at room temperature for 3 hours. The reaction mixture was then
diluted with ethyl acetate (400 mL) and washed with water (2 x 400 mL) followed by
saturated aqueous sodium bicarbonate solution (2 x 400 mL). The organic layer was
dried (MgSO4) and filtered. A solution of HCl in ethanol was made by the drop-wise
addition of acetyl chloride (21.3 mL, 300 mmol) to ice-cooled dry ethanol. This
solution of HCl in ethanol was added to the filtrate with stirring. The mixture was
chilled in an ice-bath to obtain colourless needles that were collected by filtration and
washed with ethyl acetate (3 x 100 mL). Yield = 65 %. Mass = 27.2 g.
1H NMR (500 MHz, D2O) δ 9.45 (dd, J = 1.8, 1.4 Hz, 1H, ArH), 8.08 (dd, J = 2.2,
1.9 Hz, 1H, ArH), 7.67 (dd, J = 2.2, 1.3 Hz, 1H, ArH); 13C NMR (126 MHz, D2O)
δ 137.7 (ArCH), 123.3 (ArCH), 120.1 (ArCH); IR (thin film, NaCl plate): 2920,
2853, 2171, 1456, 1428, 1231, 1192, 1162, 1139 cm-1
The spectroscopic data is in agreement with that previously reported.[3]
General procedure A- diazotransfer step
Amino acid (250 mg, 2.8 mmol), potassium carbonate (853 mg,
6.2 mmol) and copper (II) sulfate pentahydrate (7 mg, 28 μmol) were dissolved in 
methanol (15 mL) at room temperature. Imidazole-1-sulfonyl azide.HCl (704 mg,
3.4 mmol) was added to this solution, which was stirred at room temperature
overnight. The mixture was concentrated under reduced pressure and then diluted
with water (50 mL), which was then acidified with HCl (conc.). The product was
extracted in to ethyl acetate (3 x 30 mL). The organic layer was dried (MgSO4),
filtered and concentrated under reduced pressure.
Azidoglycine
Azidoglycine was synthesised by general procedure A, starting from glycine
(1.0 g, 13.3 mmol). The product was purified by flash column chromatography,
eluting with ethyl acetate/hexane/acetic acid (50 / 48 / 2) to yield a colourless oil.
Yield = 82 %. Mass = 1.1 g.
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1H NMR (500 MHz, CDCl3) δ 11.20 (s, 1H, COOH), 3.94 (s, 2H, CH2);
13C NMR
(126 MHz, CDCl3) δ 175.1 (COOH), 50.5 (CH2); IR (film) 3104, 2108, 1722, 1418,
1281, 1223 cm-1.
The spectroscopic data is in agreement with that previously reported.[4]
Azidovaline
Azidovaline was synthesised by general procedure A, starting from L-valine
(5.0 g, 43 mmol). The product was purified by flash column chromatography, eluting
with ethyl acetate/hexane/acetic acid (20 / 79 / 1) to yield a colourless oil. Yield =
88 %. Mass = 4.9 g.
1H NMR (500 MHz, CDCl3) δ 11.27 (s, 1H, COOH), 3.75 (d, J = 5.7 Hz, 1H,
N3CH), 2.29 – 2.17 (m, 1H, CH(CH3)2), 1.04 (d, J = 6.8 Hz, 3H, CH3), 0.99 (d,
J = 6.8 Hz, 3H, CH3);
13C NMR (126 MHz, CDCl3) δ 176.8 (COOH), 68.1 (CH),
31.1 (CH), 19.6 (CH3), 17.9 (CH3); IR (film) 2970, 2106, 1713, 1267, 1227 cm
-1;
[α]D = - 53.0 (c = 1.0 in CHCl3).
The spectroscopic data is in agreement with that previously reported.[4]
Azido--alanine
Azido-β-alanine was synthesised by general procedure A, starting from  
β-alanine (250 mg, 2.8 mmol). The product was purified by flash column 
chromatography, eluting with ethyl acetate/hexane/acetic acid (20 / 79 / 1) to yield a
colourless oil. Yield = 86 %. Mass = 277 mg.
1H NMR (500 MHz, CDCl3) δ 10.19 (s, 1H, COOH), 3.50 (t, J = 6.4 Hz, 2H, CH2),
2.62 (t, J = 6.4 Hz, 2H, CH2);
13C NMR (126 MHz, CDCl3) δ 177.2 (COOH), 46.6
(CH2), 34.0 (CH2); IR (film) 2943, 2099, 1713, 1402, 1244, 1179 cm
-1.




4-azidobutyric acid was synthesised by general procedure A, starting from
4-aminobutyric acid (1.0 g, 9.7 mmol). The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane/acetic acid (50 / 49 / 1) to yield a
colourless oil. Yield = 87 %. Mass = 1.1 g.
1H NMR (500 MHz, CDCl3) δ 11.43 (s, 1H, COOH), 3.39 (t, J = 6.7 Hz, 2H, CH2),
2.49 (t, J = 7.2 Hz, 2H, CH2), 1.93 (m, 2H, CH2);
13C NMR (126 MHz, CDCl3)
δ 179.3 (COOH), 50.4 (CH2), 30.9 (CH2), 23.9 (CH2); IR (film) 2940, 2097, 1707,
1414, 1281, 1242 cm-1.
The spectroscopic data is in agreement with that previously reported.[6]
General procedure B – EDC-mediated amide coupling step
Azido acid (100 mg, 1.0 mmol) and diamine (67 mg, 0.5 mmol) were
dissolved in chloroform (10 mL) at 0 ˚C and DMAP (24 mg, 0.2 mmol) was added. 
The solution was stirred for 10 minutes and then EDC.HCl (230 mg, 1.2 mmol) was
added. The solution was allowed to warm to room temperature and stirred overnight.
The reaction mixture was quenched with water (25 mL), extracted with
dichloromethane (25 mL) and washed with water (3 x 50 mL). The organic layer was
dried (MgSO4), filtered and concentrated under reduced pressure.
AZ01
AZ01 was synthesised by general procedure B, starting from azidovaline (2.0 g,
14 mmol) and m-xylylenediamine (0.9 g, 7 mmol). The product was purified by flash
column chromatography, eluting with ethyl acetate/hexane (7:3) to yield a white
solid. Yield = 66 %. Mass = 1.8 g.
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.33 (m, 1H, ArH), 7.26 – 7.20 (m, 3H, ArH),
6.69 (s, 2H, NH), 4.53 – 4.42 (m, 4H, CH2), 3.92 (d, J = 3.9 Hz, 2H, N3CH),







13C NMR (126 MHz, CDCl3) δ 168.9 (C=O), 138.4 (ArC), 129.3 (ArCH),
127.3 (ArCH), 127.1 (ArCH), 70.8 (CH), 43.3 (CH2), 32.1 (CH), 19.7 (CH3), 16.7
(CH3); HRMS (ESI+) calcd for C18H30O2N9 [M + NH4]
+ 404.2517, found 404.2520;
IR (film) 3277, 2093, 1641, 1547, 1225 cm-1; MP 148 – 151 °C; [α]D = - 49.0
(c = 1.0 in CHCl3)
AZ02
AZ02 was synthesised by general procedure B, starting from azidoglycine
(100 mg, 1.0 mmol) and m-xylylenediamine (67 mg, 0.5 mmol). The product was
purified by flash column chromatography, eluting with ethyl acetate/hexane (8:2) to
yield a white solid. Yield = 32 %. Mass = 48 mg.
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.29 (m, 1H, ArH), 7.21 – 7.15 (m, 3H, ArH),
6.72 (s, 2H, NH), 4.46 (d, J = 5.9 Hz, 4H, CH2), 4.02 (s, 4H, CH2);
13C NMR
(126 MHz, CDCl3) δ 166.6 (C=O), 138.2 (ArC), 129.3 (ArCH), 127.3 (ArCH),
127.2 (ArCH), 52.7 (CH2), 43.2 (CH2); LC/MS mass calcd for C12H15O2N8 [M + H]
+
303.1, found 303.3; HPLC (UV λ = 254 nm, Gradient B (section 5.2.2))             
purity > 90 %, retention time 2.92 min; IR (film) 3275, 2924, 2097, 1649, 1557,
1452, 1271, 1207 cm-1.
AZ03
AZ03 was synthesised by general procedure B, starting from azidovaline
(500 mg, 3.5 mmol) and 1,3-phenylenediamine (189 mg, 1.8 mmol). The product
was purified by flash column chromatography, eluting with ethyl acetate/hexane
(8:2) to yield a white solid. Yield = 57 %. Mass = 358 mg.
1H NMR (500 MHz, CDCl3) δ 8.19 (s, 2H, NH), 7.92 (t, J = 2.0 Hz, 1H, ArH), 7.43
– 7.38 (m, 2H, ArH), 7.36 – 7.30 (m, 1H, ArH), 4.00 (d, J = 4.0 Hz, 2H, N3CH),
2.60 – 2.40 (m, 2H, CH(CH3)2), 1.16 (d, J = 6.9 Hz, 6H, CH3), 0.99 (d, J = 6.8 Hz,
6H, CH3);
13C NMR (126 MHz, CDCl3) δ 167.4 (C=O), 137.6 (ArC), 129.8 (ArCH),
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116.2 (ArCH), 111.3 (ArCH), 70.9 (CH), 32.4 (CH), 19.7 (CH3), 16.8 (CH3);
LC/MS mass calcd for C16H23O2N8 [M + H]
+ 359.2, found 359.2; HPLC (UV λ = 254 
nm, Gradient B (section 5.2.2)) purity > 95 %, retention time 6.30 min; IR (film)
3283, 2967, 2097, 1661, 1607, 1533, 1489, 1424, 1219 cm-1.
AZ04
AZ04 was synthesised by general procedure B, starting from azidoglycine
(100 mg, 1 mmol) and 1,3-phenylenediamine (54 mg, 0.5 mmol). The product was
purified by flash column chromatography, eluting with ethyl acetate/hexane (7:3) to
yield a white solid. Yield = 39 %. Mass = 53 mg.
1H NMR (500 MHz, CDCl3) δ 8.06 (s, 2H, NH), 7.89 (t, J = 1.9 Hz, 1H, ArH), 7.37
– 7.26 (m, 3H, ArH), 4.12 (s, 4H, CH2);
13C NMR (126 MHz, CDCl3) δ 164.9 
(C=O), 137.7 (ArC), 130.0 (ArCH), 116.6 (ArCH), 111.7 (ArCH), 53.2 (CH2);
LC/MS mass calcd for C10H11O2N8 [M + H]
+ 275.1, found 275.1; HPLC (UV λ = 254 
nm, Gradient B (section 5.2.2)) purity > 90 %, retention time 3.17 min; IR (film)
3266, 2099, 1665, 1605, 1541, 1447, 1267, 1240 cm-1.
AZ05
AZ05 was synthesised by general procedure B, starting from azido-β-alanine 
(150 mg, 1.3 mmol) and m-xylylenediamine (89 mg, 0.65 mmol). The product was
purified by flash column chromatography, eluting with ethyl acetate/hexane (7:3) to
yield a white solid. Yield = 47 %. Mass = 101 mg.
1H NMR (500 MHz, d6-DMSO) δ 7.64 (t, J = 5.6 Hz, 2H, NH), 6.45 – 6.39 (m, 1H,
ArH), 6.31 – 6.26 (m, 3H, ArH), 2.70 (t, J = 6.4 Hz, 4H, CH2), 1.67 – 1.64 (m, 4H,
CH2), 1.63 (t, J = 6.4 Hz, 4H, CH2);
13C NMR (126 MHz, d6-DMSO) δ 169.5 
(C=O), 139.4 (ArC), 128.3 (ArCH), 126.1 (ArCH), 125.7 (ArCH), 47.0 (CH2), 42.1
(CH2), 34.5 (CH2); LC/MS mass calcd for C14H19O2N8 [M + H]
+ 331.2, found 331.4;
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HPLC (UV λ = 254 nm, Gradient B (section 5.2.2)) purity > 90 %, retention time 
3.40 min; IR (film) 3289, 2928, 2089, 1634, 1553, 1439, 1281, 1260 cm-1.
AZ06
AZ06 was synthesised by general procedure B, starting from 4-azidobutyric acid
(300 mg, 2.3 mmol) and m-xylylenediamine (158 mg, 1.2 mmol). The product was
purified by flash column chromatography, eluting with ethyl acetate (100 %) to yield
a white solid. Yield = 44 %. Mass = 183 mg.
1H NMR (500 MHz, CDCl3) δ 7.30 – 7.26 (m, 1H, ArH), 7.19 – 7.09 (m, 3H, ArH),
6.00 (s, 2H, NH), 4.40 (d, J = 5.8 Hz, 4H, CH2), 3.36 (t, J = 6.5 Hz, 4H, CH2), 2.31
(t, J = 7.2 Hz, 4H, CH2), 1.96 – 1.89 (m, 4H, CH2);
13C NMR (126 MHz, CDCl3)
δ 171.9 (C=O), 139.0 (ArC), 129.4 (ArCH), 127.3 (ArCH), 127.2 (ArCH), 51.0
(CH2), 43.7 (CH2), 33.3 (CH2), 25.0 (CH2); LC/MS mass calcd for C16H23O2N8
[M + H]+ 359.2, found 359.4; HPLC (UV λ = 254 nm, Gradient B (section 5.2.2)) 








To a solution of 4-chloro-3-nitrobenzoic acid (500 mg, 2.5 mmol) and propargyl
amine (0.2 mL, 2.5 mmol) in DCM (20 mL) at 0 ˚C, DMAP (61 mg,  
0.5 mmol) was added. The solution was stirred for 10 minutes and then EDC.HCl
(571 mg, 3.0 mmol) was added. The solution was allowed to warm to room
temperature and stirred overnight. The reaction mixture was quenched with water
(50 mL), extracted with dichloromethane (20 mL) and washed with water
(3 x 50mL). The organic layer was dried (MgSO4), filtered and concentrated under
reduced pressure. The product was purified by flash column chromatography, eluting
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with hexane/ethyl acetate (3:2) to yield a white solid. Yield = 89 %. Mass = 531 mg.
1H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 2.1 Hz, 1H, ArH), 7.94 (dd, J = 8.4,
2.1 Hz, 1H, ArH), 7.66 (d, J = 8.4 Hz, 1H, ArH), 6.46 (s, 1H, NH), 4.25 (dd, J = 5.2,
2.6 Hz, 2H, CH2C≡CH), 2.30 (t, J = 2.6 Hz, 1H, C≡CH);
13C NMR (126 MHz,
CDCl3) δ 164.0 (C=O), 148.0 (ArC), 133.7 (ArC), 132.7 (ArCH), 131.8 (ArCH),
130.9 (ArC), 124.4 (ArCH), 78.8 (-C≡), 72.8 (≡CH), 30.4 (CH2); IR (film) 3306,

















Reduced glutathione (58 mg, 0.2 mmol) and sodium carbonate (20 mg,
0.2 mmol) were dissolved in water (2.0 mL) and added to a solution of
4-chloro-3-nitro-N-prop-2-ynyl-benzamide (50 mg, 0.2 mmol) in acetonitrile
(2.0 mL). The reaction mixture was stirred at room temperature for 48 hours. The
solvent was concentrated under reduced pressure. The product was purified by flash
column chromatography using reverse phase silica and eluting with 95% water /
5% methanol to yield a yellow solid after lyophilisation. Yield = 11 %. Mass =
11 mg.
LC/MS mass calcd for C20H24O9N5S [M + H]
+ 510.1, found 510.1; HPLC (UV λ = 
254 nm, Gradient B (section 5.2.2)) purity > 95 %; IR (film) 3269, 1641, 1609, 1543,





To a solution of ethacrynic acid (100 mg, 0.3 mmol) and propargyl amine
(23 L, 0.3 mmol) in DCM (5.0 mL) at 0 ˚C, DMAP (8 mg, 0.07 mmol) was added. 
The solution was stirred for 10 minutes and then EDC.HCl (76 mg,
0.4 mmol) was added. The solution was allowed to warm to room temperature and
stirred overnight. The reaction mixture was quenched with water (20 mL), extracted
with dichloromethane (10 mL) and washed with water (3 x 20mL). The organic layer
was dried (MgSO4), filtered and concentrated under reduced pressure. The product
was purified by flash column chromatography, eluting with hexane/ethyl acetate
(1:1) to yield a white solid. Yield = 85 %. Mass = 87 mg.
1H NMR (500 MHz, CDCl3) δ 7.22 (d, J = 8.5 Hz, 1H, ArH), 6.97 (s, 1H, NH), 6.89
(d, J = 8.5 Hz, 1H, ArH), 5.99 (s, 1H, C=CH), 5.62 (s, 1H, C=CH), 4.63 (s, 2H,
OCH2), 4.22 (dd, J = 5.5, 2.5 Hz, 2H, NHCH2C=CH), 2.50 (q, J = 7.4 Hz, 2H,
CH2CH3), 2.32 (t, J = 2.5 Hz, 1H, C=CH), 1.18 (t, J = 7.5 Hz, 3H, CH3CH2);
13C NMR (126 MHz, CDCl3) δ 195.6, 166.5, 154.4, 150.2, 134.4, 131.6, 128.8, 
127.2, 123.1, 111.0, 78.7, 72.1, 68.2, 29.0, 23.4, 12.4; HRMS (ESI+) calcd for
C16H19O3N2Cl2 [M + NH4]
+ 357.0767, found 357.0768; IR (film) 3285, 1651, 1586,
1554.6, 1468, 1447, 1379, 1294, 1246 cm-1; MP 118 – 120 °C.
ALK04
To a solution of 2-naphthoic acid (1.0 g, 5.8 mmol) and propargyl alcohol
(338 L, 5.8 mmol) in chloroform (40 mL) at 0 ˚C, DMAP (142 mg,  
1.2 mmol) was added. The solution was stirred for 10 minutes and then EDC.HCl
(1.3 g, 7.0 mmol) was added. The solution was allowed to warm to room temperature
and stirred overnight. The reaction mixture was quenched with water (100 mL),
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extracted with dichloromethane (50 mL) and washed with water (3 x 100mL). The
organic layer was dried (MgSO4), filtered and concentrated under reduced pressure.
The product was purified by flash column chromatography, eluting with hexane/ethyl
acetate (3:2) to yield a white solid. Yield = 93 %. Mass = 1.1 g.
1H NMR (500 MHz, CDCl3) δ 8.63 (s, 1H, ArH), 8.06 (dd, J = 8.6, 1.4 Hz, 1H,
ArH), 7.95 (d, J = 8.1 Hz, 1H, ArH), 7.90 – 7.83 (m, 2H, ArH), 7.59 (t, J = 7.2 Hz,
1H, ArH), 7.54 (t, J = 7.5 Hz, 1H, ArH), 4.98 (d, J = 2.3 Hz, 2H, CH2C≡CH), 2.53 
(t, J = 2.3 Hz, 1H, C≡CH); 13C NMR (126 MHz, CDCl3) δ 166.2 (C=O), 135.9
(ArC), 132.7 (ArC), 131.7 (ArCH), 129.6 (ArCH), 128.7 (ArCH), 128.5 (ArCH),
128.0 (ArCH), 127.0 (ArCH), 126.8 (ArC), 125.4 (ArCH), 78.0 (-C≡), 75.3 (≡CH),
52.8 (CH2); IR (film) 3273, 1707, 1435, 1370, 1287, 1229 cm
-1.
ALK05
To a solution of 4-chloro-3-nitrobenzoic acid (250 mg, 1.2 mmol) and propargyl
amine (94 L, 1.2 mmol) in DCM (10.0 mL) at 0 ˚C, DMAP (30 mg,  
0.2 mmol) was added. The solution was stirred for 10 minutes and then EDC.HCl
(285 mg, 1.5 mmol) was added. The solution was allowed to warm to room
temperature and stirred overnight. The reaction mixture was quenched with water
(50 mL), extracted with dichloromethane (20 mL) and washed with water (3 x
50mL). The organic layer was dried (MgSO4), filtered and concentrated under
reduced pressure. The product was purified by flash column chromatography, eluting
with hexane/ethyl acetate (9:1) to yield a white solid. Yield = 83 %. Mass = 252 mg.
1H NMR (500 MHz, CDCl3) δ 8.50 (d, J = 2.0 Hz, 1H, ArH), 8.16 (dd, J = 8.4,
2.0 Hz, 1H, ArH), 7.66 (d, J = 8.3 Hz, 1H, ArH), 4.51 (t, J = 6.7 Hz, 2H, CH2), 2.67
(td, J = 6.7, 2.7 Hz, 2H, CH2C≡CH), 2.02 (t, J = 2.7 Hz, 1H, C≡CH);
13C NMR
(126 MHz, CDCl3) δ 163.7 (C=O), 148.2 (ArC), 133.9 (ArCH), 132.4 (ArCH),
132.1 (ArC), 130.1 (ArC), 126.9 (ArCH), 79.7 (-C≡), 70.6 (≡CH), 63.7 (CH2), 19.3
(CH2); LC/MS mass calcd for C11H9O4NCl [M + H]
+ 254.1, found 254.2; HPLC (UV
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λ = 254 nm, Gradient B (section 5.2.2)) purity > 95 %; IR (film) 3275, 1719, 1603, 
1537, 1354, 1296, 1240 cm-1.
ALK06
To a solution of 2-chloro-5-nitrobenzoic acid (500 mg, 2.5 mmol) and propargyl
amine (0.2 mL, 2.5 mmol) in chloroform (20.0 mL) at 0 ˚C, DMAP (61 mg,           
0.5 mmol) was added. The solution was stirred for 10 minutes and then EDC.HCl
(571 mg, 3.0 mmol) was added. The solution was allowed to warm to room
temperature and stirred overnight. The reaction mixture was quenched with water
(50 mL), extracted with dichloromethane (20 mL) and washed with water (3 x
50mL). The organic layer was dried (MgSO4), filtered and concentrated under
reduced pressure. The product was purified by flash column chromatography, eluting
with hexane/ethyl acetate (1:1) to yield a white solid. Yield = 87 %. Mass = 519 mg.
1H NMR (500 MHz, d6-DMSO) δ 9.18 (t, J = 5.3 Hz, 1H, NH), 8.30 (dd, J = 8.8,
2.8 Hz, 1H, ArH), 8.24 (d, J = 2.7 Hz, 1H, ArH), 7.84 (d, J = 8.8 Hz, 1H, ArH), 4.09
(dd, J = 5.5, 2.5 Hz, 2H, CH2C≡CH), 3.22 (t, J = 2.5 Hz, 1H, C≡CH);
13C NMR
(126 MHz, d6-DMSO) δ 164.5 (C=O), 146.5 (ArC), 137.6 (ArC), 137.5 (ArC), 131.9
(ArCH), 126.1 (ArCH), 124.2 (ArCH), 80.8 (-C≡), 74.1 (≡CH), 29.0 (CH2);
IR (film) 3279, 1649, 1613, 1537, 1435, 1352, 1310, 1277, 1238 cm-1.
ALK07
To a solution of 1-naphthoic acid (250 mg, 1.5 mmol) and propargyl alcohol
(84 L, 1.5 mmol) in dichloromethane (10.0 mL) at 0 ˚C, DMAP (35 mg,  
0.3 mmol) was added. The solution was stirred for 10 minutes and then EDC.HCl
(334 mg, 1.7 mmol) was added. The solution was allowed to warm to room
temperature and stirred overnight. The reaction mixture was quenched with water
(50 mL), extracted with dichloromethane (20 mL) and washed with water (3 x
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50mL). The organic layer was dried (MgSO4), filtered and concentrated under
reduced pressure. The product was purified by flash column chromatography, eluting
with hexane/ethyl acetate (9:1) to yield a white solid. Yield = 91 %. Mass = 287 mg.
1H NMR (500 MHz, CDCl3) δ 8.93 (d, J = 8.7 Hz, 1H, ArH), 8.26 – 8.23 (m, 1H,
ArH), 8.03 (d, J = 8.2 Hz, 1H, ArH), 7.87 (d, J = 8.2 Hz, 1H, ArH), 7.64 – 7.59 (m,
1H, ArH), 7.56 – 7.46 (m, 2H, ArH), 5.00 (d, J = 2.5 Hz, 2H, CH2C≡CH), 2.53 (t,  
J = 2.2 Hz, 1H, C≡CH); 13C NMR (126 MHz, CDCl3) δ 166.7 (C=O), 134.1
(ArCH), 134.0 (ArC), 131.6 (ArC), 131.0 (ArCH), 128.8 (ArCH), 128.2 (ArCH),
126.5 (ArCH), 126.2 (ArC), 125.9 (ArCH), 124.7 (ArCH), 78.1 (-C≡), 75.3 (≡CH),
52.7 (CH2); IR (film) 3264, 1695, 1510, 1277, 1234 cm
-1.
ALK08 3,5-Dimethoxy-benzoic acid prop-2-ynyl ester
To a solution of 3,5-dimethoxybenzoic acid (300 mg, 1.7 mmol) in dry
dichloromethane (10.0 mL), propargyl alcohol (77 mg, 1.4 mmol), DMAP
(34 mg, 0.27 mmol) and N,N’-dicyclohexylcarbodiimide (424 mg, 2.1 mmol) was
added at 0 °C. The reaction was stirred overnight at room temperature. The reaction
mixture was filtered to remove the solid N, N’-dicyclohexylcarbodiimide urea waste
and concentrated under reduced pressure. The product was purified by flash column
chromatography, eluting with hexane/ethyl acetate (4:1) to yield a white solid. Yield
= 76 %. Mass = 285 mg.
1H NMR (500 MHz, CDCl3) δ 7.19 (d, J = 2.4 Hz, 2H, ArH), 6.64 (t, J = 2.4 Hz, 1H,
ArH), 4.89 (d, J = 2.5 Hz, 2H, CH2C≡CH), 3.81 (s, 6H, OCH3), 2.49 (t, J = 2.5 Hz,
1H, C≡CH); 13C NMR (126 MHz, CDCl3) δ 165.8 (C=O), 160.9 (ArC), 131.4
(ArC), 107.6 (ArCH), 106.4 (ArCH), 77.9 (-C≡), 75.3 (≡CH), 55.8 (OCH3), 52.8




ALK09 3,5-Dimethoxy-benzoic acid but-3-ynyl ester
To a solution of 3,5-dimethoxybenzoic acid (250 mg, 1.4 mmol) in dry
dichloromethane (10.0 mL), butyne-3-ol (96.0 mg, 1.4 mmol), DMAP (34 mg,
0.3 mmol) and EDC.HCl (403 mg, 2.1 mmol) was added at 0 °C. The reaction was
stirred overnight at room temperature. The reaction mixture was quenched with
water (50 mL), extracted with dichloromethane (20 mL) and washed with water (3 x
50mL). The organic layer was dried (MgSO4), filtered and concentrated under
reduced pressure. The product was purified by flash column chromatography, eluting
with hexane/ethyl acetate (9:1) to yield a white solid, yield = 74%. Mass = 243 mg.
1H NMR (500 MHz, CDCl3) δ 7.18 (d, J = 2.4 Hz, 2H, ArH), 6.64 (t, J = 2.4 Hz, 1H,
ArH), 4.40 (t, J = 6.9 Hz, 2H, CH2), 3.81 (s, 6H, OCH3), 2.65 (td, J = 6.9, 2.7 Hz,
2H, CH2C≡CH), 2.01 (t, J = 2.7 Hz, 1H, C≡CH);
13C NMR (126 MHz, CDCl3)
δ 166.3 (C=O), 160.9 (ArC), 132.0 (ArC), 107.5 (ArCH), 106.0 (ArCH), 80.2 (-C≡), 
70.3 (≡CH), 62.9 (CH2), 55.8 (OCH3), 19.3 (CH2); LC/MS mass calcd for C13H15O4
[M + H]+ 235.1, found 235.2; HPLC (UV λ = 254 nm, Gradient B (section 5.2.2)) 
purity > 95 %; IR (thin film, NaCl plate) 3251, 2361, 1715, 1600, 1428, 1351, 1304,
1273, 1236, 1209, 1160 cm-1.
ALK10 3-Prop-2-ynyl-3H-benzooxazol-2-one
To a solution of 2-benzoxazolinone (250 mg, 1.9 mmol) in acetonitrile
(10.0 mL), propargyl bromide 80 wt % in toluene (303 mg, 2.0 mmol) and Huenig’s
base (359 mg, 2.8 mmol) was added. The reaction mixture was stirred overnight at
60 °C. The reaction mixture was quenched with water (50 mL), extracted with
dichloromethane (20 mL) and washed with water (3 x 50mL). The organic layer was
dried (MgSO4), filtered and concentrated under reduced pressure. The product was
purified by flash column chromatography, eluting with hexane/ethyl acetate (1:1) to
yield an orange solid, yield = 70 %. Mass = 230 mg.
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1H NMR (500 MHz, CDCl3) δ 7.23 – 7.10 (m, 4H, ArH), 4.62 (d, J = 2.6 Hz, 2H,
CH2C≡CH), 2.35 (t, J = 2.6 Hz, 1H, C≡CH);
13C NMR (126 MHz, CDCl3) δ 153.9 
(C=O), 142.9 (ArC), 130.2 (ArC), 124.2 (ArCH), 123.2 (ArCH), 110.4 (ArCH),
109.4 (ArCH), 75.7 (-C≡), 74.2 (≡CH), 32.0 (CH2); IR (thin film, NaCl plate): 3269,
2359, 1767, 1614, 1488, 1395, 1274, 1241 cm-1.
Triazole Library
TZ03a-01
Azide AZ01 (500 mg, 1.3 mmol) and alkyne ALK03 (440 mg, 1.3 mmol)
were dissolved in acetonitrile (30 mL). Copper (I) iodide (49 mg, 0.3 mmol) was
added and the reaction was placed under a nitrogen atmosphere and stirred overnight
at room temperature. On completion of the reaction, the solvent was removed under
reduced pressure and the reaction mixture was absorbed onto silica prior to
purification by flash column chromatography, eluting with ethyl acetate/hexane (7:3)
to yield the monotriazole product TZ03a-01 and the bistriazole product
TZ03a-01-03a both of which were white solids. Yield of monotriazole TZ03a-01 =
13 %. Mass = 123 mg.
1H NMR (500 MHz, CDCl3) δ 7.99 – 7.83 (m, 2H), 7.57 – 7.48 (m, 1H), 7.48 – 7.36 
(m, 1H), 7.22 – 7.15 (m, 1H), 7.15 – 6.96 (m, 3H), 6.96 – 6.86 (m, 1H), 6.85 – 6.72
(m, 1H), 5.91 (s, 1H), 5.54 (s, 1H), 5.03 – 4.78 (m, 1H), 4.62 – 4.19 (m, 8H), 3.78 (d,
J = 4.4 Hz, 1H), 2.57 – 2.37 (m, 3H), 2.35 – 2.23 (m, 1H), 1.10 (t, J = 7.4 Hz, 3H),
1.05 – 0.90 (m, 6H), 0.88 (d, J = 6.7 Hz, 3H), 0.75 (d, J = 6.6 Hz, 3H); 13C NMR
(126 MHz, CDCl3) δ 195.8, 169.4, 167.8, 167.2, 154.7, 150.3, 144.5, 138.6, 138.2, 
134.3, 131.5, 129.3, 129.1, 127.4, 127.2, 127.0, 123.2, 122.3, 111.2, 71.0, 70.7, 68.4,
43.7, 43.3, 35.0, 32.4, 32.0, 23.6, 19.8, 19.6, 19.5, 18.9, 17.1, 12.5; HRMS (ESI+)
calcd for C34H42O5N9Cl2 [M + H]
+ 726.2680, found 726.2668; IR (film) 3289, 2967,
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2938, 2102, 1659, 1586, 1537, 1468, 1439, 1385, 1371, 1292, 1242 cm-1;
MP 120 – 124 °C.
TZ03a-01-03a
Synthesis of TZ03a-01-03a described above in the synthesis of monotriazole
TZ03a-01. Yield = 26 %. Mass = 361 mg.
1H NMR (500 MHz, CDCl3) δ 7.96 (s, 2H), 7.72 (s, 2H), 7.52 (s, 2H), 7.13 (d,  
J = 8.4 Hz, 2H), 7.08 – 7.01 (m, 1H), 6.95 (d, J = 7.2 Hz, 2H), 6.82 (d, J = 8.4 Hz,
2H), 6.69 (s, 1H), 5.91 (s, 2H), 5.55 (s, 2H), 5.00 (s, 2H), 4.53 (s, 8H), 4.38 – 4.11
(m, 4H), 2.58 – 2.46 (m, 2H), 2.46 – 2.35 (m, 4H), 1.10 (t, J = 7.4 Hz, 6H), 1.05 (d,
J = 6.2 Hz, 6H), 0.74 (d, J = 5.3 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 195.9, 
167.9, 167.4, 154.8, 150.3, 138.2, 134.3, 131.5, 129.1, 127.4, 127.1, 126.2, 123.2,
111.3, 70.9, 68.5, 43.5, 35.0, 32.1, 23.6, 19.5, 19.0, 12.6; HRMS (ESI+) calcd for
C50H57O8N10Cl4 [M + H]
+ 1065.3109, found 1065.3100; IR (film) 3306, 3084, 2969,
2936, 1663, 1586, 1533, 1470, 1437, 1386, 1341, 1290, 1256 cm-1; MP 78 – 82 °C.
TZ04a-01
Azide AZ01 (500 mg, 1.3 mmol) and alkyne ALK04 (272 mg, 1.3 mmol)
were dissolved in acetonitrile (75 mL). Copper (I) iodide (49 mg, 0.3 mmol) was
added and the reaction was placed under a nitrogen atmosphere and stirred overnight
at room temperature. On completion of the reaction, the solvent was removed under
reduced pressure and the reaction mixture was absorbed onto silica prior to
purification by flash column chromatography, eluting with ethyl acetate/hexane (3:2)
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to yield the monotriazole product TZ04a-01 and the bistriazole product
TZ04a-01-04a both of which were white solids. Yield of monotriazole TZ04a-01 =
28 %. Mass = 217 mg.
1H NMR (500 MHz, CDCl3) δ 8.61 (s, 1H), 8.13 (s, 1H), 8.04 (dd, J = 8.6, 1.7 Hz,
1H), 7.94 (d, J = 8.1 Hz, 1H), 7.87 (dd, J = 8.3, 3.6 Hz, 2H), 7.70 (t, J = 5.8 Hz, 1H),
7.63 – 7.51 (m, 2H), 7.22 (t, J = 7.8 Hz, 1H), 7.16 – 7.09 (m, 3H), 6.92 (t, J = 5.7 Hz,
1H), 5.49 (q, J = 12.8 Hz, 2H), 5.00 (d, J = 10.0 Hz, 1H), 4.49 – 4.31 (m, 4H), 3.83
(d, J = 4.4 Hz, 1H), 2.64 – 2.53 (m, 1H), 2.42 – 2.31 (m, 1H), 1.07 (dd, J = 6.7,
5.0 Hz, 6H), 0.90 (d, J = 6.7 Hz, 3H), 0.79 (d, J = 6.7 Hz, 3H); 13C NMR (126 MHz,
CDCl3) δ 169.3, 167.8, 166.7, 143.3, 138.5, 138.2, 135.8, 132.6, 131.6, 129.5, 129.3, 
128.59, 128.4, 127.9, 127.3, 127.1, 127.0, 126.9, 125.4, 124.1, 71.1, 70.7, 58.3, 43.7,
43.34, 32.5, 32.1, 19.8, 19.5, 19.0, 17.1; HRMS (ESI+) calcd for C32H37O4N8
[M + H]+ 597.2932, found 597.2946; IR (film) 3337, 2965, 2099, 1707, 1674, 1522,
1466, 1395, 1287, 1229 cm-1; MP 141 – 145 °C; [α]D = + 17.8 (c = 0.45 in CHCl3).
TZ04a-01-04a
Synthesis of TZ04a-01-04a described above in the synthesis of monotriazole
TZ04a-01. Yield = 28 %. Mass = 294 mg.
1H NMR (500 MHz, CDCl3) δ 8.56 (s, 2H), 8.05 (s, 2H), 7.99 (dd, J = 8.6, 1.7 Hz,
2H), 7.92 (d, J = 8.1 Hz, 2H), 7.86 – 7.81 (m, 4H), 7.59 – 7.54 (m, 2H), 7.53 – 7.48
(m, 2H), 7.26 (t, J = 6.0 Hz, 2H), 7.10 – 7.05 (m, 1H), 6.97 (d, J = 1.3 Hz, 1H), 6.96
(s, 1H), 6.79 (s, 1H), 5.47 (q, J = 12.8 Hz, 4H), 4.96 (d, J = 10.1 Hz, 2H), 4.35 (dd,
J = 15.0, 6.2 Hz, 2H), 4.22 (dd, J = 15.0, 5.5 Hz, 2H), 2.67 – 2.54 (m, 2H), 1.08 (d,
J = 6.7 Hz, 6H), 0.81 (d, J = 6.6 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 167.8, 
166.8, 143.4, 138.1, 135.8, 132.6, 131.6, 129.6, 129.2, 128.7, 128.4, 128.0, 127.1,
127.0, 127.0, 126.1, 125.4, 124.3, 71.5, 58.3, 43.6, 32.1, 19.6, 19.1; HRMS (ESI+)
calcd for C46H47O6N8 [M + H]
+ 807.3613, found 807.3626; IR (film) 3395, 2969,
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1721, 1705, 1688, 1655, 1528, 1458, 1354, 1279, 1233 cm-1; MP 190 – 193 °C;
[α]D = + 68.0 (c = 1.0 in CHCl3).
TZ18a-01
Azide AZ01 (100 mg, 0.3 mmol) and alkyne ALK18 (36.4 L, 0.3 mmol)
were dissolved in acetonitrile (10 mL). Copper (I) iodide (5 mg, 0.03 mmol) was
added and the reaction was placed under a nitrogen atmosphere and stirred overnight
at room temperature. On completion of the reaction, the solvent was removed under
reduced pressure and the reaction mixture was absorbed onto silica prior to
purification by flash column chromatography, eluting with ethyl acetate/hexane (3:2)
to yield the monotriazole product TZ18a-01 and the bistriazole product
TZ18a-01-18a both of which were white solids. Yield of monotriazole
TZ18a-01 = 15 %. Mass = 23 mg.
1H NMR (500 MHz, CDCl3) δ 7.66 – 7.61 (m, 1H), 7.39 – 7.34 (m, 1H), 7.30 – 7.28 
(m, 1H), 7.28 – 7.25 (m, 1H), 7.23 (s, 1H), 7.19 – 7.15 (m, 1H), 7.13 (d, J = 6.9 Hz,
2H), 7.11 – 7.05 (m, 2H), 6.81 (s, 1H), 6.68 (s, 1H), 4.54 (d, J = 9.7 Hz, 1H),
4.46 – 4.33 (m, 4H), 3.83 (d, J = 4.1 Hz, 1H), 3.08 – 2.93 (m, 4H), 2.60 – 2.48 (m,
1H), 2.44 – 2.33 (m, 1H), 1.04 (d, J = 4.1 Hz, 3H), 1.00 (d, J = 6.7 Hz, 3H), 0.88 (d,
J = 6.7 Hz, 3H), 0.74 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 169.2, 
167.9, 141.2, 138.6, 138.2, 129.5, 128.7, 128.6, 128.1, 127.4, 127.3, 127.1, 126.4,
121.9, 71.6, 70.9, 43.8, 43.5, 35.7, 32.3, 32.3, 27.8, 19.9, 19.6, 18.9, 17.0; LC/MS
mass calcd for C28H37O2N8 [M + H]
+ 517.3, found 517.3; HPLC (UV λ = 254 nm, 
Gradient B (section 5.2.2)) purity > 90 %, retention time 6.43 min; IR (film) 3302,
2961, 2928, 2101, 1659, 1547, 1454, 1371, 1225 cm-1.
TZ18a-01-18a
Synthesis of TZ18a-01-18a described above in the synthesis of monotriazole
TZ18a-01. Yield = 42 %. Mass = 81 mg.
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1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 19.6 Hz, 4H), 7.33 – 7.26 (m, 4H),
7.26 – 7.20 (m, 3H), 7.17 (d, J = 7.2 Hz, 4H), 7.10 (d, J = 7.5 Hz, 2H), 6.79 (s, 1H),
4.99 (d, J = 8.9 Hz, 2H), 4.39 – 4.21 (m, 4H), 3.11 – 2.87 (m, 8H), 2.65 – 2.50 (m,
2H), 1.11 (d, J = 6.6 Hz, 6H), 0.81 (d, J = 6.6 Hz, 6H); 13C NMR (126 MHz, CDCl3)
δ 168.2, 141.2, 138.1, 129.3, 128.7, 128.6, 127.3, 126.8, 126.3, 71.0, 43.6, 35.6, 32.1, 
27.8, 19.6, 19.0; LC/MS mass calcd for C38H47O2N8 [M + H]
+ 647.4, found 647.4;
HPLC (UV λ = 254 nm, Gradient B (section 5.2.2)) purity > 90 %, retention time 
6.88 min.
TZ04s-01
Alkyne ALK04 (82 mg, 0.4 mmol) was dissolved in dioxane (2.5 mL)
followed by azide AZ01 (150 mg, 0.4 mmol) and this mixture was added to a
solution of Cp*RuCl(PPh3)2 (6 mg, 8.0 mol) in dioxane (2.5 mL). The reaction was
placed under a nitrogen atmosphere and heated at 60 °C overnight. On completion of
the reaction the reaction mixture was absorbed onto silica for purification by flash
column chromatography, eluting with ethyl acetate/hexane (3:2) to yield the
monotriazole product TZ04s-01 and the bistriazole product
TZ04s-01-04s both of which were white solids. Yield of monotriazole TZ04s-01 =
10 %. Mass = 24 mg.
1H NMR (500 MHz, CDCl3) δ 8.55 (s, 1H), 7.95 (dd, J = 8.6, 1.6 Hz, 1H), 7.90 (d,
J = 8.0 Hz, 1H), 7.87 (s, 1H), 7.86 – 7.82 (m, 2H), 7.61 – 7.55 (m, 1H), 7.55 – 7.49
(m, 1H), 7.27 – 7.21 (m, 1H), 7.18 – 7.12 (m, 1H), 7.08 (d, J = 7.7 Hz, 1H), 6.99 (d,
J = 7.6 Hz, 1H), 6.95 (s, 1H), 6.64 (s, 1H), 5.58 (d, J = 13.7 Hz, 1H), 5.42 (d,
J = 13.7 Hz, 1H), 4.85 (d, J = 10.1 Hz, 1H), 4.49 – 4.24 (m, 4H), 3.84 (d, J = 4.1 Hz,
1H), 2.90 – 2.78 (m, 1H), 2.43 – 2.29 (m, 1H), 1.14 (d, J = 6.7 Hz, 3H), 1.05 (d,
J = 6.9 Hz, 3H), 0.88 (d, J = 6.7 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H); 13C NMR
(126 MHz, CDCl3) δ 169.1, 167.4, 166.1, 138.5, 138.3, 136.0, 135.3, 133.8, 132.6, 
131.9, 129.7, 129.4, 128.9, 128.6, 128.0, 127.2, 127.1, 127.0, 126.8, 126.1, 125.2,
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70.8, 70.6, 54.0, 43.5, 43.4, 32.7, 32.2, 19.9, 19.6, 19.5, 17.0; LC/MS mass calcd for
C32H37O4N8 [M + H]
+ 597.3, found 597.3; HPLC (UV λ = 254 nm, Gradient C 
(section 5.2.2)) purity > 90 %, retention time 10.12 min; IR (film) 3281, 2967, 2099,
1721, 1647, 1543, 1466, 1451, 1371, 1354, 1279, 1225 cm-1.
TZ04s-01-04s
Synthesis of TZ04s-01-04s described above in the synthesis of monotriazole
TZ04s-01. Yield = 17 %. Mass = 55 mg.
1H NMR (500 MHz, CDCl3) δ 8.54 (s, 2H), 7.96 – 7.80 (m, 10H), 7.61 – 7.47 (m, 
4H), 7.18 (t, J = 5.6 Hz, 2H), 7.07 – 7.02 (m, 1H), 6.95 – 6.89 (m, 2H), 6.80 (s, 1H),
5.57 (d, J = 13.7 Hz, 2H), 5.45 (d, J = 13.6 Hz, 2H), 4.85 (d, J = 10.2 Hz, 2H), 4.36
(dd, J = 15.0, 6.1 Hz, 2H), 4.24 (dd, J = 15.0, 5.7 Hz, 2H), 2.91 – 2.75 (m, 2H), 1.25
(s, 6H), 1.09 (d, J = 6.7 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz,
CDCl3) δ 167.4, 166.1, 138.3, 136.0, 135.3, 133.8, 132.6, 131.9, 129.7, 129.3, 128.9, 
128.6, 128.0, 127.1, 126.7, 126.5, 126.2, 125.2, 70.7, 54.1, 43.5, 32.6, 19.6, 19.5.
General procedure C - for copper (I) catalysed 1,4 triazole synthesis
Azide TZ04a-01 (50 mg, 83.8 mol) and alkyne (1 eq, 83.8 mol) were
dissolved in acetonitrile (3 mL). Copper (I) iodide (3 mg, 16.8 mol) was added and
the reaction was placed under a nitrogen atmosphere and stirred overnight at room
temperature. On completion of the reaction, the solvent was removed under reduced
pressure and the reaction mixture was absorbed onto silica prior to purification by
flash column chromatography.
General procedure D - for ruthenium catalysed 1,5 triazole synthesis
Alkyne (1 eq, 83.8 mol) was dissolved in dioxane (0.5 mL) followed by
azide TZ04a-01 (50 mg, 83.8 mol) and this mixture was added to a solution of
Cp*RuCl(PPh3)2 (7 mg, 8.4 mol) in dioxane (2 mL). The reaction was placed under
a nitrogen atmosphere and heated at 60 °C overnight. On completion of the reaction
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the reaction mixture was absorbed onto silica for purification by flash column
chromatography.
TZ04a-01-01a
TZ04a-01-01a was synthesized following general procedure C, starting from
azide TZ04a-01 and alkyne ALK01. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 39 %. Mass = 27 mg.
1H NMR (500 MHz, CDCl3) δ 8.52 (s, 1H), 8.45 (s, 1H), 8.36 (d, J = 1.8 Hz, 1H),
8.23 (s, 1H), 8.05 (s, 1H), 7.96 (ddd, J = 15.1, 8.5, 1.6 Hz, 2H), 7.87 (d, J = 7.9 Hz,
2H), 7.82 (t, J = 7.4 Hz, 2H), 7.78 (s, 1H), 7.60 – 7.44 (m, 3H), 7.01 – 6.90 (m, 2H),
6.83 (d, J = 7.4 Hz, 1H), 6.70 (s, 1H), 5.53 – 5.37 (m, 2H), 5.14 (d, J = 10.1 Hz, 1H),
4.96 (d, J = 10.1 Hz, 1H), 4.68 – 4.49 (m, 2H), 4.33 – 4.04 (m, 4H), 2.63 – 2.42 (m,
2H), 1.02 (dd, J = 9.2, 6.8 Hz, 6H), 0.73 (dd, J = 24.1, 6.6 Hz, 6H); 13C NMR
(126 MHz, CDCl3) δ 168.0, 168.0, 167.0, 164.5, 147.8, 144.7, 143.4, 138.1, 138.0, 
135.8, 133.8, 132.6, 132.2, 132.1, 131.6, 130.1, 129.6, 129.0, 128.7, 128.5, 128.0,
127.1, 127.0, 126.9, 126.8, 125.9, 125.2, 124.8, 124.5, 123.4, 71.1, 70.9, 58.3, 43.4,
35.7, 32.2, 32.0, 19.5, 19.4, 19.1, 19.0; LC/MS mass calcd for C42H44O7N10Cl
[M + H]+ 835.3, found 835.2; HPLC (UV λ = 254 nm, Gradient B (section 5.2.2)) 




TZ04a-01-03a was synthesized following general procedure C, starting from
azide TZ04a-01 and alkyne ALK03. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 80 %. Mass = 63 mg.
1H NMR (500 MHz, CDCl3) δ 8.55 (s, 1H), 8.12 (s, 1H), 7.97 (dd, J = 8.6, 1.6 Hz,
1H), 7.94 (s, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.82 (t, J = 7.6 Hz, 2H), 7.73 (s, 1H),
7.62 – 7.53 (m, 2H), 7.50 (t, J = 7.0 Hz, 1H), 7.46 (s, 1H), 7.13 (d, J = 8.5 Hz, 1H),
7.06 – 7.00 (m, 1H), 6.96 (d, J = 7.5 Hz, 1H), 6.90 (d, J = 7.4 Hz, 1H), 6.81 (d,
J = 8.5 Hz, 1H), 6.75 (s, 1H), 5.90 (s, 1H), 5.54 (s, 1H), 5.44 (q, J = 12.8 Hz, 2H),
5.11 – 4.94 (m, 2H), 4.62 – 4.43 (m, 4H), 4.34 – 4.10 (m, 4H), 2.64 – 2.47 (m, 2H),
2.43 (q, J = 7.3 Hz, 2H), 1.11 (t, J = 7.4 Hz, 3H), 1.08 – 0.98 (m, 6H), 0.77 (dd,
J = 14.4, 6.6 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 195.8, 167.9, 167.9, 167.4, 
166.8, 154.7, 150.3, 138.2, 138.1, 135.8, 134.3, 132.6, 131.6, 129.6, 129.2, 129.1,
128.6, 128.4, 128.0, 127.4, 127.1, 127.0, 126.9, 126.9, 126.4, 125.4, 124.0, 123.2,
111.3, 71.0, 68.4, 58.3, 43.5, 43.5, 35.0, 32.1, 32.1, 23.6, 19.5, 19.1, 19.0, 12.6;
HRMS (ESI+) calcd for C48H52O7N9Cl2 [M + H]
+ 936.3361, found 936.3375;
IR (film) 3310, 2969, 2940, 1663, 1586, 1532, 1468, 1437, 1387, 1354, 1283,




TZ04a-01-04s was synthesized following general procedure D, starting from
azide TZ04a-01 and alkyne ALK04. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 12 %. Mass = 8 mg.
1H NMR (500 MHz, CDCl3) δ 8.59 (s, 1H), 8.56 (s, 1H), 8.07 – 8.01 (m, 2H),      
7.96 – 7.88 (m, 4H), 7.87 – 7.81 (m, 4H), 7.62 – 7.54 (m, 2H), 7.54 – 7.49 (m, 2H),
7.17 (s, 1H), 7.10 – 7.02 (m, 2H), 7.01 – 6.96 (m, 1H), 6.94 (d, J = 7.5 Hz, 1H), 6.84
(s, 1H), 5.63 – 5.36 (m, 4H), 4.84 (dd, J = 10.1, 3.8 Hz, 2H), 4.43 – 4.18 (m, 4H),
2.92 – 2.79 (m, 1H), 2.65 – 2.50 (m, 1H), 1.19 (d, J = 6.7 Hz, 3H), 1.06 (d, J =
6.7 Hz, 3H), 0.86 (d, J = 6.5 Hz, 3H), 0.77 (d, J = 6.7 Hz, 3H); 13C NMR (126 MHz,
CDCl3) δ 167.7, 167.3, 166.7, 166.3, 138.4, 138.0, 136.0, 135.8, 132.6, 132.0, 131.6, 
129.7, 129.6, 129.3, 129.0, 128.7, 128.6, 128.4, 128.0, 127.2, 127.1, 126.9, 126.4,
126.1, 125.5, 125.2, 124.1, 71.3, 70.7, 58.4, 54.1, 43.7, 43.4, 32.5, 32.4, 19.6, 19.6,
19.5, 19.0; HRMS (ESI+) calcd for C46H47O6N8 [M + H]
+ 807.3613, found
807.3612; IR (film) 3316, 3069, 2928, 1715, 1672, 1651, 1526, 1466, 1447, 1354,
1279, 1227, 1194, 1128, 1088 cm-1; MP 94 – 98 °C.
TZ04a-01-07a
TZ04a-01-07a was synthesized following general procedure C, starting from
azide TZ04a-01 and alkyne ALK07. The product was purified by flash column
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chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 50 %. Mass = 34 mg.
1H NMR (500 MHz, CDCl3) δ 8.84 (d, J = 8.7 Hz, 1H), 8.55 (s, 1H), 8.15 – 8.07 (m,
3H), 8.00 – 7.94 (m, 2H), 7.88 (d, J = 7.8 Hz, 1H), 7.82 (dd, J = 11.6, 6.2 Hz, 3H),
7.59 – 7.46 (m, 6H), 7.44 – 7.37 (m, 1H), 7.06 – 6.99 (m, 1H), 6.96 – 6.88 (m, 2H),
6.79 (s, 1H), 5.52 – 5.36 (m, 4H), 5.05 (dd, J = 10.1, 2.6 Hz, 2H), 4.33 – 4.11 (m,
4H), 2.65 – 2.49 (m, 2H), 1.07 (dd, J = 6.6, 2.6 Hz, 6H), 0.78 (d, J = 6.6 Hz, 6H);
13C NMR (126 MHz, CDCl3) δ 167.9, 167.4, 166.8, 143.4, 138.1, 135.8, 134.0, 
133.9, 132.6, 131.6, 131.5, 130.8, 129.6, 129.2, 128.8, 128.6, 128.4, 128.1, 127.9,
127.1, 127.1, 127.0, 126.9, 126.5, 126.5, 126.4, 125.8, 125.4, 124.7, 124.1, 124.1,
71.1, 71.1, 58.3, 43.6, 43.5, 32.1, 19.5, 19.0, 19.0, 14.4; LC/MS mass calcd for
C46H47O6N8 [M + H]
+ 807.4, found 807.3; HPLC (UV λ = 254 nm, Gradient C 
(section 5.2.2)) purity > 95 %, retention time 11.50 min.
TZ04a-01-07s
TZ04a-01-07s was synthesized following general procedure D, starting from
azide TZ04a-01 and alkyne ALK07. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 9 %. Mass = 5 mg.
1H NMR (500 MHz, CDCl3) δ 8.85 (d, J = 8.4 Hz, 1H), 8.60 (s, 1H), 8.13 (d,
J = 7.3 Hz, 1H), 8.06 – 7.98 (m, 3H), 7.97 – 7.89 (m, 2H), 7.85 (t, J = 7.5 Hz, 3H),
7.62 – 7.48 (m, 4H), 7.46 – 7.40 (m, 1H), 7.15 (s, 1H), 7.09 (t, J = 7.6 Hz, 1H), 7.04
– 6.93 (m, 3H), 6.80 (s, 1H), 5.60 – 5.44 (m, 4H), 4.85 (t, J = 10.1 Hz, 2H),
4.45 – 4.19 (m, 4H), 2.92 – 2.78 (m, 1H), 2.68 – 2.47 (m, 1H), 1.16 (d, J = 6.7 Hz,
3H), 1.03 (d, J = 6.7 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H), 0.77 (d, J = 6.7 Hz, 3H);
13C NMR (126 MHz, CDCl3) δ 167.7, 167.3, 166.7, 166.7, 143.4, 138.4, 138.0, 
135.9, 135.4, 134.6, 134.0, 133.9, 132.7, 131.6, 131.6, 131.2, 129.6, 129.3, 129.0,
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128.6, 128.5, 128.4, 128.0, 127.2, 127.1, 127.0, 126.9, 126.7, 126.4, 125.6, 125.5,
125.3, 124.7, 124.1, 71.3, 70.5, 58.4, 54.2, 43.7, 43.4, 32.4, 32.3, 19.6, 19.6, 19.5,
19.0; LC/MS mass calcd for C46H47O6N8 [M + H]
+ 807.4, found 807.3; HPLC (UV λ 
= 254 nm, Gradient C (section 5.2.2)) purity > 95 %, retention time 11.42 min.
TZ04a-01-08a
TZ04a-01-08a was synthesized following general procedure C, starting from
azide TZ04a-01 and alkyne ALK08. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 57 %. Mass = 39 mg.
1H NMR (500 MHz, CDCl3) δ 8.54 (s, 1H), 8.12 (s, 1H), 8.06 (s, 1H), 7.97 (dd,  
J = 8.6, 1.5 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.85 (t, J = 7.3 Hz, 2H), 7.64 – 7.46
(m, 4H), 7.11 (d, J = 2.3 Hz, 2H), 7.06 (t, J = 7.6 Hz, 1H), 6.97 (t, J = 7.5 Hz, 2H),
6.82 (s, 1H), 6.62 (t, J = 2.3 Hz, 1H), 5.47 – 5.30 (m, 4H), 5.09 (t, J = 10.9 Hz, 2H),
4.34 – 4.16 (m, 4H), 3.79 (s, 6H), 2.64 – 2.46 (m, 2H), 1.08 – 1.00 (m, 6H),
0.80 – 0.73 (m, 6H); 13C NMR (126 MHz, CDCl3) δ 167.9, 167.8, 166.8, 166.4, 
160.8, 138.1, 135.8, 132.6, 131.6, 129.6, 129.2, 128.6, 128.4, 127.9, 127.2, 126.9,
126.9, 126.6, 125.4, 124.2, 107.5, 106.1, 71.1, 58.3, 55.8, 53.6, 43.6, 32.2, 19.5,
19.0; LC/MS mass calcd for C44H49O8N8 [M + H]
+ 817.4, found 817.3; HPLC (UV λ 




TZ04a-01-08s was synthesized following general procedure D, starting from
azide TZ04a-01 and alkyne ALK08. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 15 %. Mass = 10 mg.
1H NMR (500 MHz, CDCl3) δ 8.59 (s, 1H), 8.07 – 8.00 (m, 2H), 7.92 (d, J = 8.1 Hz,
1H), 7.89 – 7.83 (m, 3H), 7.57 (t, J = 6.9 Hz, 1H), 7.52 (t, J = 7.0 Hz, 1H),
7.19 – 7.06 (m, 5H), 7.03 (d, J = 7.6 Hz, 1H), 6.99 – 6.91 (m, 1H), 6.82 (s, 1H), 6.62
(t, J = 2.3 Hz, 1H), 5.51 (d, J = 4.9 Hz, 2H), 5.45 (d, J = 13.7 Hz, 1H), 5.36 (d,
J = 13.7 Hz, 1H), 4.89 (d, J = 10.0 Hz, 1H), 4.80 (d, J = 10.2 Hz, 1H), 4.43 – 4.21
(m, 4H), 3.77 (s, 6H), 2.89 – 2.76 (m, 1H), 2.63 – 2.50 (m, 1H), 1.14 (d, J = 6.7 Hz,
3H), 1.05 (d, J = 6.7 Hz, 3H), 0.82 (d, J = 6.5 Hz, 3H), 0.77 (d, J = 6.6 Hz, 3H);
13C NMR (126 MHz, CDCl3) δ 167.7, 167.3, 166.7, 165.9, 161.0, 138.4, 138.0, 
135.8, 132.6, 131.6, 130.8, 129.6, 129.3, 128.6, 128.4, 128.0, 127.3, 127.1, 126.9,
126.9, 126.5, 125.5, 124.0, 107.5, 106.8, 71.3, 70.6, 58.4, 55.9, 54.1, 43.8, 43.4, 32.4,
32.3, 30.5, 29.9, 19.6, 19.5, 19.0; LC/MS mass calcd for C44H49O8N8 [M + H]
+
817.4, found 817.3; HPLC (UV λ = 254 nm, Gradient B (section 5.2.2))             
purity > 95 %, retention time 7.23 min.
TZ04a-01-09a
TZ04a-01-09a was synthesized following general procedure C, starting from
azide TZ04a-01 and alkyne ALK09. The product was purified by flash column
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chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid.
Yield = 56 %. Mass = 39 mg.
1H NMR (500 MHz, CDCl3) δ 8.55 (s, 1H), 8.11 (s, 1H), 8.00 – 7.95 (m, 1H), 7.92 
(d, J = 8.1 Hz, 1H), 7.86 – 7.80 (m, 2H), 7.79 (s, 1H), 7.64 – 7.45 (m, 4H),
7.12 – 7.05 (m, 3H), 7.02 – 6.94 (m, 2H), 6.81 (s, 1H), 6.61 (t, J = 2.3 Hz, 1H), 5.42
(q, J = 12.8 Hz, 2H), 5.04 (d, J = 10.1 Hz, 1H), 4.99 (d, J = 10.1 Hz, 1H), 4.53 (t,
J = 6.8 Hz, 2H), 4.34 – 4.16 (m, 4H), 3.78 (s, 6H), 3.14 (t, J = 6.7 Hz, 2H),
2.65 – 2.43 (m, 2H), 1.08 – 1.00 (m, 6H), 0.80 (d, J = 6.6 Hz, 3H), 0.73 (d, J = 6.6
Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 168.1, 167.9, 166.8, 166.4, 160.8, 138.1, 
138.1, 135.8, 132.6, 132.0, 131.6, 129.6, 129.2, 128.6, 128.4, 128.0, 127.1, 127.1,
127.0, 126.9, 126.6, 125.4, 124.1, 122.1, 107.4, 105.9, 71.1, 71.0, 63.9, 58.3, 55.8,
43.6, 43.5, 32.2, 32.1, 25.7, 19.5, 19.0, 18.9; LC/MS mass calcd for C45H51O8N8
[M + H]+ 831.4, found 831.3; HPLC (UV λ = 254 nm, Gradient B (section 5.2.2)) 
purity > 95 %, retention time 7.24 min.
TZ04a-01-09s
TZ04a-01-09s was synthesized following general procedure D, starting from
azide TZ04a-01 and alkyne ALK09. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 22 %. Mass = 15 mg.
1H NMR (500 MHz, CDCl3) δ 8.60 (s, 1H), 8.09 – 8.01 (m, 2H), 7.92 (d, J = 8.1 Hz,
1H), 7.86 (s, 1H), 7.83 (s, 1H), 7.60 – 7.49 (m, 4H), 7.30 (s, 1H), 7.12 (t, J = 7.6 Hz,
1H), 7.10 – 7.04 (m, 3H), 7.00 (d, J = 7.6 Hz, 1H), 6.88 (s, 1H), 6.59 (t, J = 2.3 Hz,
1H), 5.57 – 5.46 (m, 2H), 4.92 (d, J = 10.0 Hz, 1H), 4.58 (d, J = 10.1 Hz, 1H), 4.53
(t, J = 6.6 Hz, 2H), 4.44 – 4.20 (m, 4H), 3.78 (s, 6H), 3.26 – 3.07 (m, 2H),
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2.84 – 2.71 (m, 1H), 2.64 – 2.49 (m, 1H), 1.13 (d, J = 6.7 Hz, 3H), 1.05 (d,
J = 6.7 Hz, 3H), 0.82 (d, J = 6.5 Hz, 3H), 0.76 (d, J = 6.7 Hz, 3H); 13C NMR (126
MHz, CDCl3) δ 167.8, 167.5, 166.7, 166.3, 160.9, 138.4, 138.1, 135.8, 133.1, 132.6, 
132.3, 132.2, 132.2, 131.6, 131.4, 129.6, 129.3, 128.6, 128.4, 128.0, 127.3, 127.2,
127.0, 126.9, 126.8, 125.5, 124.0, 107.5, 106.2, 71.2, 70.2, 67.3, 62.1, 58.4, 55.8,
43.8, 43.5, 32.5, 32.5, 23.4, 19.5, 19.0; LC/MS mass calcd for C45H51O8N8 [M + H]
+
831.4, found 831.3; HPLC (UV λ = 254 nm, Gradient B (section 5.2.2))             
purity > 90 %, retention time 7.21 min.
TZ04a-01-10a
TZ04a-01-10a was synthesized following general procedure C, starting from
azide TZ04a-01 and alkyne ALK10. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 74 %. Mass = 48 mg.
1H NMR (500 MHz, CDCl3) δ 8.59 (s, 1H), 8.13 (s, 1H), 8.07 (s, 1H), 8.02 (dd,  
J = 8.6, 1.6 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.88 (t, J = 7.9 Hz, 2H), 7.66 – 7.58
(m, 1H), 7.58 – 7.52 (m, 2H), 7.38 (t, J = 5.7 Hz, 1H), 7.19 – 7.06 (m, 5H), 7.02 (d,
J = 7.7 Hz, 1H), 6.96 (d, J = 7.5 Hz, 1H), 6.79 (s, 1H), 5.49 (q, J = 12.9 Hz, 2H),
5.08 (d, J = 5.2 Hz, 1H), 5.06 – 4.98 (m, 2H), 4.42 – 4.28 (m, 2H), 4.21 (td, J = 14.3,
5.5 Hz, 1H), 2.72 – 2.53 (m, 2H), 1.78 (s, 2H), 1.12 (d, J = 6.6 Hz, 3H), 1.07 (d,
J = 6.7 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H), 0.78 (d, J = 6.6 Hz, 3H); 13C NMR
(126 MHz, CDCl3) δ 167.9, 167.7, 166.8, 154.6, 142.7, 138.2, 138.1, 135.8, 132.6, 
131.6, 130.7, 129.6, 129.1, 128.7, 128.4, 128.0, 127.1, 127.1, 127.0, 127.0, 126.1,
125.4, 124.3, 124.1, 123.4, 123.0, 110.3, 109.4, 71.3, 71.2, 58.3, 43.5, 43.5, 37.7,
32.0, 32.0, 19.5, 19.5, 19.1, 19.0; LC/MS mass calcd for C42H44O6N9 [M + H]
+
770.3, found 770.4; HPLC (UV λ = 254 nm, Gradient B (section 5.2.2))             




TZ04a-01-11a was synthesized following general procedure C, starting from
azide TZ04a-01 and alkyne ALK11. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 76 %. Mass = 50 mg.
1H NMR (500 MHz, CDCl3) δ 8.56 (s, 1H), 8.20 (s, 1H), 8.18 (s, 1H), 8.07 (s, 1H), 
8.00 (dd, J = 8.6, 1.6 Hz, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.86 – 7.80 (m, 3H), 7.74 (t,
J = 8.4 Hz, 2H), 7.59 – 7.54 (m, 1H), 7.34 (d, J = 5.6 Hz, 1H), 7.31 (s, 1H),
7.15 – 7.04 (m, 4H), 7.00 – 6.92 (m, 2H), 6.74 (s, 1H), 5.54 (q, J = 12.8 Hz, 2H),
5.04 (dd, J = 26.4, 10.2 Hz, 2H), 4.40 (ddd, J = 28.8, 15.0, 6.3 Hz, 2H), 4.23 – 4.08
(m, 2H), 3.90 (s, 3H), 2.74 – 2.50 (m, 2H), 1.16 (d, J = 6.6 Hz, 3H), 1.08 (d,
J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H), 0.80 (d, J = 6.6 Hz, 3H); 13C NMR (126
MHz, CDCl3) δ 168.1, 167.8, 166.8, 158.3, 148.5, 143.4, 138.1, 138.0, 135.8, 134.7, 
132.6, 131.6, 129.9, 129.6, 129.2, 129.1, 128.6, 128.4, 128.0, 127.7, 127.2, 127.1,
126.9, 126.1, 125.6, 125.4, 124.6, 124.4, 124.2, 119.9, 119.6, 106.0, 71.4, 71.4, 58.4,
55.5, 43.6, 43.6, 32.0, 31.9, 30.5, 29.9, 19.6, 19.5, 19.1; LC/MS mass calcd for
C45H47O5N8 [M + H]
+ 779.4, found 779.3; HPLC (UV λ = 254 nm, Gradient B 
(section 5.2.2)) purity > 95 %, retention time 7.53 min.
TZ04a-01-11s
TZ04a-01-11s was synthesized following general procedure D, starting from
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azide TZ04a-01 and alkyne ALK11. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 35 %. Mass = 23 mg.
1H NMR (500 MHz, CDCl3) δ 8.59 (s, 1H), 8.07 (s, 1H), 8.02 (dd, J = 8.6, 1.7 Hz,
1H), 7.94 (d, J = 8.1 Hz, 1H), 7.87 – 7.81 (m, 4H), 7.80 – 7.75 (m, 2H), 7.56 (ddd,
J = 8.2, 6.9, 1.3 Hz, 1H), 7.53 – 7.47 (m, 2H), 7.38 (dd, J = 8.4, 1.7 Hz, 1H), 7.31 (t,
J = 5.6 Hz, 1H), 7.23 – 7.18 (m, 2H), 7.16 (d, J = 2.4 Hz, 1H), 7.14 – 7.08 (m, 2H),
7.03 (s, 1H), 5.51 (d, J = 3.5 Hz, 2H), 4.95 (d, J = 10.0 Hz, 1H), 4.70 (d, J = 10.1 Hz,
1H), 4.52 – 4.22 (m, 4H), 3.93 (s, 3H), 2.80 – 2.66 (m, 1H), 2.64 – 2.49 (m, 1H),
1.07 (d, J = 6.7 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H), 0.79 (d, J = 6.7 Hz, 3H), 0.66 (d,
J = 6.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 168.1, 167.8, 166.7, 159.1, 143.3, 
140.7, 138.5, 138.1, 135.8, 135.2, 133.3, 132.6, 131.6, 130.2, 129.6, 129.4, 129.2,
128.7, 128.6, 128.4, 128.3, 128.0, 127.3, 127.1, 127.1, 127.0, 126.9, 126.7, 125.5,
124.0, 120.8, 120.4, 105.9, 71.2, 69.9, 58.4, 55.7, 43.9, 43.6, 33.5, 32.6, 19.5, 19.4,
19.3, 19.0; LC/MS mass calcd for C45H47O5N8 [M + H]
+ 779.4, found 779.3; HPLC
(UV λ = 254 nm, Gradient B (section 5.2.2)) purity > 95 %, retention time 7.43 min.
TZ04a-01-18a
TZ04a-01-18a was synthesized following general procedure C, starting from
azide TZ04a-01 and alkyne ALK18. The product was purified by flash column
chromatography, eluting with ethyl acetate/hexane (8:2) to yield a white solid. Yield
= 63 %. Mass = 38 mg.
1H NMR (500 MHz, CDCl3) δ 8.56 (s, 1H), 8.10 (s, 1H), 7.99 (d, J = 8.4, 1H), 7.91
(d, J = 8.2 Hz, 1H), 7.83 (t, J = 7.4 Hz, 2H), 7.56 (t, J = 7.1 Hz, 1H), 7.53 (t,
J = 7.3 Hz, 1H), 7.38 (s, 3H), 7.23 – 7.17 (m, 2H), 7.17 – 7.06 (m, 4H), 7.05 – 6.96
(m, 2H), 6.91 (s, 1H), 5.55 – 5.43 (m, 2H), 5.21 (s, 2H), 4.40 – 4.14 (m, 4H),
3.14 – 2.87 (m, 4H), 2.66 – 2.35 (m, 2H), 1.10 (dd, J = 18.2, 6.5 Hz, 6H), 0.83 – 0.61
(m, 6H); 13C NMR (126 MHz, CDCl3) δ 167.7, 166.8, 138.1, 135.8, 132.6, 131.6, 
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129.6, 129.2, 128.7, 128.6, 128.6, 128.4, 128.0, 127.2, 127.0, 126.9, 126.4, 125.4,
71.2, 58.3, 43.7, 43.6, 35.6, 32.3, 32.1, 30.5, 29.9, 27.7, 22.9, 19.5, 19.5, 19.0, 18.9,
14.3; LC/MS mass calcd for C42H47O4N8 [M + H]
+ 727.4, found 727.3; HPLC (UV λ 
= 254 nm, Gradient B (section 5.2.2)) purity > 90 %, retention time 7.26 min.
5.2 Target-guided synthesis reactions
5.2.1 Dynamic combinatorial chemistry reactions
HPLC conditions for analysis of DCL libraries
Column, Luna 5  C18(2), 50 mm x 2.0 mm, and Luna 5  C18(2), 30 mm x
4.6 mm, in sequence; flow rate, 1 mL min-1; wavelength, 254 nm; temperature,
30 C.
Gradient A: H2O/MeCN (0.01 % TFA) from 95 % H2O to 80 % H2O over 15 min,
then to 60 % over a further 15 min, and finally to 5 % H2O over 5 min.
DCL01 Blank equilibrium - Aniline catalysis of reversible hydrazone
formation.
The four bishydrazide linkers HZD01 to HZD04 (4 x 9.0 L, 10 mM,
DMSO), aldehyde ALD01 (9.0 L, 10 mM, water) and aniline (75 L, 0.1 M,
DMSO) were added to a mixture of DMSO (114 L, 15 % by vol.) and ammonium
acetate buffer (1.3 mL, 100 mM, pH 6.4). The DCL was allowed to stand at room
temperature with occasional shaking, and was monitored periodically by direct
injection onto HPLC (Gradient A) to establish the blank composition until the
relative populations of the hydrazones became constant.
Chapter 5
201
Figure 1: DCL01 – library set up between aldehyde ALD01 and hydrazide linkers
HZD01-HZD04
DCL01 Blank equilibrium – Approaching equilibrium starting from one
hydrazone and three hydrazides.
Three bishydrazide linkers HZD01 to HZD03 (3 x 9 L, 10 mM, DMSO),
acylhydrazone HZN01-04-01 (45 L, 2 mM, DMSO) and aniline (75 L, 0.1 M,
DMSO) were added to a mixture of DMSO (78 L, 15 % by vol.) and ammonium
acetate buffer (1.3 mL, 100 mM, pH 6.4). The DCL was allowed to stand at room
temperature with occasional shaking, and was monitored periodically by HPLC
(Gradient A) to establish the blank composition until the relative populations of the
hydrazones became constant.
DCL01 Enzyme-templated DCL reaction – enzyme added initially
Protein, GST (to a final concentration of 20 M, for mGSTM1-1; 152.8 L,
1.1 mg mL-1, in potassium phosphate buffer 0.1 M, pH 6.8) or BSA (to a final
concentration of 20 M, 199.5 L, 2.0 mg mL-1, in 0.9 % aqueous NaCl solution
containing sodium azide), the four hydrazide linkers HZD01 to HZD04 (4 x 1.8 L,
10 mM, DMSO), aldehyde ALD01 (1.8 L, 10 mM, water) and aniline (15 L,
0.1 M, DMSO) were added to a mixture of DMSO (22.8 L, 15 % by vol.) and
ammonium acetate buffer (to a total volume of 255 L, for mGSTM1-1; 100.4 L,
100 mM, pH 6.4). The DCL was allowed to stand at room temperature, with
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occasional shaking, for 48 hours. HPLC analysis (Gradient A) was performed and
the traces were compared with the blank equilibrium.
DCL01 Enzyme-templated DCL reaction – enzyme added at equilibrium
The four hydrazide linkers HZD01 to HZD04 (4 x 1.8 L, 10 mM, DMSO),
aldehyde ALD01 (1.8 L, 10 mM, water) and aniline (15 L, 0.1 M, DMSO) were
added to a mixture of DMSO (22.8 L, 15 % by vol.) and ammonium acetate buffer
(to a total volume of 255 L, for mGSTM1-1; 100.4 L, 100 mM, pH 6.4). The DCL
was allowed to stand at room temperature, with occasional shaking, for 24 hours.
GST (to a final concentration of 20 M, for mGSTM1-1; 152.8 L, 1.1 mg mL-1, in
potassium phosphate buffer 0.1 M, pH 6.8) was added to the equilibrated DCL,
which was left to stand at room temperature, with occasional agitation, for a further
48 hours. HPLC analysis (Gradient A) was performed and the traces were compared
with the blank equilibrium.
DCL01 Enzyme-templated DCL reaction with inhibitors
GST (to a final concentration of 20 M, for mGSTM1-1; 152.8 L,
1.1 mg mL-1, in potassium phosphate buffer 0.1 M, pH 6.8), the four hydrazide
linkers HZD01 to HZD04 (4 x 1.8 L, 10 mM, DMSO), aldehyde ALD01 (1.8 L,
10 mM, water), aniline (15 L, 0.1 M, DMSO) and one inhibitor (6 L, 10mM,
DMSO) were added to a mixture of DMSO (16.8 L, 15 % by vol.) and ammonium
acetate buffer (to a total volume of 255 L, for mGSTM1-1; 100.4 L, 100 mM,
pH 6.4). The DCL was allowed to stand at room temperature, with occasional
shaking, for 48 hours. HPLC analysis (Gradient A) was performed and the traces
were compared with the blank equilibrium.
DCL01 Enzyme-templated DCL reaction – concentration study of
inhibitor DNP GSH
GST (to a final concentration of 20 M, for mGSTM1-1; 152.8 L,
1.1 mg mL-1, in potassium phosphate buffer 0.1 M, pH 6.8), the four hydrazide
linkers HZD01 to HZD04 (4 x 1.8 L, 10 mM, DMSO), aldehyde ALD01 (1.8 L,
10 mM, water), aniline (15 L, 0.1 M, DMSO) and GSH DNP (to a final
concentration of 200, 400 and 600 M, 6, 12 or 18 L, 10mM, water) were added to
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a mixture of DMSO (22.8 L, 15 % by vol.) and ammonium acetate buffer (to a total
volume of 255 L, for mGSTM1-1; 94.4, 88.4 or 82.4 L, 100 mM, pH 6.4). The
DCL was allowed to stand at room temperature, with occasional shaking, for
48 hours. HPLC analysis (Gradient A) was performed and the traces were compared
with the blank equilibrium.
Figure 2: DCL02 – library set up between aldehydes ALD01-ALD03 and hydrazide linkers
HZD01-HZD04.
DCL02 Blank equilibrium - Aniline catalysis of reversible hydrazone
formation.
The four bishydrazide linkers HZD01 to HZD04 (4 x 2.4 L, 10 mM,
DMSO), aldehyde ALD01 (2.4 L, 10 mM, water), aldehydes ALD02 and ALD03
(2 x 2.4 L, 10 mM, DMSO) and aniline (15 L, 0.1 M, DMSO) were added to a
mixture of DMSO (15.6 L, 15 % by vol.) and ammonium acetate buffer (252.6 L,
100 mM, pH 6.4). The DCL was allowed to stand at room temperature with
occasional shaking, and was monitored periodically by HPLC (Gradient A) to
establish the blank composition until the relative populations of the hydrazones
became constant.
DCL02 Enzyme-templated DCL reaction – enzyme added initially
Protein, GST (to a final concentration of 20 M, for mGSTM1-1; 152.8 L,
1.1 mg mL-1, in potassium phosphate buffer 0.1 M, pH 6.8) or BSA (to a final
concentration of 20 M, 199.5 L, 2.0 mg mL-1, in 0.9 % aqueous NaCl solution
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containing sodium azide), the four hydrazide linkers HZD01 to HZD04 (4 x 2.4 L,
10 mM, DMSO), aldehyde ALD01 (2.4 L, 10 mM, water), aldehydes ALD02 and
ALD03 (2 x 2.4 L, 10 mM, DMSO) and aniline (15 L, 0.1 M, DMSO) were added
to a mixture of DMSO (15.6 L, 15 % by vol.) and ammonium acetate buffer (to a
total volume of 255 L, for mGSTM1-1; 99.8 L, 100 mM, pH 6.4). The DCL was
allowed to stand at room temperature, with occasional shaking, for 48 hours. HPLC
analysis (Gradient A) was performed and the traces were compared with the blank
equilibrium.
DCL02 Enzyme-templated DCL reaction – enzyme added at equilibrium
The four hydrazide linkers HZD01 to HZD04 (4 x 2.4 L, 10 mM, DMSO),
aldehyde ALD01 (2.4 L, 10 mM, water), aldehydes ALD02 and ALD03 (2 x
2.4 L, 10 mM, DMSO) and aniline (15 L, 0.1 M, DMSO) were added to a mixture
of DMSO (15.6 L, 15 % by vol.) and ammonium acetate buffer (to a total volume
of 255 L, for mGSTM1-1; 99.8 L, 100 mM, pH 6.4). The DCL was allowed to
stand at room temperature, with occasional shaking, for 24 hours. GST (to a final
concentration of 20 M, for mGSTM1-1; 152.8 L, 1.1 mg mL-1, in potassium
phosphate buffer 0.1 M, pH 6.8) was added to the equilibrated DCL, which was left
to stand at room temperature, with occasional agitation, for a further 48 hours. HPLC
analysis (Gradient A) was performed and the traces were compared with the blank
equilibrium.
DCL02 Enzyme-templated DCL reaction – concentration study of
inhibitor DNP GSH
GST (to a final concentration of 20 M, for mGSTM1-1; 152.8 L,
1.1 mg mL-1, in potassium phosphate buffer 0.1 M, pH 6.8), the four hydrazide
linkers HZD01 to HZD04 (4 x 2.4 L, 10 mM, DMSO), aldehyde ALD01 (2.4 L,
10 mM, water), aldehydes ALD02 and ALD03 (2 x 2.4 L, 10 mM, DMSO), aniline
(15 L, 0.1 M, DMSO) and GSH DNP (to a final concentration of 200, 400 and
600 M, 6, 12 or 18 L, 10mM, water) were added to a mixture of DMSO (15.6 L,
15 % by vol.) and ammonium acetate buffer (to a total volume of 255 L, for
mGSTM1-1; 93.8, 87.8 or 81.8 L, 100 mM, pH 6.4). The DCL was allowed to
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stand at room temperature, with occasional shaking, for 48 hours. HPLC analysis
(Gradient A) was performed and the traces were compared with the blank
equilibrium.
5.2.2 In situ click chemistry reactions
LC-MS/SIM conditions for analysis of ISCC reactions
Column, Atlantis 3  C18, 20 mm x 3.0 mm IS™ column; flow rate,
0.9 mL min-1; wavelength, 254 nm; temperature, 30 C.
Gradient B: H2O/MeCN (0.2 % Formic Acid) from 98 % H2O to 2 % H2O over 10
min, remaining at 2 % H2O for 2 min.
Gradient C: H2O/MeCN (0.2 % Formic Acid) from 98 % H2O to 70 % H2O over 5
min, then to 20 % H2O over 10 min, and eventually to 2 % H2O over 3 min, then
remaining at 2 % H2O for 2 min.
Table 1: The gradient used to monitor ISCC reactions with the following alkyne present in
the reaction mixture
Gradient Alkyne fragment in reaction
Gradient B
- ALK01 to ALK03
- ALK05 to ALK06




Measure of GST activity under in situ click chemistry conditions
L-Glutathione (reduced) (33.3 μL, 3mM aqueous), CDNB (25 μL, 4mM, 
ethanol) and GST (to a final concentration of 150 nM, for hGSTP1-1; 2.1 μL,  
2.0 mg mL-1, stored in potassium phosphate buffer 0.1 M, pH 6.8) were added to
ammonium acetate buffer (939.6 μL 10mM, pH 7.2). Fractions of the reaction 
mixture (100 L) were removed and quenched in methanol (400 L) every ten
minutes for one hour. The fraction was monitored for the formation of glutathione
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conjugate by LC/MS (Gradient B) searching for m/z 472 in negative mode.
GST (for hGSTP1-1; 21 μL, 2.0 mg mL-1, stored in potassium phosphate
buffer 0.1 M, pH 6.8) was added to a mixture of DMSO (15 μL, 15 % by vol.) and 
ammonium acetate buffer (64 μL 10mM, pH 7.2). Samples of these mixtures were 
incubated at 25 C over several days. The GST activity was then measured as
described above.
Bisazide (AZ01 to AZ06) + Alkyne (ALK01 to ALK04) ISCC reaction –
protein-templated reaction
One azide (7.5 L, 10 mM, DMSO) and one alkyne (7.5 L, 10 mM, DMSO)
were added to a mixture of DMSO (30 L, 15 % by vol.) and ammonium acetate
buffer (for hGSTP1-1; 184.8 L, for mGSTM1-1; 140 L, for BSA; 105.6 L,
10 mM, pH 7.0). Protein, GST (for hGSTP1-1; 70.2 L, 1.8 mgmL-1, for
mGSTM1-1; 115 L, 1.1 mg mL-1, stored in potassium phosphate buffer 0.1 M,
pH 6.8) or BSA (149.4 L, 2.0 mg mL-1, stored in 0.9 % aqueous NaCl solution
containing sodium azide) was added and the reaction mixture was allowed to stand at
room temperature, with occasional shaking, for 7 days. A sample of the reaction
mixture (200 L) was removed and quenched in methanol (400 L). LC/MS analysis
(Gradient B or C, see Table 1) was performed in single ion monitoring (SIM) mode
monitoring for [M + H]+ and [M + Na]+ mass peaks for monotriazole and bistriazole
products.
Bisazide (AZ01) + Alkyne (ALK03/ALK04) ISCC reaction – optimisation
of time of assay
Azide AZ01 (62.5 L, 10 mM, DMSO) and one alkyne ALK03/ALK04
(62.5 L, 10 mM, DMSO) were added to a mixture of DMSO (250 L, 15 % by
vol.) and ammonium acetate buffer (to a final volume of 2.125 mL, for hGSTP1-1;
1.75 mL, for background; 2.125 mL, 10 mM, pH 7.0). Reactions were set up in
duplicate with one to measure the background reaction and to the second protein,
hGSTP1-1 (to a final concentration of 15 M, 375 L, 2.8 mg mL-1, stored in
potassium phosphate buffer 0.1 M, pH 6.8) was added and the reaction mixture was
allowed to stand at room temperature, with occasional shaking, for 7 days. A sample
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of the reaction mixture (200 L) was removed over several time points and quenched
in methanol (600 L). LC/MS analysis (Gradient B or C, see Table 1) was performed
in SIM mode monitoring for [M + H]+ and [M + Na]+ mass peaks for monotriazole
and bistriazole products.
Bisazide (AZ01) + Alkyne (ALK04) ISCC reaction – optimisation of
fragment concentration
Azide AZ01 (final concentration 50/100/250 M, 2.5/5.0/12.5 L, 10 mM,
DMSO) and alkyne ALK04 (final concentration 50/100/250 M, 2.5/5.0/12.5 L,
10 mM, DMSO) were added to a mixture of DMSO (to a total volume of 75 L,
15 % by vol.) and ammonium acetate buffer (to a final volume of 425 L, for
hGSTP1-1; 140 L, for background; 105.6 L, 10 mM, pH 7.0). Reactions were set
up in duplicate with one to measure the background reaction and to the second
protein, hGSTP1-1 (to a final concentration of 15 M, 105 L, 2.0 mg mL-1, stored
in potassium phosphate buffer 0.1 M, pH 6.8) was added and the reaction mixture
was allowed to stand at room temperature, with occasional shaking, for 7 days. A
sample of the reaction mixture (200 L) was removed and quenched in methanol
(400 L). LC/MS analysis (Gradient B or C, see Table 1) was performed in SIM
mode monitoring for [M + H]+ and [M + Na]+ mass peaks for monotriazole and
bistriazole products.
Bisazide (AZ01) + Alkyne (ALK03/ALK04) ISCC reaction – optimisation
of GST concentration
Azide AZ01 (20 L, 10 mM, DMSO), one alkyne ALK03/ALK04 (20 L,
10 mM, DMSO) and protein, hGSTP1-1 (to a final concentration of 0/1/5/15/35/
50 M, 0/8/40/120/280/400 L, 2.8 mg mL-1, stored in potassium phosphate buffer
0.1 M, pH 6.8) were added to a mixture of DMSO (80 L, 15 % by vol.) and
ammonium acetate buffer (to a final volume of 680 L, 680/672/640/560/400/
280 L, 10 mM, pH 7.0). The reaction mixture was allowed to stand at room
temperature, with occasional shaking, for 7 days. A sample of the reaction mixture
(200 L) was removed and quenched in methanol (600 L). LC/MS analysis
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(Gradient B or C, see Table 1) was performed in SIM mode monitoring for [M + H]+
and [M + Na]+ mass peaks for monotriazole and bistriazole products.
Bisazide (AZ01) + Alkyne (ALK01 to ALK20) ISCC reaction –
Background reaction
Azide AZ01 (7.5 L, 10 mM, DMSO) and one alkyne (7.5 L, 10 mM,
DMSO) were added to a mixture of DMSO (30 L, 15 % by vol.) and ammonium
acetate buffer (255 L, 10 mM, pH 7.0). The reaction mixture was allowed to stand
at room temperature, with occasional shaking, for 7 days. A sample of the reaction
mixture (200 L) was removed and quenched in methanol (400 L). LC/MS analysis
(Gradient B or C, see Table 1) was performed in SIM mode monitoring for [M + H]+
and [M + Na]+ mass peaks for monotriazole and bistriazole products.
Bisazide (AZ01) + Alkyne (ALK01 to ALK20) ISCC reaction –
protein-templated reaction
Azide AZ01 (7.5 L, 10 mM, DMSO) and one alkyne (7.5 L, 10 mM,
DMSO) were added to a mixture of DMSO (30 L, 15 % by vol.) and ammonium
acetate buffer (to a final volume of 255 L, for mGSTM1-1; 140 L, for BSA;
105.6 L, 10 mM, pH 7.0). Protein, GST (to a final concentration of 15 M, for
mGSTM1-1; 115 L, 1.1 mg mL-1, stored in potassium phosphate buffer 0.1 M,
pH 6.8) or BSA (149.4 L, 2.0 mg mL-1, stored in 0.9 % aqueous NaCl solution
containing sodium azide) was added and the reaction mixture was allowed to stand at
room temperature, with occasional shaking, for 7 days. A sample of the reaction
mixture (200 L) was removed and quenched in methanol (400 L). LC/MS analysis
(Gradient B or C, see Table 1) was performed in SIM mode monitoring for [M + H]+
and [M + Na]+ mass peaks for monotriazole and bistriazole products.
Bisazide (AZ01) + Alkyne (ALK01 to ALK20) ISCC reaction –
protein-templated reaction + inhibitor
Azide AZ01 (7.5 L, 10 mM, DMSO), one alkyne (7.5 L, 10 mM, DMSO)
and one inhibitor (15 L, 10mM, DMSO) were added to a mixture of DMSO (15 L,
15 % by vol.) and ammonium acetate buffer (to a final volume of 255 L, for
mGSTM1-1; 140 L, 10 mM, pH 7.0). GST (to a final concentration of 15 M, for
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mGSTM1-1; 115 L, 1.1 mg mL-1, stored in potassium phosphate buffer 0.1 M,
pH 6.8) was added and the reaction mixture was allowed to stand at room
temperature, with occasional shaking, for 7 days. A sample of the reaction mixture
(200 L) was removed and quenched in methanol (400 L). LC/MS analysis
(Gradient B or C, see Table 1) was performed in SIM mode monitoring for [M + H]+
and [M + Na]+ mass peaks for monotriazole and bistriazole products.
Monoazide (TZ03a-01 or TZ04a-01) + Alkyne (ALK01 to ALK20) ISCC
reaction – Background reaction
Azide TZ03a-01 or TZ04a-01 (1.5 L, 10 mM, DMSO) and one alkyne
(7.5 L, 10 mM, DMSO) were added to a mixture of DMSO (36 L, 15 % by vol.)
and ammonium acetate buffer (255 L, 10 mM, pH 7.0). The reaction mixture was
allowed to stand at room temperature, with occasional shaking, for 7 days. A sample
of the reaction mixture (200 L) was removed and quenched in methanol (400 L).
LC/MS analysis (Gradient B or C, see Table 1) was performed in SIM mode
monitoring for [M + H]+ and [M + Na]+ mass peaks for bistriazole product.
Monoazide (TZ03a-01 or TZ04a-01) + Alkyne (ALK01 to ALK20) ISCC
reaction – protein-templated reaction
Azide TZ03a-01 or TZ04a-01 (1.5 L, 10 mM, DMSO) and one alkyne
(7.5 L, 10 mM, DMSO) were added to a mixture of DMSO (36 L, 15 % by vol.)
and ammonium acetate buffer (to a total volume of 255 L, for mGSTM1-1; 140 L,
10 mM, pH 7.0). Protein, GST (final concentration 15 M, for mGSTM1-1; 115 L,
1.1 mg mL-1, stored in potassium phosphate buffer 0.1 M, pH 6.8) or BSA (105.6 L,
1.1 mg mL-1, stored in 0.9 % aqueous NaCl solution containing sodium azide) was
added and the reaction mixture was allowed to stand at room temperature, with
occasional shaking, for 7 days. A sample of the reaction mixture (200 L) was
removed and quenched in methanol (400 L). LC/MS analysis (Gradient B or C, see
Table 1) was performed in SIM mode monitoring for [M + H]+ and [M + Na]+ mass
peaks for bistriazole product.
Chapter 5
210
Monoazide (TZ03a-01 or TZ04a-01) + Alkyne (ALK01 to ALK20) ISCC
reaction – protein-templated reaction + inhibitor
Azide TZ03a-01 or TZ04a-01 (1.5 L, 10 mM, DMSO), one alkyne (7.5 L,
10 mM, DMSO) and one inhibitor (15 L, 10mM, DMSO) were added to a mixture
of DMSO (21 L, 15 % by vol.) and ammonium acetate buffer (to a total volume of
255 L, for mGSTM1-1; 140 L, 10 mM, pH 7.0). GST (final concentration 15 M,
for mGSTM1-1; 115 L, 1.1 mg mL-1, stored in potassium phosphate buffer 0.1 M,
pH 6.8) was added and the reaction mixture was allowed to stand at room
temperature, with occasional shaking, for 7 days. A sample of the reaction mixture
(200 L) was removed and quenched in methanol (400 L). LC/MS analysis
(Gradient B or C, see Table 1) was performed in SIM mode monitoring for [M + H]+
and [M + Na]+ mass peaks for bistriazole product.
Small scale thermal click reaction for reference
One alkyne (25 L, 10 mM, acetonitrile) and one azide linker (25 L,
10 mM, acetonitrile) were dissolved in acetonitrile (450 L). The reaction was
placed under a nitrogen atmosphere and heated to 70 °C. After 24 hours of heating
the reaction mixture was filtered and injected directly onto the LC/MS column to
analyse the product retention times (Gradient B or C, see Table 1).
LC/MS-SIM response to ISCC library fragments and products
Azide AZ01, alkynes ALK04 and ALK18 and triazole products TZ04a-01,
TZ04a-01-04a, TZ18a-01 and TZ18a-01-18a were monitored on the LC/MS-SIM
over a range of concentrations. For each sample, compound (final concentrations
0.1, 1, 10 and 100 M, 3 L, from stock solution 0.01, 0.1, 1 and 10 mM, DMSO)
was dissolved in DMSO (42 mL, 15 % by vol.) and ammonium acetate buffer
(255 L, 10 mM, pH 7.0). A sample of the mixture (200 L) was removed and
quenched in methanol (500 L). LC/MS analysis (Gradient B or C, see Table 1) was




5.3 GST Binding assays
Inhibition assays were carried out on a Molecular Devices SpectraMax M5
multimode plate reader, using costar clear 96-well plates. Kinetic data was analysed
using SigmaPlot®.
5.3.1 CDNB binding assay – to determine KM and VMAX
The KM values for GSH and CDNB for each GST isoform in a DMSO
concentration of 15 % were determined using the CDNB assay described by Habig
and co-workers.[7]
To determine KM (CDNB): To a 360 μL well were added phosphate buffer 
(225 μL, 0.1 M, pH 6.8), DMSO (15 L, 15 % by vol.), GST (15 μL, for mGSTM1-1 
0.022 mg mL-1) and GSH (15 μL, 40 mM stock, phosphate buffer - 0.1 M pH 6.8). 
The solution was mixed well and after incubation at 25 °C for 5 minutes, CDNB
(15 L, 12 samples to a final concentration of 20 M – 2 mM, ethanol) was added
quickly and mixed. Absorbance was measured at 340 nm, 25 °C for 3 minutes.
To determine KM (GSH): To a 360 μL well were added phosphate buffer  
(225 μL, 0.1 M, pH 6.8), DMSO (15 L, 15 % by vol.), GST (15 μL, 0.022 mg mL-1)
and CDNB (15 μL, 40 mM stock, ethanol). The solution was mixed well and after 
incubation at 25 °C for 5 minutes, GSH (15 L, 12 samples to a final concentration
of 20 M – 2 mM, phosphate buffer - 0.1 M pH 6.8) was added quickly and mixed.
Absorbance was measured at 340 nm, 25 °C for 3 minutes.




mGSTM1-1 0.21  0.03 0.55  0.06
hGSTP1-1 0.72  0.12 0.58  0.18
SjGST 3.02  0.81 0.55  0.07
mGSTA4-4 0.99  0.64 1.19  0.29
Chapter 5
212
5.3.2 CDNB binding assay – to determine IC50 values
To a 360 μL well were added phosphate buffer (225 μL, 0.1 M, pH 6.8), 
DMSO (15 L, 15 % by vol.), GST (15 μL, 22.0 g mL-1) and inhibitor (15 μL, final 
concentration 0.001 - 100 μM). The solution was mixed well and after incubation at 
25 °C for 5 minutes, CDNB (15 μL, at the KM value for each GST isoform) and GSH
(15 μL, 40 mM, in large excess of the KM) were added quickly and mixed.
Absorbance was measured at 340 nm, 25 °C for 3 minutes.










ALD01 2.534  0.344 > 2.7 2.424  0.141 > 2.7
ALD03 > 2.7 - - -
HZD03 > 2.7 > 2.7 - -
HZN01-01-01 0.082  0.097 2.102  0.422 0.534  0.085 > 2
HZN01-02-01 -0.473  0.081 1.072  0.117 -0.599  0.068 > 2
HZN01-03-01 -1.30  0.26 1.129  0.203 -0.005  0.091 > 2
HZN01-04-01 -0.384  0.086 -0.449  0.172 0.255  0.054 > 2
HZN02-02-02 0.305  0.143 - - -
HZN02-03-02 0.970  0.107 - - -
HZN02-04-02 1.698  0.346 - - -
HZN03-02-03 0.528  0.120 - - -
HZN03-03-03 2.027  0.332 - - -
HZN03-04-03 > 2 - - -
Chapter 5
213










ALK03 0.042  0.038 1.434  0.154 1.021  0.064 > 2
ALK04 > 2 > 2 - -
TZ03a-01 -0.860  0.082 1.472  0.117 0.902  0.199 > 2
TZ04a-01 2.112  0.433 > 2 > 2 > 2
TZ04s-01 > 2 - - -
TZ18a-01 > 2 - - -
TZ03a-01-03a -2.427  0.132 0.879  0.173 -1.850  0.097 > 2
TZ03a-01-04a -1.259  0.102 1.388  0.127 1.117  0.086 > 2
TZ04a-01-01a 0.889  0.070 - - -
TZ04a-01-04a 1.119  0.119 2.222  0.392 1.639  0.094 > 2
TZ04a-01-04s 1.229  0.093 2.148  0.285 - -
TZ04a-01-07a 1.407  0.133 1.742  0.266 - -
TZ04a-01-07s 0.583  0.118 1.748  0.204 - -
TZ04a-01-08a 1.530  0.130 - - -
TZ04a-01-08s 1.793  0.236 - - -
TZ04a-01-09a 1.471  0.143 - - -
TZ04a-01-09s 1.812  0.284 - - -
TZ04a-01-10a 1.589  0.108 1.565  0.165 - -
TZ04a-01-11a 0.986  0.081 - - -
TZ04a-01-11s 1.545  0.071 - - -
TZ04a-01-18a 1.484  0.129 0.337  0.143 - -
Chapter 5
214
5.3.3 CDNB competition assay – to determine Ki values
Four different inhibitor concentrations were paired with six substrate
concentrations in order to determine Ki. To a 360 μL well were added phosphate 
buffer (225 μL, 0.1 M, pH 6.8), DMSO (15 L, 15 % by vol.), GST (15 μL,  
22.0 g mL-1) and inhibitor at four concentrations (15 μL, 0 - 10 μM). The solution 
was mixed well and after incubation at 25 °C for 5 minutes, CDNB (15 μL,           
0.05 - 0.2 mM, at six concentrations around the KM value) and GSH (15 μL, 40 mM, 
in large excess of the KM) were added quickly and mixed. Absorbance was measured
at 340 nm, 25 °C for 3 minutes.
5.3.4 Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was carried out in collaboration with
Dr Elizabeth Blackburn at the biophysical characterization facility in the centre for
translational and chemical biology at the University of Edinburgh. The ITC
measurements were performed on a MicroCal LLC Auto-ITC HT Microcalorimeter
at 25 °C. mGSTM1-1 was dialysed against a 0.1 M potassium phosphate buffer,
pH 6.8. The final dialysis buffer was used to make up the ligand solution as well as
for instrument calibration and baseline controls. HZN01-02-01 and HZN01-03-01
were dissolved in the dialysis buffer to concentrations of 300 M and 260 M
respectively. The concentration of mGSTM1-1 was determined by measuring the
absorption at 280 nm to give a final concentration of 17.7 M. The protein
mGSTM1-1 was placed in the 2 mL sample chamber and compounds HZN01-02-01
or HZN01-03-01 in the syringe. A typical ITC measurement consisted of a first
control injection of 1 L followed by 29 successive injections of 10 L for
20 seconds with a 3 minute interval between each injection. Raw data were collected,
corrected for ligand heats dilution, and the peaks generated integrated using ORIGIN
software (Microcal Inc) by plotting the values in microcalories against the molar
ratio of injectant to reactant within the cell. Data was fitted using the one single-site
binding model.[8] From the dissociation constant Kd and the reaction enthalpy value
ΔH, the change in free Gibbs energy (ΔG°) and entropy change (ΔS°) can be
calculated using the equation ΔG° = -RT ln(1/Kd) = ΔH - TΔS° where R is the
universal gas constant and T the absolute temperature.
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5.4 Expression and purification of GST
Plasmid pET15-b-hGSTP1 was a kind gift from Dr. Sylvie Blond (University
of Illinois, USA) to Dr Dominic Campopiano. All protein expression and purification
was carried out in the lab of Dr Dominic Campopiano. All media were sterilized by
autoclaving at 121 °C for 20 minutes at 15 psi prior to use.
5.4.1 Expression and purification of hGSTP1-1
Overexpression of His6-Tagged hGSTP1-1 was carried out by transforming
E. coli BL21 (DE3) cells with the pET15b/hGSTP1 vector. A single colony was
added to 200 mL Luria Bertani (LB) medium (tryptone (10 g L-1), yeast extract
(5 g L-1), sodium chloride (10 g L-1); pH adjusted to 7.5 with sodium hydroxide)
supplemented with ampicillin (100 μg mL-1) and grown overnight at 37 °C and
250 rpm. This seed culture was then used to inoculate 3 L of fresh LB medium and
grown to OD600 of 0.6 before induction with isopropyl β-D-1-thiogalactopyranoside
(IPTG, 1.0 mM final concentration) for 3 to 4 hours at 37 °C and 250 rpm. The cells
were then harvested by centrifugation (4 000 x g for 15 min at 4 °C) and stored at
-20 °C. Cells overexpressing His6-hGSTP1-1 were resuspended in binding buffer
(50 mM Tris- HCl, 0.5 M NaCl, 5 mM imidazole, pH 7, 4 mL per gram of wet cell
paste) with one protease inhibitor cocktail tablet (EDTA-free) and disrupted by
sonication (15 pulses of 30 s at 30 s intervals) at 4 °C. The cell debris were removed
by centrifugation at 27 000 x g for 30 minutes at 4 °C, after which the supernatant
was filtered through a 0.45 μm membrane prior to chromatography. The cell lysate 
was loaded onto a 5 mL HisTrap™ HP column (GE Healthcare) previously
equilibrated with the same binding buffer. The column was then washed with
5 column volumes of binding buffer before the bound material was eluted using a
linear gradient of 0-100 % elution buffer (50 mM Tris-HCl, 0.5 M NaCl, 0.5M
imidazole, pH 8) over 20 column volumes at 4 °C. Fractions were analysed by
SDS-PAGE and those containing hGSTP1-1 were pooled and dialysed against 2 L of
a 0.1 M potassium buffer containing 150mM NaCl, pH 6.8 at 4 °C. The dialysed
fractions were then applied onto a 320 mL HiPrep Sephacryl S-300 HR column (GE
Healthcare) pre-equilibrated with a 0.1 M potassium phosphate buffer containing
150 mM NaCl, pH 6.8. The column was then eluted with one column volume of the
same buffer. Fractions containing hGSTP1-1 were pooled and dialysed against 2 L of
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a 0.1 M potassium phosphate buffer, pH 6.8 at 4 °C.
5.4.2 Polyacrylamide Gel Electrophoresis (PAGE)
SDS-PAGE was used to analyse the fractions collected during the
purification of the protein.
SDS sample 2x loading buffer contained Tris/HCl (1.5 M, pH 8.0, 1 ml),
glycerol (2 ml), bromophenol blue (0.05 %, 2 ml), SDS (10 %, 1.6 ml) and
β-mercaptoethanol (0.4 ml). Samples for analysis by SDS-PAGE were prepared by 
addition of appropriate volume of this buffer, followed by heating (100 °C, 5 min)
and centrifugation (13,000 rpm, 5 min).
A standard method was used for the production of acrylamide gels with a
running gel containing 15 % acrylamide and a stacking gel of 4 % acrylamide.
Briefly, the running gel (acrylamide/bis (29:1) 15 % w/v, SDS 0.1 % w/v, TEMED
0.15 % v/v and APS 0.1 % w/v in Tris buffer (375 mM, pH 8.8)) and was poured
between glass plates, leveled and set at room temperature. The stacking gel
(acrylamide/bis (29:1) 4% w/v, SDS 0.1 % w/v, TEMED 0.15 % v/v and APS 0.1 %
w/v in Tris buffer (375 mM, pH 6.8)) was then added and set at room temperature
using a mould to produce the wells in the finished gel. Gels were run in
protein-running buffer (TGS buffer – 25 mM Tris, 192 mM glycine, 0.1 % (w/v)
SDS, pH 8.3) at 150 V and then visualized using Coomassie Brilliant Blue R250,
GelCode (Pierce) in accordance with manufacturer’s instructions.
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Figure 3: Elution profiles of His6-hGST P1-1 from A) 5ml Ni HisTrap column and B) S200
size exclusion column showing the A280 and SDS-PAGE analyses of the fractions collected.
5.4.3 Expression and purification of mGSTM1-1, SjGST and
mGSTA4-4
The expression and purification of mGSTM1-1, SjGST and mGSTA4-4 was
done by Anne Caniard.[2, 9]
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6.1 Identification of peaks observed in DCL01 and DCL02
6.1.1 Identification of peaks observed in DCL01
Figure 1: Identification of peaks in DCL01 using isolated reference samples. A) DCL01,
B) HZN01-01-01, C) HZN01-02-01, D) HZN01-03-01, E) HZN01-04-01.
Appendix
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Figure 2: LC/MS-SIM trace of DCL01 monitoring for mass of bis acylhydrazone products
and MS spectrum for peak one identifying HZN01-01-01 (mass = 1051.3).
Appendix
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Figure 3: LC/MS-SIM trace of DCL01 monitoring for mass of bis acylhydrazone products
and MS spectrum for peak two identifying HZN01-04-01 (mass = 1241.4).
Appendix
A4
Figure 4: LC/MS-SIM trace of DCL01 monitoring for mass of bis acylhydrazone products
and MS spectrum for peak three identifying HZN01-03-01 (mass = 1213.3).
Appendix
A5
Figure 5: LC/MS-SIM trace of DCL01 monitoring for mass of bis acylhydrazone products
and MS spectrum for peak four identifying HZN01-02-01 (mass = 1071.2).
Appendix
A6
Figure 6: LC/MS-SIM traces of DCL01 in the presence of GST, monitoring for mass of bis
acylhydrazone products. A) blank equilibrium, B) BSA, C) mGSTM1-1, D) SjGST.
Appendix
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MSD2 TIC, MS File (E:\MS DATA\ALEX D DRIVE\07-10\AJC500AMONO1-010710.D) ES-API, Pos, SIM, Frag: 80, "SIM1"
MSD2 TIC, MS File (E:\MS DATA\ALEX D DRIVE\07-10\AJC500BMONO1-010710.D) ES-API, Pos, SIM, Frag: 80, "SIM1"
Figure 7: LC/MS-SIM trace monitoring for mass of four mono acylhydrazones for DCL01 in
the absence (blue) and presence (red) of hGSTP1-1.
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6.1.2 Identification of peaks observed in DCL02
Figure 8: Deconvolution of DCL02 to assign peaks. A) DCL02, B) ALD01 + HZD01 to
HZD04, C) ALD01 + HZD01, D) ALD01 + HZD02, E) ALD01 + HZD03, F) ALD01 + HZD04.
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Figure 9: Deconvolution of DCL02 to assign peaks. A) DCL02, B) ALD02 + HZD01 to
HZD04, C) ALD02 + HZD01, D) ALD02 + HZD03.
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Figure 10: Deconvolution of DCL02 to assign peaks. A) DCL02, B) ALD03 + HZD01 to
HZD04, C) ALD03 + HZD01, D) ALD03 + HZD03, E) ALD03 + HZD04.
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Figure 11: Deconvolution of DCL02 to assign peaks. A) DCL02, B) ALD01 + ALD02 +
HZD01 to HZD04, C) ALD01 to ALD03 + HZD01, D) ALD01 to ALD03 + HZD02, E) ALD01
to ALD03 + HZD03, F) ALD01 to ALD03 + HZD04.
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Figure 12: Deconvolution of DCL02 to assign peaks. A) DCL02, B) ALD01 + ALD03 +
HZD01 to HZD04, C) ALD01 to ALD03 + HZD01, D) ALD01 to ALD03 + HZD02, E) ALD01
to ALD03 + HZD03, F) ALD01 to ALD03 + HZD04.
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Figure 13: Deconvolution of DCL02 to assign peaks. A) DCL02, B) ALD02 + ALD03 +
HZD01 to HZD04, C) ALD01 to ALD03 + HZD01, D) ALD01 to ALD03 + HZD02, E) ALD01
to ALD03 + HZD03, F) ALD01 to ALD03 + HZD04.
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6.2 LC/MS-SIM traces from in situ click chemistry reactions
6.2.1 In situ click reactions between AZ01 and ALK04
Examples of the LC/MS-SIM traces for the in situ click chemistry reactions
described in Chapter 3. The results for reactions containing the naphthalene-based
alkyne ALK04 have been shown.
Figure 14: LC/MS-SIM traces for A) the background (blank) reaction and B) the
hGSTP1-1-templated reaction between AZ01 and ALK04.
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Figure 15: LC/MS-SIM traces for A) the hGSTP1-1-templated reaction between AZ01 and
ALK04 and comparison with reference samples from B) the thermal reaction,


























Figure 16: LC/MS-SIM traces for the reaction between AZ01 and ALK04, A) in the presence
of BSA, B) in the presence of hGSTP1-1 and C) in the presence of hGSTP1-1 with added
inhibitor (ethacrynic acid).
6.2.2 In situ click reactions between TZ04a-01 and ALK04
Figure 17: LC/MS-SIM traces for A) the background (blank) reaction and B) the
hGSTP1-1-templated reaction between TZ04a-01 and ALK04.
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Figure 18: LC/MS-SIM traces for A) the hGSTP1-1-templated reaction between TZ04a-01
and ALK04 and comparison with reference samples from B) the thermal reaction and















Figure 19: LC/MS-SIM traces for the reaction between TZ04a-01 and ALK04, A) in the
presence of BSA, B) in the presence of SjGST and C) in the presence of hGSTP1-1.
Figure 20: LC/MS-SIM traces for the reaction between TZ04a-01 and ALK04, A) in the




6.2.3 Reference samples for in situ click reactions between azide
AZ01 and alkyne library
Figure 21: Reference for the reaction between AZ01 and ALK03, SIM monitoring for mass
of monotriazole. A) product from the thermal reaction, B) product from the in situ reaction in
the presence of hGSTP1-1.
Figure 22: Reference for the reaction between AZ01 and ALK07, SIM monitoring for mass
of monotriazole. A) product from the thermal reaction, B) product from the in situ reaction in
the presence of hGSTP1-1.
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Figure 23: Reference for the reaction between AZ01 and ALK08, SIM monitoring for mass
of monotriazole. A) product from the thermal reaction, B) product from the in situ reaction in
the presence of hGSTP1-1.
6.2.4 Reference samples for in situ click reactions between azide
TZ04a-01 and alkyne library
Figure 24: Reference for the reaction between TZ04a-01 and ALK01, SIM monitoring for
mass of ditriazole. A) product from the thermal reaction, B) product from the in situ reaction




Figure 25: Reference for the reaction between TZ04a-01 and ALK03, SIM monitoring for
mass of ditriazole. A) product from the thermal reaction, B) product from the in situ reaction
in the presence of hGSTP1-1.
Figure 26: Reference for the reaction between TZ04a-01 and ALK07, SIM monitoring for
mass of ditriazole. A) product from the thermal reaction, B) product from the in situ reaction
in the presence of hGSTP1-1.
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Figure 27: Reference for the reaction between TZ04a-01 and ALK08, SIM monitoring for
mass of ditriazole. A) product from the thermal reaction, B) product from the in situ reaction
in the presence of hGSTP1-1.
Figure 28: Reference for the reaction between TZ04a-01 and ALK09, SIM monitoring for
mass of ditriazole. A) product from the thermal reaction, B) product from the in situ reaction
in the presence of hGSTP1-1.
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Figure 29: Reference for the reaction between TZ04a-01 and ALK11, SIM monitoring for
mass of ditriazole. A) product from the thermal reaction, B) product from the in situ reaction
in the presence of hGSTP1-1.
6.3 Results from in situ click reactions between TZ04a-01 and
alkyne hits using hGSTP1-1
The following figures are the results from the ISCC screen of the reaction
between TZ04a-01 and the alkyne library using hGSTP1-1 as the biological





























































1, 5 triazole 1, 4 triazole both regioisomers
Figure 30: ISCC reaction between TZ04a-01 and alkyne ‘hits’ in the presence of hGSTP1-1.
Graph shows the ratio of triazole observed in the presence of GST over the background

















































1, 5 triazole 1, 4 triazole Both regioisomers
Figure 31: ISCC reaction between TZ04a-01 and alkyne ‘hits’ in the presence of hGSTP1-1.
Graph shows the ratio of triazole observed in the presence of GST over the reaction in the























































Figure 32: ISCC reaction between TZ04a-01 and alkyne ‘hits’ in the presence of hGSTP1-1.
Graph shows the ratio of triazole observed in the presence of hGSTP1-1 over the reaction in





























































Cibacron blue Ethacrynic Acid DNP GSH BITC Sulfasalazine
Figure 33: ISCC reaction between TZ04a-01 and alkyne ‘hits’ in the presence of hGSTP1-1.
Graph shows the ratio of triazole observed in the presence of hGSTP1-1 over the reaction in
the presence of hGSTP1-1 plus GST inhibitor. Error bars represent standard deviation.
